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Abstract 
Introduction and hypothesis: Peritoneal dialysis (PD) is an important option for renal replacement therapy. 
Peritoneal sclerosis (PS) limits PD duration due to loss of ultrafiltration (UF) capacity, while about 3% of PD 
patients experience a condition termed encapsulating peritoneal sclerosis (EPS). In many fibrotic diseases 
reduced Extracellular matrix (ECM) breakdown due to lowered matrix metalloproteinase (MMP) activity 
occurs, often from over-expression of tissue inhibitors of MMP (TIMPs) that underlie fibrotic remodeling. 
Furthermore, recent application of 2D gel proteomics on peritoneal dialysis effluent (PDE) samples has 
identified several proteins that are elevated in patients with membrane damage.  These observations have 
led to the hypothesis that: changes in proteins in PDE samples, in particular those associated with ECM 
breakdown have value as non-invasive biomarkers of PS and the switch to EPS.  To test this hypothesis, 
PDE samples from 3 patient cohorts was analysed for ECM proteolytic activity.  A range of ECM processing 
proteins and 3 proteins identified from previous proteomic studies of patients developing EPS (intellectin-1, 
dermatopontin and collagen α1 (I)) were analysed in PDE samples. 
Methods: Three patient cohorts were studied:  two were from Sheffield Kidney Institute (SKI) that consisted 
of 32 spot PDE samples (SKI-1) that included 1 EPS patient & 51 PDE & plasma samples collected during a 
peritoneal equilibrium test (PET) with multiple dwell times in patients who did not have EPS (SKI-2).  The 
third cohort consisted of 209 samples from the Global Fluid Study (GFS) including sequential samples from 
12 EPS & 42 matched controls patients.  MMP activity was assessed using the ENZchek assay system.  
Plasmin activity was assessed by using cleavage of the V0882 substrate. TIMPs, MMPs, intelectin-1, 
dermatopontin, and collagen (α1) I were quantified by commercial ELISA in PDE and plasma samples.  PDE 
cytology (macrophages, leukocytes, fibroblasts and mesothelial cells) was performed to determine if 
changes in any protein could be associated with changes in cell types.  Clinical data were recovered from 
either the peritoneal dialysis database (PDDB) at Sheffield or the GFS archives.  The analysis was 
performed using Microsoft Excel 2010 software, SPSS, and Graphpad prism (prism 5.01 for windows).  
Results: Plasmin activity in PDE samples decreases with long duration of PD therapy. Minimal MMP activity 
was found in all PDE samples.  In the SKI-1 cohort, MMP-1, -9, & -13 were almost undetectable with only 
MMP-2 & -3 being measurable with levels of ((mean±SD) 46±37 & 2.1±2.2 ng/mL respectively). In contrast 
TIMP-1 and TIMP-2 and to lesser extent TIMP-3 had significant levels in PDE samples from commencing 
PD (109±88, 17±12, and 0.28±0.33 ng/mL respectively). All TIMPs & MMP-2 were raised in the single 
patient who had a diagnosis of EPS.  In samples from the GFS cohort, there was a rapid 6 fold increases in 
TIMP-1 within 100 days of the diagnosis of EPS, which when normalised to TIMP-2 levels was a good 
predictor of EPS.  Calculation of the plasma to dialysate transfer rate by reference to that of circulating 
proteins with no peritoneal production and of known molecular weight (albumin, beta2microglobulin (B2M), 
transferrin, IgG, and creatinine) demonstrated that TIMPs & MMPs (especially TIMP-1 and MMP-2) have 
significant peritoneal production.  Plasma levels for TIMP-1,-2, MMP-2,-3, and intelectin-1 (mean±SD) were 
121±27, 85±16, 176±35, 11±5, and 374±136 ng/mL in healthy individuals respectively. Plasma levels in PD 
patients for TIMP-1,-2, MMP-2,-3, and intelectin-1 (mean±SD) were 297±78, 158±33, 309±112, 42±28, and 
749 ±722 ng/mL respectively.  None of the proteins identified by proteomics as predictors of EPS were able 
to be validated by ELISA.  However TIMP-1,-2, MMP-2, intelectin-1, and collagen (α1) I in PDE samples had 
significant correlations with the loss of ultrafiltration and thus membrane damage.  PDE cytology showed 
that peritoneal fibroblast and leukocyte numbers increase with time on PD, while peritoneal macrophage 
decreases with time on PD.  There were no significant changes in mesothelial cells. 
Conclusions: Negligible MMP activity in PDE samples results from high TIMP levels which could underlie 
the development of PS.  The rapid increase in TIMP-1 within 100 days of EPS development offers value as 
a diagnostic tool or a late biomarker.  Plasma levels of TIMP-1,2, MMP-2,3, and intelectin-1 are higher in 
patients on PD compare to healthy individuals.  The increase in peritoneal fibroblasts may be a source of 
TIMP-1.     
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1.1 Peritoneal dialysis (PD)  
PD was originally described in the 1970s as an option for renal replacement 
therapy in patients with end-stage renal failure (ESRF) (Barratt 2009).  Solute 
and fluid exchange occur between dialysate placed in the peritoneal cavity and 
peritoneal capillary blood across the peritoneal membrane.  In order to perform a 
peritoneal dialysis exchange, a dialysis solution of approximately 2 litres is 
drained by the gravity into the peritoneal cavity via a surgically placed silastic 
catheter allowing dialysis.  The fluid is left to dwell for a variable period (usually 4 
– 6 hours) in the peritoneal cavity while dialysis occurs by means of diffusion and 
convection across the peritoneal membrane (Levy, Morgan et al. 2004).  At the 
end of the dwell, the spent effluent is drained out using the catheter.   
1.1.1 Types of peritoneal dialysis 
There are two main types of peritoneal dialysis. 
1.1.1.1 Continuous ambulatory peritoneal dialysis (CAPD) 
In this form of dialysis the patient will be trained to do three to five 
exchanges/day.  There are three phases during each exchange.  The infusion (or 
fill) phase for 10 minutes, followed by the dwell phase (when the dialysis fluid 
remains inside the peritoneal cavity).  The dwell time is dependent on the 
peritoneal dialysis technique (usually 6 to 8 hours).  Finally the drain phase is 
where the dialysis fluid is removed under gravity (20-30 minutes).  Each cycle of 
draining and refilling is named as an exchange.  Dwell time is the time that the 
solution remains in the peritoneal cavity between exchanges. 
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The equipment required to perform CAPD consists of: 
 dialysate fluid bag  
 a drain bag for collecting waste products  
 connecting tubes and clips.  These are used for connecting both 
bags to the catheter  
 a wheeled stand for hanging both bags. 
1.1.1.2 Automated Peritoneal Dialysis (APD) 
In this form of dialysis the patient uses an automatic cycling device.  The 
aim is to perform multiple (6-7) exchanges during the night time.  In APD, 
patients usually have one or two exchanges manually in the day time when they 
are off the machine (this is known as a ―wet-day‖ i.e. dialysate in the peritoneum 
in the day time).  
1.1.2 Different modes of peritoneal dialysis 
 Nocturnal intermittent peritoneal dialysis (NIPD) is a high-volume dialysis for 
short-duration that takes place for 8-12 hours/day (Brophy, Sowinski et al. 
1999).  The exchanges are overnight only with no exchange during day time 
(dry peritoneum during the day). 
 Continuous cyclic peritoneal dialysis (CCPD) in this mode of dialysis there are 
exchanges during night time with one exchange during day time. The day 
exchange will be at various times.  
 Optimized continuous peritoneal dialysis (OCPD) is a combination of APD 
with extra exchanges (classically day time).  OCPD is ideal if the patient 
needs maximal solute transfer e.g. in anuric patients 
 Tidal Peritoneal Dialysis (TPD) is a manipulation of the prescription in which a 
significant percent of the dwell is left remaining in the peritoneal cavity, for 
example 30% to suit the individual patient needs.  TPD is used if there are 
difficulties with catheter flow since it avoids drainage alarms and is useful to 
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prevent catheter tip pain that can occur when the peritoneal cavity is empty. 
 Intermittent Peritoneal Dialysis (IPD) is an old modality of peritoneal dialysis 
and can be used to treat acute kidney injury in hospitalized patients.  It can be 
used as a chronic treatment where the patient does a period of dialysis in part 
of the week then has a few days off.   
1.1.3 Advantages of Peritoneal dialysis  
There are several advantages of PD in comparison to the alternative 
dialysis modality of hemodialysis (HD).  These include relative patient 
independence since PD is performed at home.  It does not require anti-
coagulation therapy, avoids vascular access and related complications.  There is 
some suggestion that PD may be preferable for patients who have 
cardiovascular instability, although not all studies demonstrate better cardiac 
outcomes for patients on PD in comparison with HD (Sens, Schott-Pethelaz et al. 
2011).  Patients are free to move around while they are in the dwell phase.  In 
most health care systems PD is less expensive than the alternative, HD.  Several 
studies have indicated better preservation of residual renal function (RRF) for 
patients on PD than on HD (Tam 2009).  RRF is of vital significance in patients 
with ESRF such as better control in blood pressure, and reduction in left 
ventricular hypertrophy and is an important indicator of patient survival.  Sodium 
removal will be increased and fluid status will be improved (Marron, Remon et al. 
2008).  PD patients have less fluid restriction than hemodialysis patients. 
1.1.4 Disadvantages of Peritoneal dialysis   
Peritoneal dialysis also has disadvantages, these include the requirement to 
perform PD daily, while HD is usually performed three days a week.  PD patients 
need enough space at home to store their dialysis supplies.  The time taken to 
perform the dialysis exchanges can impact patient lifestyle.  Nutritional 
complications can result from protein loss across the peritoneal membrane 
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(Blumenkrantz, Gahl et al. 1981).Reduced appetite, dyslipidaemia, and weight 
gain due to the absorption of glucose from the dialysate are also issues.  
Increased intra-abdominal pressure from dialysis fluid can result in hernias, fluid 
leaks, chronic back pain, rectal and/or vaginal prolapses and loss of appetite 
(Levy, Morgan et al. 2004). 
Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS) was 
established for better understanding in causes of peritoneal dialysis technique 
failure.  PDOPPS and ISPD (International Society for Peritoneal Dialysis) 
identified 7 primary causes for PD technique failure with a hope that this will help 
in standardizing international registry data reporting (Table 1.1) (Lambie M, 
Davies S et al. 2012, Perl, Davies et al. 2015).  The most frequent and important 
complication of PD is infection.  This can occur at several sites such as the exit-
site for the peritoneal dialysis catheter (most common causative agents are 
Staph. aureus and Pseudomonas spp.), catheter tunnel infection, and peritonitis 
(this could be bacterial, fungal, tuberculous or water-borne atypical mycobacterial 
peritonitis).  Peritoneal membrane change is another important complication of 
PD that may lead to decline in ultrafiltration (UF).  Encapsulating Peritoneal 
Sclerosis (EPS) is a rare but potentially fatal complication for PD.  The other 
potential PD complications include inflow pain and eosinophilic peritonitis (Levy, 
Morgan et al. 2004).  
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Primary cause 
Infection-related  Peritonitis  
Exit-site infection 
Catheter-related problems  Catheter displacement 
Catheter blockage 
Peritoneal leaks/hernia  
Problems with solute/ water 
clearance 
Fluid/UF-related 
Solute-related 
Risk or diagnosis of EPS  
Psychosocial /medical   
Other For example, intra-abdominal pathology, and hemoperitoneum 
Table 1.1 Standardizing Causes of Peritoneal Dialysis Technique Failure 
The primary causes for technique failure modified from Perl, J et al 2015 (Perl, Davies et al. 2015).     
1.2 Anatomy and physiology of the peritoneal membrane 
The space between abdominal wall and the abdominal viscera is called the 
peritoneal cavity.  The peritoneal membrane lines the peritoneal cavity.  It 
consists of parietal and visceral peritoneal membranes.  The parietal membrane 
lines the abdominal wall, whereas the visceral layer covers the intra-abdominal 
viscera.  The peritoneal membrane is lined by mesothelial cells (MCs).  
Mesothelial cells are supported by submesothelial connective tissue containing 
lymphatics and peritoneal capillaries.  The peritoneal vasculature has a central 
role in PD.  The peritoneal capillary acts as a barrier to fluid and solute removal 
between dialysis fluid and the blood.  The peritoneal membrane is 
semipermeable.  PD uses this membrane to filter patient‘s blood.  In addition, 
peritoneal lymphatics have a role in fluid removal from the peritoneal cavity 
(Barratt 2009). 
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The movement of solute and water movement between dialysis fluid and 
the patient‘s blood across the peritoneal membrane is generally descried using a 
three-pore theory.  There are three different sizes of pores (Figure 1.1) (Saxena 
and West 2006), which are large (>200 angstrom (A)), small (40-60 A), and ultra-
small pores (3-5 A).  Large pores are located in inter-endothelial cell clefts and 
are relatively few in number.  They allow macromolecules such as protein to 
move from the patient‘s blood to the dialysate.  Small pores make up the majority 
of the overall pore area.  They are located in the gaps between endothelial cells.  
They allow diffusion of small solutes between dialysate in the peritoneal space 
and blood including the absorption of glucose from dialysate and the removal of 
urea and creatinine from blood to the dialysate. Small pores also play a role in 
fluid removal by ultrafiltration.  Finally, ultra-small pores are transcellular 
aquaporin water channels that allow passage of water only, but impermeable to 
solutes.  They are responsible for 50% of water removal during a glucose based 
dialysate exchange (Barratt 2009). 
 
 
Figure 1.1 The three-pore model of peritoneal transport 
 Solute and water transport through the three pores (Ultra-small or transcellular pores, Small pores, large 
pores).  It is reproduced by permission of the American Board of Family Medicine (Saxena and West 
2006) 
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Aquaporin-1 (28 kDa) protein is a water-specific membrane channel which 
is impermeable to urea and glycerol (Zeidel, Nielsen et al. 1994, Agre 2004).  It is 
found in the endothelial lining of the peritoneal capillaries and post capillary 
venules (Devuyst, Nielsen et al. 1998, Devuyst and Yool 2010).  Aquaporin-1‘s 
role in peritoneal water permeability was first recognised in studies using Mercury 
chloride in a rat model (Carlsson, Nielsen et al. 1996).  Aquaporin-1 knockout 
mice also demonstrated that osmotically driven water transport was significantly 
decreased across the peritoneal membrane compared to the wild-type littermates 
(Yang, Folkesson et al. 1999).  Further studies using a standard peritoneal 
exchange test in mice (Ni, Cnops et al. 2005), revealed that aquaporin-1 
knockout mice had an approximately 50% reduction in  UF  during peritoneal 
dialysis with a hypertonic dialysate as same as the three pore model prediction 
(Ni, Verbavatz et al. 2006). 
1.3 Peritoneal membrane permeability 
The un-physiological nature of the dialysate results in time dependent 
changes to the membrane such as the development of mesothelial intracellular 
oedema, oedema of the interstitium, destruction of organelles, collagen fiber 
deposition in the submesothelial region and a reduction in the number of 
microvilli (Levy, Morgan et al. 2004).  Episodes of peritonitis may lead to 
destruction of the microvilli on the mesothelium and the formation of layers of 
fibrin on the peritoneal surface.  After a single episode of peritonitis the 
membrane can recover to a large extent, however if there are repeated episodes, 
the changes are likely to become irreversible and the damage will alter 
membrane permeability (Levy, Morgan et al. 2004).  Several studies suggest an 
impact of peritoneal membrane function on patient survival (Ates, Nergizoglu et 
al. 2001, Brown, Davies et al. 2003, Jansen, Termorshuizen et al. 2005).  
Therefore, it is important to identify the causative factors that damage the 
peritoneal membrane and to design strategies to preserve peritoneal membrane 
function (Davies, Phillips et al. 1998).  There is increasing evidence that with time 
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on PD, there will be an increase in peritoneal solute transport rate (Struijk, 
Krediet et al. 1991, Selgas, Fernandez-Reyes et al. 1994, Struijk, Krediet et al. 
1994, Davies, Bryan et al. 1996, Davies, Phillips et al. 1998).  High solute 
transport increases the risk of mortality, which is independent of age, residual 
renal function and co-morbidity of the patient (Davies 2006).  UF capacity and the 
small solute transport rate are linked and they are affecting the clinical outcome.  
However, patients with severe UF failure, have a combination of high solute 
transport and reduced osmotic conductance of the membrane – a measure of the 
effectiveness by which UF is induced by glucose (Heimburger, Waniewski et al. 
1990, Davies 2004, Smit, Schouten et al. 2004, Parikova, Smit et al. 2005, 
Waniewski, Sobiecka et al. 2005).  Loss of osmotic conductance is due to 
membrane and interstitial changes.   
1.3.1 High peritoneal solute transport 
High solute transport is defined as an increase in the ratio of creatinine in 
the dialysate to plasma after a dwell time of 4 hr (D/Pcr4) during PET (Chang, 
Park et al. 2010).  PD duration is frequently limited by failure of the peritoneal 
membrane, which is associated with increase in solute transport, UF dysfunction 
with degenerative changes of the peritoneal membrane such as loss of 
mesothelial cells, sub-mesothelial ECM accumulation and vasculopathy 
(Williams, Craig et al. 2002, Fraser and Topley 2009). 
Early studies of high peritoneal solute transport revealed it was associated 
with increased hospital admissions (Heaf 1995), increased technique failure (Wu, 
Huang et al. 1996) and increased peritoneal protein and creatinine clearance 
(Nolph, Moore et al. 1993, Heaf 1995).  One of the largest studies published from 
the Australia and New Zealand dialysis and transplant (ANZDATA) registry has 
confirmed an increase in mortality and technique failure among those patients on 
PD having high transport rates (Rumpsfeld, McDonald et al. 2006).  
10 
 
Managing patients with high transport status requires two strategies.  First, 
using appropriate dwell times with the aim of draining the peritoneal cavity at 
optimal UF volume and before fluid starts to be reabsorbed across the peritoneal 
membrane.  Second, the use of icodextrin to prevent fluid reabsorption.  These 
two points can be achieved by allowing shorter exchanges to occur overnight by 
APD and using icodextrin.  Icodextrin provides slow sustained UF, avoiding 
glucose absorption and consequently fluid reabsorption (Davies 2006).  
Icodextrin in diabetic patients showed improvement in PD technical survive 
(Takatori, Akagi et al. 2011). 
A case series was published in 2001 (Sheffield) following 6 PD patients with 
EPS.  All of them had UF inadequacy, and five of them were treated with 
icodextrin for variable durations (Jenkins, Leng et al. 2001).  The icodextrin role 
in these cases is not clear.  However, icodextrin use is associated with an 
extension in technique survival (Wilkie, Plant et al. 1997), as well as use in PD 
patients with UF inadequacy and high transport status (Paniagua, Ventura et al. 
2009)  Both of these are defined EPS risk factors (Sampimon, Coester et al. 
2011).  In general, PD patients with EPS are on PD for long periods and 
nowadays it is likely that for this reason they had been treated with icodextrin 
(Wilkie 2011). 
1.3.2 Ultrafiltration (UF) 
Ultrafiltration is equal to the volume of fluid that is drained from the 
peritoneal cavity minus the volume of fluid that was infused to the peritoneal 
cavity.  UF is obtained after a standard dwell time during PD.  It is varies 
according to the glucose concentration of the dialysate.  Ultrafiltration failure 
(UFF) diagnosis is made if the net UF was less than 100 mL after a dwell time of 
4 hours with using a dialysate of 2.5% glucose, or less than 400 mL after a dwell 
time of 4 hours with using a dialysate of 4.25% glucose, in the absence of fluid 
leaks, catheter malfunction or extensive intraperitoneal adhesions (Twardowski, 
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Nolph et al. 1987, Davies, Brown et al. 1993, Krediet, Imholz et al. 1993, Ho-dac-
Pannekeet, Atasever et al. 1997).  The formula that describes the forces involved 
in ultrafiltration is as following: 
Transcapillary UF = Co-efficient of UF x hydrostatic pressure + oncotic 
pressure + osmotic pressure 
In general, the Co-efficient of UF defines as the ability of the dialyzer to 
transfer water across the membrane at a certain transmembrane pressure (Kher, 
Schnaper et al. 2006).  In peritoneal dialysis, Co-efficient of UF is the amount of 
water across the peritoneal membrane in respond to the osmotic gradient by the 
dialysis solution, while other forces in the system are negligible. 
There is individual variability in UF, and it can be positive or negative UF 
(negative UF, means retained fluid from dialysate to vascular compartment).  It is 
mainly governed by the osmotic pressure gradient.  Ultrafiltration failure is an 
important cause of long-term failure of PD.  Ultrafiltration failure can be defined 
either clinically or by changes in peritoneal membrane function.  Clinically, UF 
failure is the inability to maintain dry weight despite the requirement for excessive 
amounts of hypertonic glucose solutions and this would also requires a fluid 
restriction for the patient.  UF failure can be predicted by the PET or any 
equivalent test, and is commonly associated with high solute transport (Davies, 
Brown et al. 1993, Krediet, Ho-Dac-Pannekeet et al. 1996, Ho-dac-Pannekeet, 
Atasever et al. 1997).  The chance of getting ultrafiltration failure increases for 
those who have been on long term PD, and UF failure leading to technique 
failure (Heimburger, Waniewski et al. 1990). 
It is important to overcome low ultrafiltration capacity of the peritoneal 
membrane by preventing long-term membrane damage.  For example, by 
reducing the exposure of the membrane to the hypertonic glucose.  The exact 
mechanism is unknown, but it could be due to glucose degradation product injury 
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in addition to hypertonic glucose itself (Wieslander 1996).  There is evidence that 
using icodextrin and APD in anuric patients over two years preserves UF better 
(Davies, Brown et al. 2005).  There is no long-term data to confirm that newer 
biocompatible solutions prevent long-term membrane damage. 
There are 3 types of the Ultrafiltration failure (UFF).  Type I membrane 
failure and this is accompanied by the rapid solute transport.  Type II membrane 
failure and this is accompanied by the impaired solute transport.  Finally, Type III 
membrane failure is associated with excessive lymphatic absorption.   
Type I membrane failure is the commonest cause of UFF in comparison to 
the other 2 types.  One of the proposed mechanisms is where aquaporin 
mediated water transport is impaired (Monquil et al.1995).  UFF prevalence 
increases with longer time on PD.  This is may be due to increase in glucose 
derived substances and reactive carbonyl compounds (RCOs) (Buemi et al. 
2004).  Type I UFF may also arise during peritonitis, but the UF losses during 
peritonitis is usually reversible.  There is an increase in the effective peritoneal 
surface area in Type I UFF through increase in vascular permeability or vascular 
neoproliferation.  
 Type II membrane failure is comparatively rare and mainly seen in patients 
who are suffering from peritoneal sclerosis.   Solute transport is frequently intact, 
but there is reduction in peritoneal surface area which is due to fibrosis or 
extensive adhesions.  Type II UFF can cause reduction in the overall solute and 
fluid removal.  Finally, Type III membrane failure is associated with increase in 
dialysate resorption from the peritoneal cavity which is because increase in 
lymphatic flow.  Mechanical problems such as catheter dysfunction and leaks are 
among the differential diagnosis of normal membrane function and low UF. 
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1.4 Adequacy of Peritoneal dialysis  
The dose of peritoneal dialysis is calculated by two methods: weekly 
creatinine clearance and weekly urea clearance or Kt/V urea (NKF-DOQI 1997) 
The updated Renal Association Clinical Practice Guidelines has suggested that a 
combined peritoneal and urinary Kt/V urea of >1.7/week or a creatinine clearance 
of >50L/week/1.73m2 should be regarded as minimal treatment doses.  The 
treatment dose should be raised in patients experiencing uraemic symptoms.  
Methods of calculations and units for Kt/V urea and creatinine clearance are 
provided in appendix 1. 
1.5 Simple peritoneal sclerosis  
There are several changes of the peritoneum that happen during the course 
of PD treatment. These changes are mesothelial layer denudation, progressive 
fibrosis of peritoneal vasculature as well as media hyalinization due to collagen 
IV deposition (vasculopathy).  In addition to the development of new vessels 
(neoangiogenesis), there is an increase in thickness of the submesothelial 
compact zone due to interstitial fibrosis which consists of different types of 
collagen such as collagen IV as well as myofibroblasts.  Furthermore, 
accumulation of advanced glycation end products (AGEs) in the mesothelial and 
submesothelial layers as well as vascular wall after a long time on PD.  AGE 
deposition is linked with the peritoneal fibrosis in previous studies (Nakayama, 
Kawaguchi et al. 1997, Honda, Nitta et al. 1999).  Peritoneal morphological 
changes may impact its function such as increased peritoneal permeability and 
decrease in UF (Korte, Sampimon et al. 2011) 
Simple peritoneal sclerosis develops with time on peritoneal dialysis.  It is 
common and characterised by increase in peritoneal membrane thickness.  
Uraemic patients already have an increase in peritoneal membrane thickness 
prior to dialysis (Williams, Craig et al. 2003).  There are changes in morphology 
14 
 
of the parietal peritoneal membranes. In normal subjects, the median thickness is 
50µm for the submesothelial compact collagenous zone.  In PD patients, the 
median thickness is 270µm.  There is an increase in compact zone thickness 
with the time of PD therapy from 180µm in first 2 years on PD to 700µm for 
patients on PD for more than 8 years (Williams, Craig et al. 2002).  There is an 
absence of encapsulation in simple peritoneal sclerosis (Garosi 2009) 
1.5.1 Pathology and pathogenesis of simple peritoneal sclerosis 
Simple peritoneal sclerosis is associated with a decrease in arteriolar and 
venular lumen/vessel diameter ratio (Augustine, Brown et al. 2009).  Triggering 
factors for PS include dialysate (which contains glucose and glucose degradation 
products), bacteria, peritoneal catheters, plastic particles and plasticizers (Ronco 
2005).  At a cellular level, dialysis-related peritoneal sclerosis is associated with 
numerous changes in the immunobiology of the peritoneum such as leukocyte 
attraction, production of inflammatory mediators such as interleukins and 
chemotactic factors, as well as macrophage activation.  Interleukin-1 (IL-1) 
subsequently activates endothelial cells increasing vascular permeability and 
causing vasodilation.  IL-1 also instigates fibroblast proliferation.  Lymphocytes 
show irregular chemical mediator production and changes in surface antigens.  
All these biochemical changes influence fibroblast and stimulate fibrosis (Ronco 
2005).  In animal models, after 2 months of peritoneal dialysis in rabbits, it is 
possible to observe the typical submesothelial and mesothelial modification of 
simple peritoneal sclerosis, but it is not possible to recognize the factors 
activating the transformation from PS to EPS in many cases (Ronco 2005).  
1.6 Encapsulating Peritoneal Sclerosis (EPS) 
EPS is a rare but serious complication of PD.  The mortality rate of EPS is 
60-93% (Spence, Gillespie et al. 2013).  EPS was described in 1980 for the first 
time (Gandhi, Humayun et al. 1980).  In EPS, fibrous tissues encapsulate the 
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viscera leading to decreased intestinal motility, intestinal malfunctions and 
sometimes ascites.  A prospective study performed in Japan showed an increase 
in the incidence and mortality rates with time on PD.  The incidence rates were 
0% at 3 years, 5.8% at 10 years, and 17.2% over 15 years on PD (Kawanishi 
and Moriishi 2005). 
1.6.1 Pathology and pathogenesis of EPS 
The initiating event in EPS is unknown; however a ‗two-hit‘ hypothesis has 
been suggested.  First hit is long term exposure to dialysate fluid which will lead 
to changes in peritoneal/mesothelial physiology.  The second hit could be 
peritonitis, surgical procedures, genetic tendency or discontinuation of PD.  In 
EPS there is denudation of the mesothelium, capillary angiogenesis, fibrosis of 
the interstitium and vascular sclerosis  There is deposition of fibrin, mainly 
disturbing the visceral membrane (Honda and Oda 2005).  The Pathobiology of 
EPS is unclear.  One theory connects plasma exudation and deposition of fibrin 
with the formation of adhesions and fibrosis (Figure 1.2).  Inflammation of the 
peritoneal membrane will lead to fibrinous exudation, which may lead to 
adherence of membrane surfaces.  This adhesion either be re-absorbed or will 
be invaded by fibroblasts which lead to a permanent adhesion.  Mesothelial cells 
lose normal physiological responses, including the production of fibrinolytic 
agents which are pre-disposed to fibrinous adhesion formation (Augustine, 
Brown et al. 2009).  Plasmin plays a vital role in fibrin degeneration, ECM 
breakdown, and activation of both metalloproteinases and uPlasminogen 
activator (Holmdahl 1997).  Increased expression of transforming growth factor- 
β1 (TGF-β1) is linked to adhesion formation, probably via increasing production 
of plasminogen activator inhibitor type 1 (Holmdahl, Kotseos et al. 2001).  The 
molecular mechanisms involved in EPS are complex and include subclinical 
bowel ischemia and growth factor dysregulation. 
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Apart from fibrosis, there is also vasculopathy and progressive 
angiogenesis i.e. increase in capillary number.  This leads to UF failure because 
of increased solute transport through the peritoneal membrane (Aguilera, Yanez-
Mo et al. 2005).  Angiogenesis inhibition with TNP-470 reduced the number of 
vessels and inhibited thickening of the submesothelial zone in a mouse model 
(Yoshio, Miyazaki et al. 2004).  Angiostatin (angiogenesis inhibitor) reduced the 
number of vessels and improved peritoneal function, but it did not change the 
thickness of the peritoneal membrane in a rat model (Margetts, Gyorffy et al. 
2002).  The difference in these results may be due to a difference in mechanism 
of the action for TNP-470 and angiostatin (Miyazaki and Yuzawa 2005)  
 
 
Figure 1.2 Two-hit hypothesis for EPS 
The diagram shows a possible pathogenetic mechanism for EPS development.  Abbreviations: EMT = 
Epithelial mesenchymal transformation; GDP = glucose degradation product; IL-6 = interleukin-6; MMP = 
matrix metalloproteinase; PAI-1 = plasminogen activator inhibitor type 1; TGF = transforming growth 
factor; VEGF = vascular endothelial growth factor; TNF = Tumor necrosis factor.  It is reproduced by 
permission of the Karger Publishers.  Copyright © 2009, Karger Publishers (Augustine, Brown et al. 
2009). 
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1.6.2 Histology of PS and EPS 
Histologically EPS tissue consists mainly of organized fibrin which is most 
likely derived from plasma exudation that comes from the peritoneal 
microvasculature (Honda and Oda 2005).  The fibroblasts in the peritoneum 
appear swollen with an increased level of cellularity.  They are accompanied by 
the appearance of various activation and proliferation markers.  Fibrin deposition 
and alteration of fibroblast phenotype are proposed as significant findings for 
early detection of EPS.  In addition, EPS can be predicted by the presence of 
persistent inflammatory changes (Honda and Oda 2005).  Vasculopathy and 
neoangiogenesis may be of more significance in early EPS cases.  Most of these 
histological findings can be found in patients on long-term peritoneal dialysis 
even without EPS (Sherif, Yoshida et al. 2008).  The capsular membrane in EPS 
is derived from exudative fibrin.  In addition, perivascular bleeding is frequently 
observed (Figure 1.3 A).  Enlarged fibroblasts are distributed throughout the 
fibrous tissue (Figure 1.3 B).  Peritoneal fibroblasts produce large amounts of 
ECM proteins and their accumulation will drive fibrosis (Figure 1.3 C).  Capillary 
angiogenesis and mononuclear cell infiltration are present (Figure 1.3 D).  
Mesothelial denudation and interstitial fibrosis are due to PD-induced chronic 
tissue damage after a long history of PD (Figure 1.3 E).  Specific 
microvasculopathy can be seen (Figure 1.3 F) (Honda and Oda 2005). 
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1.6.3 Comparison between simple PS and EPS 
It is not even clear whether EPS is an evolution of a simple sclerosis or is a 
different disorder.  The positive ﬁbrin stain on the membrane surface and a thick 
degenerative compact zone layer are main pathological ﬁndings in patients with 
EPS.  Angiogenesis, vasculopathy, ﬁbrosis, degenerative changes of the 
compact zone layer, and new membrane formation are common pathological 
findings in both simple sclerosis and EPS (Figure 1.4) (Sherif, Yoshida et al. 
2008). 
 
Figure 1.3 Various histologic characteristics of EPS 
(A) Perivascular bleeding and fibrin deposition are apparent on the superficial part of the peritoneum, 
accompanied by inflammatory cell infiltration [hematoxylin and eosin (H&E) stain, 100×].  (B) Enlarged 
fibroblasts with increased cellularity (H&E stain, 200×).  (C) Fibrous matrices produced by peritoneal 
fibroblasts have accumulated, resulting in peritoneal fibrosis (H&E stain, 100×).  (D) Mononuclear cell 
infiltration and capillary angiogenesis are present in some regions (H&E stain, 100×).  (E) Mesothelial 
denudation and interstitial fibrosis (Masson trichrome stain, 25×).  (F) Vasculopathy of the peritoneal 
microvessels: hyalinized thickening of the small venules, with luminal obliteration (H&E stain, 80×).  It is 
reproduced by permission of the Peritoneal Dialysis International (Honda and Oda 2005). 
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1.6.4 Risk factors 
There are several factors behind our poor understanding of the risk factors 
for EPS development.  These include the sporadic nature of EPS, difficulty in 
diagnosis during the early stage and the requirement for better animal models.  
Clinical associations of EPS have been identified.  These include acetate buffer 
(Slingeneyer 1987), exposure to glucose in dialysate (Hendriks, Ho-dac-
Pannekeet et al. 1997), low UF (Yamamoto, Otsuka et al. 2005), and absence of 
residual renal function (at least in children) (Hoshii, Honda et al. 2000).  
 
Figure 1.4 Peritoneal 
membrane with EPS 
stained with Mason 
Noguchi stain   
A) (×20) a positive (red) ﬁbrin 
stain on the membrane surface.  
B) (×20) degenerative changes 
in both the surface mesothelium 
(with epidermaltrans formation) 
and the compact zone. C) (×10) 
new ﬁbrinous encapsulating 
membrane formation.  It is 
reproduced by permission of 
the John Wiley and Sons 
Publishers (Sherif, Yoshida et 
al. 2008). 
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Discontinuing PD sometimes acts as a trigger for EPS and this may explain the 
increase rate of developing EPS after renal transplantation (Fieren, Betjes et al. 
2007).  There is a possibility of genetic predisposition for developing EPS 
(Davies, Phillips et al. 1998). 
Several studies show that progression to EPS correlates with high 
membrane permeability, long-term PD and loss of UF (Nomoto, Kawaguchi et al. 
1996, Rigby and Hawley 1998, Yamamoto, Nakayama et al. 2002, Kawanishi, 
Kawaguchi et al. 2004).  However, EPS has also been reported in patients with 
adequate UF and low membrane transport status (Balasubramaniam, Brown et 
al. 2009).  There is an association between EPS and icodextrin (Wilkie 2011).  
The patient, who starts PD at a younger age, is at greater risk of developing EPS 
(Korte, Sampimon et al. 2011). 
Patients at high risk for EPS are those patients who have been on 
peritoneal dialysis for a long time (more than 8 years on PD), with high peritoneal 
transport and a history of repeated episodes of peritonitis (Korte, Yo et al. 2007), 
although a history of peritonitis is not essential for developing EPS (Nomoto, 
Kawaguchi et al. 1996).  This is not surprising because patients with a greater 
frequency of peritonitis tend to have shorter technique survival 
(Balasubramaniam, Brown et al. 2009).  Those PD patients, who do not get 
peritonitis, continue longer on PD and they are more likely to get EPS due to a 
―survivor‖ bias.   
The literature reports on the significance of peritonitis in the EPS 
development remain unclear.  Peritonitis episodes caused by the fungal 
peritonitis, Haemophilus Influenza, Pseudomonas spp, and Staphylococcus 
Aureus have been linked to the development of EPS (Chew, Clarkson et al. 
1997, Afthentopoulos, Passadakis et al. 1998, Rigby and Hawley 1998, 
Nakamura, Okada et al. 1999).  A prospective study in Japan showed that 
quarter of the EPS cases were associated by bacterial peritonitis, whereas a 
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single centre controlled study displayed no relationship (Hendriks, Ho-dac-
Pannekeet et al. 1997, Kawanishi, Kawaguchi et al. 2004).  Both the Dutch multi-
centre study and the Scottish registry could not prove the association between 
EPS and peritonitis incidence (Betjes, Fieren et al. 2009, Brown, Simpson et al. 
2009).  However, the frequency of peritonitis episodes caused by fungal 
peritonitis, Pseudomonas spp and Staphylococcus Aureus were higher in the 
EPS compared to control groups.  This may indicate that it is not the incidence, 
but the source of the peritonitis episode that is important for the EPS 
development (Korte, Sampimon et al. 2011, Korte, Sampimon et al. 2011).  
1.6.5 Clinical presentation 
The onset of EPS is often insidious.  The presenting features vary from one 
patient to another, but typically features of inflammation, abdominal pain and 
weight loss are seen.  In advanced cases, the patient may suffers from 
malfunction of the gastrointestinal tract and death (Augustine, Brown et al. 2009). 
1.6.6 Diagnosis 
There are three aspects to EPS diagnosis; clinical presentation, radiological 
imaging and the pathology.  The development of these diagnostic criteria was 
undertaken by the International Society of Peritoneal Dialysis (ISPD).  EPS is a 
clinical syndrome with the presence of intestinal obstruction (persistent or 
recurrent).  The clinical syndrome is with or without the presence of inflammation.  
There are peritoneal thickening, sclerosis, calcifications and encapsulation, which 
are confirmed by radiological findings or macroscopic inspection (Kawaguchi, 
Kawanishi et al. 2000, Korte, Fieren et al. 2011).  
Diagnosis of EPS is made after establishing both functional and structural 
abnormalities.  Initially any symptom that suggests intestinal obstruction, ranging 
in severity from mild symptoms such as anorexia to severe symptoms such as 
marked weight loss would raise concern.  Diagnosis is confirmed by the 
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demonstration of peritoneal membrane thickening by imaging techniques or at 
laparotomy.  The increasing thickness is a pre requisite to encapsulation and 
bowel cocooning.  Gastrointestinal symptoms may include loss of appetite, 
abdominal pain and fullness, disturbance in bowel motions, early satiety, nausea, 
vomiting, weight loss (Nakamoto 2005).  There may be signs of inflammation 
(fever, raised CRP, anaemia, ascites and blood in dialysate), abdominal masses 
and pain (features of adhesions in the peritoneum and/or cocooning), signs of 
intestinal obstruction either acute or subacute, failure of peritoneal ultrafiltration 
capacity and a rapid rise in small solute peritoneal transport.  
EPS is not only associated with PD, but it is also associated with other 
conditions such as systemic autoimmune disease, gastrointestinal tract diseases, 
malignancies involving the peritoneum or intra-abdominal organs, exposure of 
the peritoneum to talc or particulate material, peritoneal lavage by intraperitoneal 
disinfectant, and administration of β-blockers (Kawanishi and Moriishi 2005).  In 
animal models, infusing a variety of intraperitoneal sclerosing agents can induce 
peritoneal sclerosis as well as encapsulation (Hoff 2005).  Adenovirus can be 
used to introduce pro-fibrotic agents to the peritoneum of the animal models (Hoff 
and Margetts 2006).  The differential diagnosis for EPS includes tuberculous 
peritonitis, small bowel lymphoma especially after transplantation, carcinomatosis 
and peritoneal mesothelioma (Augustine, Brown et al. 2009). 
1.6.7 Imaging techniques 
1.6.7.1 Computed tomography scan (CT scan) 
The CT scan is useful for diagnosis, but not screening.  Abdominal CT 
could be normal in up to 50% of EPS patients up to two years before diagnosis 
(Tarzi, Lim et al. 2008).  There are peritoneal abnormalities (thickening and 
enhancement being most common) in approximately 7% of patients, who are on 
long-term PD, but without developing EPS (Stafford-Johnson, Wilson et al. 
1998).  Despite all of the above, CT scanning of the abdomen is the investigation 
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of choice for those patients with established EPS (Stafford-Johnson, Wilson et al. 
1998, George, Al-Zwae et al. 2007).  The progression of EPS can be monitored 
by abdominal CT. 
The CT scan findings show peritoneal enhancement following the 
administration of intravenous contrast media (Figure 1.5) and it is usually 
accompanied with peritoneal thickening.  The differential diagnoses of peritoneal 
enhancement and thickening are peritoneal carcinomatosis, pseudomyxoma 
peritoneii, tuberculosis in addition to EPS.  There could also be peritoneal 
calcification and bowel tethering.  Bowel tethering is due to fibrosis in the 
mesenteric root as well as previsceral membrane formation.  Bowel tethering and 
peritoneal calcification are more specific radiological features than others.  Other 
CT features are bowel wall thickening and dilatation with or without obstruction 
(Stafford-Johnson, Wilson et al. 1998, George, Al-Zwae et al. 2007, Tarzi, Lim et 
al. 2008).  
 
    
Figure 1.5 A CT scan of a 
patient with established EPS 
Various diagnostic features of EPS by 
CT scan.  .  It is reproduced by 
permission of the Karger Publishers.  
Copyright © 2009, Karger Publishers 
(Augustine, Brown et al. 2009) 
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1.6.7.2 Other imaging techniques  
Ultrasound findings include increase of intestinal peristalsis, tethering of the 
bowel, visualisation of a previsceral membrane and ascites (Krestin, Kacl et al. 
1995).  The main feature in barium studies is delayed transit with possibility of 
sudden change in calibre in the joining point of normal and encapsulated bowel 
segment and disconnection of rigid bowel loops with disordered peristalsis 
(Holland 1990, Krestin, Kacl et al. 1995).  MRI is not particularly useful because 
of poor assessment of peritoneal calcification.  Furthermore, there is a risk of 
nephrogenic systemic fibrosis in dialysis patients, if gadolinium used as a 
contrast in MRI. 
1.6.8 Management   
There are some evidence-based management regimens for EPS.  There 
are case reports and clinical series rather than randomized controlled trials.  
Reported treatments include the use of steroids in the early ‗inflammatory‘ phase 
(Kawanishi, Kawaguchi et al. 2004), immunosuppressants (Junor and McMillan 
1993, Rigby and Hawley 1998, Rajani, Smyth et al. 2002, Lafrance, Letourneau 
et al. 2008), tamoxifen (an estrogen receptor antagonist) (Allaria, Giangrande et 
al. 1999, Summers, Clancy et al. 2005, Eltoum, Wright et al. 2006, Moustafellos, 
Hadjianastassiou et al. 2006), nutritional support, and surgery including 
enterolysis/adhesiolysis to remove the fibrotic material (Kawaguchi, Saito et al. 
2005).  In established EPS, surgery is possibly the only definitive line of 
treatment at the current time (Kawanishi, Moriishi et al. 2006).  The surgery is 
difficult and requires to be conducted by a surgeon with expertise in EPS 
(Yamamoto, Otsuka et al. 2005).  EPS requires multidisciplinary input including a 
nephrologist, dietitian, gastroenterologist and surgeons.  Management includes 
medication, nutritional support, control of the symptoms control and surgery 
(Spence, Gillespie et al. 2013) 
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1.6.9 Prevention  
It is necessary to understand the aetiology of EPS as this will lead to better 
ways to reduce the risk of developing EPS for patients on PD (Mactier 2000).  
Preserved residual renal function, low glucose exposure, low small solute 
transport status, and little or no peritoneal infection may give a lower individual 
risk.  It is important to minimise glucose exposure and peritonitis rates.  
According to Japanese data, the incidence rate of EPS is markedly increased 
after 8 years on PD.  Pre-emptive discontinuation of PD is recommended at this 
stage (Kawaguchi, Saito et al. 2005).  The problem is that discontinuation of PD 
by itself is a risk factor for some patients developing EPS (Fieren, Betjes et al. 
2007).  Therefore the decision to discontinue PD is an individual decision and is 
based on a balance of risks.  For example a younger PD patient with lower co-
morbidity who starts PD during young age is at more risk to develop EPS and 
this influences the clinical decision. 
1.7 Factors associated with peritoneal fibrosis 
The human bodies‘ responses to acute and chronic wounding are very 
different.  In chronic wound, there are continuous insults to organs leading to 
what most people believe is an aberrant unresolved wound response with 
perpetual inflammation in contrast to acute wounding which fully resolves.  The 
unresolved nature of chronic wounding leads to a total remodeling of the organ in 
an attempt to protect it from the continuous insult.  This remodeling in itself is 
ultimately harmful as the formation of scar tissue on such a gross level affects 
architecture and thus organ function. 
Peritoneal fibrosis has many similarities to fibrosis in other organs.  There 
are major pathological changes in the peritoneal fibrosis such as.  First, there are 
chronic inflammatory responses to the peritoneal dialysate fluid.  Second, there 
are a proliferation and activation of fibroblasts which have multiple sources that 
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produce a large amount of interstitial ECM proteins.  Third, there are changes in 
cytokine and growth factor signaling in response to the above.  Fourth, there are 
metabolic changes to the glucose and ROS that alter cellular signaling and 
biology.  Fifth, there are loss of MCs and a change in their biology.  Finally, there 
are changes in ECM processing and deposition to stabilize the peritoneal 
membrane.  The following changes are described in more detail below (sections 
1.7.1 – 1.7.7 and 1.8).  There are also major fibrosis contributors such as 
inflammation, profibrotic signaling, aberrant ECM processing (low clearance with 
elevated ECM deposition), fibroblast proliferation, ROS generation, and cellular 
death. 
1.7.1 Epithelial to mesenchymal transition (EMT)  
 EMT is a potential mechanism whereby the epithelial cell de-differentiates 
into a mesenchymal cell via a complex process.  The event begins by the 
dissociation of intercellular junctions and loss of microvilli followed by loss of 
apical-basal polarity.  Finally, there is basement membrane degradation and 
invasion with up-regulation of MMPs (Aroeira, Aguilera et al. 2007).  
Myofibroblastic cells may arise from conversion of mesothelial cells (MCs) 
through EMT during PD (Margetts, Bonniaud et al. 2005).  Transdifferentiated 
MC may play a crucial role in the beginning of fibrosis and subsequent decline of 
peritoneal function (Aroeira, Aguilera et al. 2007).   More details on EMT are 
illustrated in (section 6.1.4).  
1.7.2 Myofibroblasts in peritoneal fibrosis 
After peritoneal injury, myofibroblasts can also accumulate in the 
peritoneum as a consequence of activation and proliferation of resident 
fibroblasts in the peritoneum, infiltration and proliferation of circulating and 
resident fibrocytes, transformation of local pericytes, mesenchymal transition and 
dedifferentiation of peritoneal MCs, mesenchymal transition and dedifferentiation 
27 
 
of endothelial cells, and differentiation of local mesenchymal stem cells 
(Abraham, Eckes et al. 2007, Liu, Dong et al. 2015, Witowski, Kawka et al. 
2015). 
Myofibroblasts represent a subset of the fibroblast population that are highly 
activated, producing large quantities of ECM proteins, are highly proliferative and 
invasive. They are believed to be involved in various scarring and fibrotic 
diseases, where they play an important role in the fibrotic process after the initial 
of the injury.  In acute and resolving wounding, Myofibroblasts will undergo 
apoptosis after the tissue integrity has been adequately restored.  (Darby, Skalli 
et al. 1990, Desmouliere, Redard et al. 1995).  However, myofibroblasts fail to 
undergo apoptosis in many scarring and fibrotic conditions thus providing a much 
higher percentage of the cell population and this contributes significantly to the 
fibrosis (Aarabi, Bhatt et al. 2007, van der Veer, Bloemen et al. 2009).  
Myofibroblasts apoptosis is controlled by a decline in the local growth factors 
which sustain and drive differentiation in the myofibroblasts.  In particular, 
endothelin-1 and TGF-β1 local concentrations play an important role in the 
myofibroblast survival by activation of the protein kinase B (AKT) (Kulasekaran, 
Scavone et al. 2009). 
Peritoneal fibrosis is much less well characterised than fibrosis in many 
other organs, but it is likely that many of the processes described above do play 
key roles in peritoneal fibrosis.  Recent in vitro studies have suggested that MCs 
to be an important source of myofibroblasts via epithelial to mesenchymal 
transition (EMT), but there are no in vivo studies to support this currently.  
Duffield and colleagues used primary cultures of MCs and submesothelial 
fibroblasts that were expressing alpha smooth muscle actin under a TGFbeta-1 
stimulus.  In these studies alpha smooth muscle actin was only expressed in the 
submesothelial fibroblasts after peritoneal fibrosis induction in mice (Chen, 
Chang et al. 2014).  In renal fibrosis, blockade of platelet-derived growth factor 
(PDGF) receptor signaling decreases the numbers of myofibroblast and 
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decreases renal fibrosis (LeBleu and Kalluri 2011).  In peritoneal fibrosis, PDGF 
receptor expressed by submesothelial fibroblasts was antagonised 
pharmacologically and this led to a reduced the peritoneal fibrosis (Chen, Chang 
et al. 2014). 
Numerous studies have suggested that MCs are the main source of 
myofibroblasts through the EMT process (Yanez-Mo, Lara-Pezzi et al. 2003, 
Yang, Chen et al. 2003, Margetts, Bonniaud et al. 2005, Patel, West-Mays et al. 
2010, Bajo, Pérez-Lozano et al. 2011).  These are in vitro experiments only 
which is limiting in translatability, but they do suggest that MCs can be stimulated 
to express alpha smooth muscle actin and are thus taking on a fibroblastic 
phenotype with associated matrix protein production under a TGFbeta-1 driver 
(Wong, Phillips et al. 2003, Yanez-Mo, Lara-Pezzi et al. 2003, Yang, Chen et al. 
2003, Margetts, Bonniaud et al. 2005, Bajo, Pérez-Lozano et al. 2011) .  
1.7.3 Heat shock protein 47 (HSP47)  
HSP47 presence has been implicated in different fibrotic disorders including 
fibrotic peritoneal tissue obtained from patients on PD (Shioshita, Miyazaki et al. 
2000), peritoneal fibrosis in rats induced by chlorhexidine gluconate (CG) 
(Mishima, Miyazaki et al. 2003), kidney scarring (Razzaque, Ahsan et al. 2000), 
liver fibrosis (Masuda, Fukumoto et al. 1994), and lung fibrosis (Iwashita, Kadota 
et al. 2000).   
The degree of HSP47 expression shows a significant relationship with 
collagen types I and III accumulation in humans and with peritoneal fibrosis 
induced by CG (Miyazaki and Yuzawa 2005).  Changes induced by CG in the 
expression of HSP47, α smooth-muscle actin and collagen types I and III are 
abrogated by HSP47 anti-sense oligonucleotides.  In addition, the number of 
infiltrating vessels and macrophages are reduced after suppression of HSP47 
(Nishino, Miyazaki et al. 2003).  
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 1.7.4 Angiotensin II   
Angiotensin II has a variety of biological activities, including cell 
proliferation, collagen synthesis, promotion of macrophage infiltration, and 
induction of many cytokines and growth factors (Luft 2002, Suzuki, Ruiz-Ortega 
et al. 2003).  Angiotensin II may also play a role in peritoneal fibrosis.  The 
possible benefit of using angiotensin converting enzyme inhibitors (ACEI) and 
angiotensin II type 1 receptor blockers for the prevention and/or therapy of 
peritoneal fibrosis remain to be determined.   
In an experimental animal model, peritoneal fibrosis was induced by 
injection of CG, then angiotensin II modulated by benazepril (ACEI) and 
candesartan (angiotensin II type 1 receptor blocker) (Abe, Miyazaki et al. 2002, 
Miyazaki and Yuzawa 2005).  The effect of Angiotensin II inhibition reduced the 
number of CD31+ vessels, the thickness of the submesothelial tissue, and 
expression of Transforming Growth Factor-β (TGFβ) and vascular endothelial 
growth factor (VEGF).  In another experiment the inhibition of ACE ameliorated 
peritoneal fibrosis in mice (Sawada, Ishii et al. 2002).   
In humans, little is known about the effects of ACEI and ARB in PD patients.  
There are some studies on effects of these drugs on peritoneal membrane 
transport.  These studies are divided into short-term and long-term.  One of the 
short-term studies showed a decline in peritoneal protein loss in CAPD patients 
treated with captopril (ACEI) (Coronel, Hortal et al. 1989), and irbesartan (ARB) 
(Coronel, Berni et al. 2004).  In contrast, another study showed higher β2-
microglobulin and peritoneal clearances of creatinine in enalapril (ACEI) treated 
PD patients in comparison to clonidine and nifedipine treatment (Favazza, 
Motanaro et al. 1992).  Other short-term studies were unable to show any effect 
of losartan or enalapril on peritoneal membrane transport in CAPD (Ripley, Gehr 
et al. 1994, Rojas-Campos, Cortes-Sanabria et al. 2005).  More studies with long 
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follow-up are needed to resolve this difference of results between different 
research groups (Kolesnyk, Struijk et al. 2010).   
1.7.5 Growth factors and cytokines 
Several key fibrogenic cytokines have been identified in tissue scarring.  
Most notable amongst them is TGF1, which has been found in numerous types 
of fibrosis (Cutroneo 2007).  TGF1 has been shown to have a direct effect on 
peritoneal fibrosis (Margetts, Kolb et al. 2001).  TGF1 is unique in that it cannot 
only induce numerous ECM components such as collagen I and III, but also 
decrease the transcription of several MMPs (Yan and Boyd 2007) and elevate 
the expression of several TIMPs (Cotton, Herrick et al. 1998) as well as both 
PAI1 and 2 (Willis and Borok 2007, Samarakoon, Higgins et al. 2008).  Further, 
TGFβ1 can induce EMT and cause fibroblast proliferation (Willis and Borok 
2007).  
 Peritoneal thickening is induced by gene transfer of TGFβ, and this 
thickening is resolved naturally.  Decorin is a natural inhibitor of TGFβ, that can 
prevent TGFβ-induced peritoneal thickening (Honda, Nitta et al. 2003).  There is 
some evidence to suggest that fibroblast growth factor (FGF) and TGFβ1 play a 
role in both PS & EPS (Mlambo, Hylander et al. 1999, Honda, Nitta et al. 2003).  
During PD there is production of VEGF, which plays an essential role in 
peritoneal neoangiogenesis and decline in PD function (Aguilera, Yanez-Mo et al. 
2005).  Other signaling molecules have also been ascribed roles in tissue 
scarring including platelet-derived growth factor (PDGF) (Floege, Eitner et al. 
2008), insulin-like growth factor 1 (IGF-1) (Krein and Winston 2002) and tumor 
necrosis factor-alpha (TNF-α) (Tilg 2001).  Dialysate which contains glucose and 
glucose degradation products may trigger VEGF and TGF-β1 production by 
mesothelial cells.  TGF-β1, which is a strong pro-fibrotic factor, will affect 
mesothelial cells by inducing EMT (Aguilera, Yanez-Mo et al. 2005).  
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Growth factors have a major effect on the protein levels of ECM, but the 
same growth factor may causes difference responses from a range of cell types.  
A growth factor may lead to increased deposition of ECM in some cell types, 
however the same growth factor may also lead to decreased deposition of ECM 
in other cell types (Ito, Aten et al. 1998).  Cell signaling is triggered by various 
growth factors and cytokines such as TNF-α, TGF-β, interferons, and 
interleukins.  Cell signaling causes activation of promoters for MMPs (Yan and 
Boyd 2007).  TGFβ can work with other growth factors to produce a synergistic 
effect such as TNFα.  TGFβ alone is able to induce production of collagen to 
around 25% of its maximum.  TNFα alone can also induce the production of 
collagen to around 25% of its maximum.  TGFβ and TNFα together maximally  
induce production of collagen to around 100%, although their levels were less 
than maximum level of TGFβ and TNFα independently (Border 1994). 
1.7.6 The role of inflammation in peritoneal fibrosis  
The role of inflammation in the development of peritoneal fibrosis remains 
unclear.  Histologically, advanced peritoneal fibrosis demonstrated little infiltration 
by macrophages.  Elevation in levels of interleukin-1β (IL-1β) and interleukin-6 
(IL-6) are seen in the ascites of EPS patients and also in an animal experimental 
model of EPS (Imai, Nakamoto et al. 2003, Masunaga, Muto et al. 2003).  
Expression of adhesion molecules was observed in the peritoneum of rats with 
EPS  in conjunction with an increase of IL-6 in the dialysate (Imai, Nakamoto et 
al. 2003).  Gene transfer of TNFα and IL-1β into rat peritoneum caused an 
increased peritoneal inflammatory cell infiltration, particularly by neutrophils 
(Margetts, Kolb et al. 2002).  However, peritoneal membrane thickening induced 
by TNFα eventually resolved and the membrane returned to normal.  In contrast, 
peritoneal membrane thickening associated with IL-1β did not return to normal.  
Net ultrafiltration declined in both TNFα and IL-1β induced rats, however UF 
returned to normal levels in the TNFα group, but remained low in the IL-1β 
induced rats (Miyazaki and Yuzawa 2005). 
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  1.7.7 The roles of proteolytic enzyme systems in fibrosis: 
Excessive extra cellular matrix accumulation can lead to fibrotic diseases in 
most organs such as the kidney  (Johnson, Haylor et al. 2002) and is this likely to 
also occur in peritoneal fibrosis.  Shutdown of proteolytic enzymes or over 
expression of their inhibitors will lead to ECM accumulation.  Different studies 
have shown changes in the MMP and plasmin systems in PD.  These may be 
useful as markers of increased solute transport, peritoneal injury or progression 
to EPS.  Matrix metalloproteinases, cysteine/aspartic proteases and the serine 
proteases (e.g. plasmin) are the main proteolytic enzyme systems.  An 
understanding of ECM metabolism is an important building block in exploring the 
role of these agents in fibrosis.   
1.8 The Extracellular Matrix  
1.8.1 Structure and Function of the ECM 
The ECM is a multi-component protein material found outside the cell.  It 
has several functions such as structural support, extracellular feedback, 
formation of basement membrane, storage of growth factors such as TGFβ1, cell 
adhesion and a role in the wound healing response (Levey, Eckardt et al. 2005).  
Components of ECM are synthesized intracellularly then passed extracellularly 
for assembly.  The balance between matrix degradation and synthesis is crucial 
to preserve the function of matrix and the balance of tissue homeostasis (Figure 
1.6).   
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1.8.2 Components of ECM 
The ECM may take different forms in various organisms and tissues, but it 
has a tendency to be composed of similar components of macromolecules 
(Figure 1.7) (Gerald 2013).  The ECM consists of structural proteins such as 
collagens which are complemented by more specialized proteins such as elastin 
which can convey flexible properties.  Fibronectin is involved in adhesion and 
proteoglycans are the key in determining charge.   
 
Figure 1.6 ECM synthesis and deposition 
Components of ECM are synthesized intra-cellularly then passed extracellularly for deposition.  Some of 
the collagen is degraded prior to deposition.  Once deposited 2 main systems degrade the ECM.  These 
are the MMP and Plasmin system. Each has its own regulatory system.  MMP activity is inhibited by 
TIMPs, while plasminogen activator inhibitors (PAIs) prevent the activation of plasminogen.  Note TG2 
is abbreviation for (Transglutaminase type 2). 
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1.8.2.1 Collagens 
Collagen molecules have  a helical structure consisting of three polypeptide 
chains coiled around each other in a triple helix (Alberts, Johnson et al. 2002).  
Fibrils are formed from staggered arrays of collagen molecules that are arranged 
to form collagen fibers (Figure 1.8) (Buehler 2006).  Collagens in general are the 
most abundant proteins in mammals, especially collagen I (Di Lullo, Sweeney et 
al. 2002).  Collagens vary in α chain composition of amino acids.  So far 29 types 
of collagens have been described.  Collagen I, II, III and IV form over 90% of 
body collagen.  Localization of different types of collagen varies: for example, 
type I collagen is located in skin, tendon, bone, etc., type II collagen is located in 
cartilage, vitreous humor, type III collagen is located in skin, muscle, and type IV 
collagen located in basal lamina; eye lens, and basement membranes, including 
the glomerular, tubular basement and peritoneal membranes (Williams, Craig et 
 
Figure 1.7 An overview of the extracellular matrix macromolecular organisation 
The proteins shown are collagen, laminin and fibronectin.  They contain sites for binding with each 
other, in addition to the binding sites for the integrins.  Integrins are receptors which are located at the 
cell surface and are involved in cell adhesion, out-in cell communication and growth factor 
recruitment/activation.  Large protein–polysaccharide complexes can form through the ECM which are 
typically formed of proteoglycans such as perlecan and syndecans.  .  It is reproduced by permission of 
the John Wiley and Sons Publishers (Gerald 2013). 
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al. 2003).  Type III collagen is frequently associated with type I collagen and they 
are known as interstitial collagens.  Type IV collagen is composed of three α 
chains interrupted at several sites via non-collagenous sequences allowing 
collagen IV to self-associate with other components of ECM.  This provides 
highly specialized characteristics of the basement membrane (Costigan, 
Chambers et al. 1995).  Interstitial collagens are mainly synthesized by 
fibroblasts, with basement membrane collagens produced by epithelial and 
endothelial cells.   
 
1.8.2.2 Elastin 
Elastin is a structural protein in the ECM with elastic properties.  It plays a 
role in stretch and recoil for example in alveoli of lungs, arteries, and skin.  In 
elastin, the arrangement of fibrous proteins is somewhat amorphous (i.e. relaxed 
cross-linked coils) arrangement, while the arrangement in collagen is dense 
fibrous bundles (Alberts, Johnson et al. 2002). 
 
Figure 1.8 Schematic view of some of the hierarchical structure of collagen 
Structure commences at the amino acid sequence level (nanoscale) with generation of the individual 
alpha chains, which generate a triple helix that amass to form fibrils or nets which can amalgamate to 
create collagen fibers with lengths on the order of 10 μm.  It is reproduced by permission.  Copyright 
(103) National Academy of Sciences, U.S.A. (Buehler 2006). 
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1.8.2.3 Proteoglycans  
Proteoglycans are formed by linkage between core proteins and 
glycosaminoglycans (GAGs).  GAGs are side chains/sugars on proteoglycans.  
The structure of proteoglycans is a brush-like structure due to the extension of 
GAGs perpendicularly from the core.  A specific tetrasaccharide is involved in the 
linkage between GAGs and the protein core.  This tetrasacharide is composed of 
a xylose residue, two galactose residues, and glucuronic acid (Figure 1.9).  The 
O-glycosidic bond links a tetrasaccharide and a serine (S) residue in the protein.  
Some forms of keratan sulfates link to the protein core through an N-asparaginyl 
bond.  Multiple GAGs attach to the protein cores of proteoglycans because these 
cores are rich in both serine (S) and threonine (T) residues. 
Glycosaminoglycans (Figure 1.9) are long unbranched polysaccharides and 
they include repeating disaccharide units.  Glycosaminoglycans are the most 
abundant heteropolysaccharides in the body.  The disaccharide units include 
either N-acetylglucosamine (GlcNAc) or N-acetylgalactosamine (GalNAc) 
(modified sugars), and uronic acids such as iduronate or glucuronate.  GAG 
molecules are highly negatively charged.  They are located primarily in the 
extracellular matrix or on the surface of cells.  These molecules confer high 
viscosity and low compressibility.  In addition, they provide rigidity and which 
gives  structural integrity to cells as well as forming passageways between cells 
to allow cell migration (Alberts, Johnson et al. 2002).  In membranes such as 
glomerular basement membrane (GBM), proteoglycans provide a negative 
charge through their glycosaminoglycans side chains (Fischer, Mougenot et al. 
2000). 
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1.8.2.4 Laminin 
Laminins are glycoproteins.  Laminin is an integral part of almost every 
tissue and it is vital for their maintenance and survival.  Structurally, laminin 
consists of three polypeptide chains (alpha, beta, and gamma chain subunits).  In 
basement membranes laminins provide an integral part of the supporting 
structure of the membranes by binding to other macromolecules in the ECM.  
Laminins have unique and shared interactions with cells, mediated by 
dystroglycan, integrins and other receptors.  Cell interactions give laminins the 
ability to contribute to cell differentiation, cell movement, cell shape, maintenance 
of tissue phenotypes and promotion of tissue survival (Colognato and Yurchenco 
2000). 
1.8.2.5 Fibronectin 
A high molecular weight glycoprotein, fibronectin is also involved in 
interaction with different macromolecules of the ECM.  It is involved in basement 
membrane assembly by acting as a scaffold protein to assist matrix deposition 
(Czirok, Zamir et al. 2006).  Fibronectin contains at least 6 firmly folded domains.  
Each of these domains has a high affinity for different substrates such as 
 
Figure 1.9 Structure of proteoglycans 
This diagram demonstrates  the linkage between glycosaminoglycan and protein core through 
tetrasaccharide link.   
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collagen, heparin sulfate, fibrin, and cell surface receptors (Magnusson and 
Mosher 1998).  Fibronectin connects cells with collagen fibers, allowing 
movement of the cells through the ECM.  It binds cell surface integrins and 
collagen, causing a reorganization of the cytoskeleton and facilitating cell 
movement.  In addition, fibronectin assists at the site of tissue injury during 
wound healing by binding to platelets.  This leads to blood clotting and facilitating 
movement of the cells to the affected area (Lewin 2007). 
1.8.3 ECM accumulation 
The ECM is in a continual state of turnover and under normal 
circumstances there exists a homeostatic balance between the rate of synthesis 
and deposition of ECM and its breakdown and clearance.  If an imbalance 
occurs, this can lead to either ECM accumulation (such as may occur in kidney 
fibrosis) (Lenz, Elliot et al. 2000) or ECM loss.  ECM accumulation can be due to 
increase in ECM synthesis due to qualitative and quantitative changes, as well as 
increased deposition and stabilization or decreased breakdown. 
1.8.3.1 Increased synthesis and changes of ECM components   
Increase in synthesis of ECM components such as collagens, elastin, and 
fibronectin to a greater extent than degradation will lead to ECM accumulation.  
The formation of scar tissue is also associated with a change in ECM 
composition.  Collagen production increases with a relative increase in collagen 
types I and III as a percentage of the total collagen load (Johnson, Fisher et al. 
2007).  The regulation of ECM processing is controlled at many levels from 
response to metabolic, oxidative or physical stress to tissue tension.  Often 
changes in the cell type can be the key to changes in ECM characteristics.  In 
many cases, growth factors and cytokines are mediators of either production of 
ECM related molecules or changes in cell types. 
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1.8.3.2 Stabilisation of ECM     
Stabilisation of the ECM to proteolytic decay favours ECM accumulation. 
Collagen fibrils can be stabilised by enzymes such as tissue transglutaminase 
(TG2) and lysyl oxidase.  Up-regulation of these enzymes in disease will lead to 
ECM accumulation, with both lysyl oxidase and TG2 being implicated (Kagan 
1994, Kagan 2000, Fisher, Jones et al. 2009).  In addition TG2 released into the 
ECM during the wound response can accelerate the deposition of ECM 
components by short circuiting the standard deposition pathways (Telci and 
Griffin 2006).  TG2‘s ability to both stabilize and accelerate ECM deposition is 
normally part of an efficient wound response, however when the wounding 
becomes chronic then the non-resolving elevated levels of TG2 are central to 
fibrotic disease. 
1.8.3.3 Deposition and Degradation of the ECM 
1.8.3.3.1 Deposition of the ECM 
Matrix deposition increases, if syntheses of the ECM components go up or 
if the mechanisms essential for the deposition for these components are up 
regulated (Bennett and Schultz 1993).  The collagens are synthesised de novo.  
The collagen and pro-peptides are making up the ECM.  They are mainly 
controlled by cytokines and growth factors such as TGF 1.  The other inducer 
for de novo synthesis is induced by feedback from the ECM (Bennett and Schultz 
1993). 
1.8.3.3.2 Degradation of the ECM 
ECM breakdown is by three main proteolytic enzyme systems.  These 
systems are matrix metalloproteinases, cysteine/aspartic proteases and the 
serine proteases (e.g. plasmin).  They are the main proteolytic enzyme systems 
responsible for the degradation of extracellular matrix (Figure 1.6).  There are 
other molecules involved in the ECM breakdown.  For instance, phagocytes 
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control the deposition of the ECM components by removing apoptotic 
myofibroblasts (Douglass, Wallace et al. 2008).  Moreover, macrophages slow 
the progression of fibrosis by removing extra collagen from damaged tissues or 
scared tissue (Atabai, Jame et al. 2009).  The ADAMTSs play role in the 
breakdown of the ECM and this is explained in more detail in (section 1.8.4.4). 
1.8.3.4 Impairment of ECM degradation 
Net accumulation of ECM will increase if there is impairment of degradation.  
Excessive ECM accumulation can occur, for example as a result of shutdown of 
ECM proteolytic enzymes.  This can be due to lower synthesis, failure to be 
converted to an active form or the presence of their natural inhibitors (Johnson, 
Haylor et al. 2002).  
1.8.4 Proteolytic enzyme systems and their inhibitors 
1.8.4.1 Matrix metalloproteinases (MMPs) 
MMPs are a closely related family of  zinc-dependent endoproteinases (Van 
Lint and Libert 2007).  To date, at least 25 different vertebrate MMPs (23 in 
humans) have been identified.  They are either anchored to the plasma 
membrane or secreted from the cell.  MMPs can degrade ECM components 
involved in many essential processes such as  cell proliferation, differentiation, 
migration and even cell death, in addition to cell–cell interactions (Elkington, 
O'Kane et al. 2005).  MMPs also have many non-matrix substrates.  For 
example, chemokines, growth factors, and receptors.  This shows that MMPs 
have role in a wide range of physiological and pathological processes (McCawley 
and Matrisian 2001).  Dysregulated inflammatory conditions are often associated 
with increased MMP activities (Parks, Wilson et al. 2004).   
MMPs consist of three domains: pro-peptide, catalytic and the haemopexin-
like C-terminal (Figure 1.10) (Lafleur, Handsley et al. 2003).  The last two 
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domains are connected by a flexible hinge region.  The significance of MMP 
types varies between organ types.  For example in the kidney, MMPs 1, 2, 3, 8, 
9, and 13 have significant expression (Lenz, Elliot et al. 2000).  MMPs play a 
significant role in several biological processes, such as normal tissue remodeling, 
embryogenesis, angiogenesis, and wound healing.  They also have been 
implicated in diseases such as arthritis, atheroma, tissue ulceration and cancer.  
MMPs can be classified into six groups by their domain organization, substrate 
specificity and sequence similarity (Figure 1.10) (Lafleur, Handsley et al. 2003).  
These groups are described below.   
1.8.4.1.1 Interstitial Collagenases 
These enzymes have the ability to preferentially breakdown interstitial 
collagens I, II, and III by cleavage of these collagens at a specific cleavage points 
towards(three fourths from the N-terminus) (Visse and Nagase 2003).  In 
addition, interstitial collagenases can digest other ECM molecules such as 
collagens VII and X (Collier, Bruns et al. 1991).  Interstitial collagenases have the 
ability to degrade triple-helical fibrillar collagens in to distinctive ¾ and ¼ 
fragments.  The majority of degraded collagen fragments come from the major 
components of cartilage and bone.  Interstitial collagenases include MMP-1, 
MMP-8, and MMP-13.  MMP 14 (an MT-MMP) and MMP2 (a gelatinase) have 
some similarities to interstitial collagenases (Aimes and Quigley 1995, Ohuchi, 
Imai et al. 1997).  The distinctive ¾ and ¼ fragments are unstable at normal body 
temperature and thus can be readily cleared.  Aberrant collagen degradation may 
cause atherosclerosis, arthritis, cancer and fibrosis (Woessner 1998, Brinckerhoff 
and Matrisian 2002).   
MMP1 needs a catalytic domain and a hemopexin domain to cleave the 
triple helix (Clark and Cawston 1992).  In rodents, MMP-1 is absent and its role is 
taken by MMP-13.  MMP8 is a neutrophil collagenase and is present in the 
connective tissue in most mammals.   It can degrade interstitial collagenases 
(collagens I, II and III) (Hasty, Pourmotabbed et al. 1990) and process 
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interleukin-8 (Tester et al., 2007).  MMP13 is cleaves type II collagen better than 
I or III.  It has been ascribed a role in breast carcinoma as well as osteoarthritis 
(Freije, Diez-Itza et al. 1994).  The collagenases have other functions such as 
processing insulin-like growth factor binding proteins and protease-activated 
receptor-1 (Overall, McQuibban et al. 2002, Boire, Covic et al. 2005). 
1.8.4.1.2 Gelatinases 
This group includes gelatinase A (MMP-2) and gelatinase B (MMP-9).  
Gelatinases have a fibronectin type II insert within their catalytic region.  This 
insertion makes MMP-2 and MMP-9 different from other MMPS conveying 
membrane adhesive properties to gelatinases assisting attachment to basement 
membranes to facilitate degradation (Weckroth, Vaheri et al. 1996).  Gelatinases 
can degrade collagen types I, IV, VII, X, IX, fibronectin, elastin, laminin, aggrecan 
(Overall, McQuibban et al. 2002), and pro-TNF (Gearing, Beckett et al. 1995). 
1.8.4.1.3 Stromelysins 
This group includes Stromelysin 1 (MMP-3) and stromelysin 2 (MMP-10).  
The stromelysins degrade many components of ECM proteins, but they are 
unable to degrade collagen I.  MMP3 has the ability to degrade several collagens 
(collagen II, III, IV, IX and X), fibronectin, proteoglycans, elastin, and laminin.  
MMP-3 has the ability to initiate MMPs 1, 7 and 9 activation (Ye, Eriksson et al. 
1996) and suggests why MMP-3 is important in tissue remodeling.  MMP-3 can 
also process pro-interleukin-1 beta and E-cadherin (Overall, McQuibban et al. 
2002).  MMP10 is important in the degradation of proteoglycans and fibronectin 
(Muller, Quantin et al. 1988).  The proteolytic efficiency of MMP-3 is higher than 
that of MMP-10.  MMP-11 is known as stromelysin 3; however it is now not 
grouped with "Stromelysins" for reasons of substrate specificity and the 
sequence divergence from those of MMP-3.  
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1.8.4.1.4 Matrilysins 
This group includes matrilysin 1 (MMP-7) and matrilysin 2 (MMP-26) (Uria 
and Lopez-Otin 2000).  The lack of a hemopexin domain is a characteristic 
feature of this group.  MMP-7 and MMP-26 digest a number of ECM 
components, such as gelatin and fibronectin (Salmela, Karjalainen-Lindsberg et 
al. 2001).  MMP-7 also processes cell surface molecules such as pro–tumor 
necrosis factor (TNF)-α, pro–α-defensin, Fas-ligand, and E-cadherin.  Matrilysins 
are also known as the minimal-domain MMPs because the C-terminal 
hemopexin-like domain is present in all MMPs except matrilysins (Bode 1995, 
Stamenkovic 2003). 
1.8.4.1.5 Membrane-Type MMPs (MT-MMPs) 
This group is subdivided to: type I transmembrane proteins that include 
(MMP-14, MMP-15, MMP-16, and MMP-24), and glycosylphosphatidylinositol 
(GPI) anchored proteins that include (MMP-17 and MMP-25).  All MT-MMPs 
except MT4-MMP (MMP-24) are capable of activating MMP-2.  They can digest a 
number of ECM molecules such as gelatin, laminin, and fibronectin (Jones, Sane 
et al. 2003).  In addition MT1-MMP (MMP-14) digests type I, II, and III collagens 
(Ohuchi, Imai et al. 1997). 
1.8.4.1.6 Other MMPs 
Some MMPs are not classified in any groups mentioned above.  These 
include MMP-12, MMP-19, MMP-20, MMP-22, MMP-23, and MMP-28.  
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Figure 1.10 Structure-dependent subgrouping of the MMPs 
(a) Variable structural domains of MMPs.  (b) Subgroupings based on structural domains.  Most 
MMPs (with the exception of MMP-7, MMP-23A/B and MMP-26) contain a C-terminal 
haemopexin domain and a hinge region.  Other MMP subgroups contain unique features such 
as: a transmembrane domain, cytoplasmic tail and a membrane-type (MT)-loop (MT1-, MT2-, 
MT3- and MT5-MMP; also known as MMP-14, MMP-15, MMP-16 and MMP-24, respectively); a 
glycosylphosphatidylinositol (GPI) anchor (MT4-MMP and MT6-MMP; also known as MMP-17 
and MMP-25, respectively); a furin recognition site (MT-MMPs, and MMP- 11, -21, -23A/B and -
28); fibronectin type II repeats (MMP-2 and -9); and an N-terminal signal anchor, a cysteine 
array and an Ig-like domain (MMP-23).  It is reproduced by permission of the Cambridge 
University Press (Lafleur, Handsley et al. 2003). 
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1.8.4.2 MMP Regulation 
MMPs are not only regarded as proteinases of matrix catalysis, but also 
regarded as extracellular processing enzymes which are involved in a range of 
different processes for example cell-cell signaling (Vu and Werb 2000, Page-
McCaw, Ewald et al. 2007).  MMPs are regulated at four points.  These points 
are gene expression, compartmentalization, activation and inactivation of 
enzyme (Ra and Parks 2007).  In addition to that, they are controlled via 
substrate availability and substrate affinity.  In general, MMP activity is higher in 
organs that are rich in basement membrane. 
1.8.4.2.1 The Cysteine Switch. 
MMPs are synthesized in a large latent form (pro-MMPs) which requires 
activation.  Cysteine residue 73 (Cys73) is present in the propeptide which acts 
as a stabilizer of the proenzyme (Springman, Angleton et al. 1990, Van Wart and 
Birkedal-Hansen 1990) via interaction with a Zn2+ in the catalytic domain (Figure 
1.11) (Snoek-van Beurden and Von den Hoff 2005).  Activation of MMPs involves 
breakdown of this Cys73- Zn2+ bond.  This mechanism is called ―the cysteine 
switch‖ (Springman, Angleton et al. 1990, Van Wart and Birkedal-Hansen 1990).  
Here a water molecule must bind to the Zn2+ ion causing dissociation of the Zn2+ 
- cysteine bond.  This leads to partial activation of the enzyme (Springman, 
Angleton et al. 1990).  The pro-domain of the MMP is then detached via autolytic 
cleavage or via other proteases (Springman, Angleton et al. 1990, Van Wart and 
Birkedal-Hansen 1990).  This cleavage leads to a reduction in molecular mass 
and a fully active enzyme.  MMPs are generally activated via other proteinases in 
vivo, while in vitro, MMPs are also activated via chemical and physical agents 
such as low pH, aminophenylmercuric acetate (APMA) and heat treatment 
(Springman, Angleton et al. 1990, Nagase and Woessner 1999, Visse and 
Nagase 2003). 
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1.8.4.2.2 Allosteric Activation 
Cysteine-zinc forms undergo allosteric disruption, which leads to a 
transitional active state that permits pro-domain autolytic cleavage (Ra and Parks 
2007). 
1.8.4.2.3 Furin Activation 
MMPs are mostly activated by proteolysis and 1/3 of the MMPs have an 
RRKR or RXKR motif sequence and they are located in between the pro and 
catalytic domains.  Furins (a subtilisin-like serine protease) or pro-protein 
convertases target these motifs.  Furin locates in the trans-Golgi network 
(Thomas 2002).  Furin cleavage of MMPs leading to activation occurs inside 
cells, with secretion of active enzyme (Pei and Weiss 1995, Illman, Keski-Oja et 
al. 2003).   
 
Figure 1.11 The activation 
of pro-MMPs 
The activation of latent MMPs 
involves a disruption of the Cys73-
Zn
2+
 bond that results in an 
intermediate active form.  The fully 
active MMP form is formed in vivo 
through proteolysis.  MMP, matrix 
metalloproteinase.  It is reproduced 
by permission of the 
BioTechniques (Snoek-van 
Beurden and Von den Hoff 2005) 
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1.8.4.2.4 Activation of Pro-MMPs by MMPs 
Several MMPs have the ability to activate other MMPs by cleavage of the 
pro-domain of MMP zymogens.  The final proteolytic step may be mediated by 
active MMPs to yield the fully active enzyme (Nagase 1997).  
 Cleavage initially takes place courtesy of a serine protease or an MMP; 
however it is not clear if the activation is a result of direct proteolysis or of 
downstream mechanisms.  Cleavage of pro-MMP2 by MMP14 is an example of 
direct activation of Pro-MMPs by MMPs (Strongin, Collier et al. 1995, Caterina, 
Yamada et al. 2000).  The activation occurs at the cell surface in a process in 
which pro-MMP2 requires MMP14 and TIMP2 with a stoichiometric ratio of 1:1:1.  
A specific amount of TIMP2 boosts proMMP2 activation, on the other hand 
additional amounts of TIMP2 block the activation (Strongin, Collier et al. 1995, 
Worley, Thompkins et al. 2003).   
1.8.4.2.5 Activation by Plasmin 
The MMP and fibrinolytic (plasminogen/plasmin) systems work to 
breakdown most ECM components.  Some ECM components, such as 
fibronectin and laminin, are better degraded directly by plasmin (Lijnen 2001).  
MMPs also degrade other components like elastin and collagen.  However, 
several pro-MMPs are activated by the plasmin system (Galis and Khatri 2002) 
such as MMPs-1, 3, 7, 9, 10 and 13 (Amalinei, Caruntu et al. 2007).  In cell 
culture, pro-MMP2 and 9 are activated by plasmin without requiring other 
proteases (Monea, Lehti et al. 2002).  Of note, other groups showed that plasmin 
does not activate pro-MMP9 (Okada, Gonoji et al. 1992).   
1.8.4.2.6 Activation by other Serine Proteases  
Mast cell chymases is another group of serine proteases that may play a 
role in activating MMPs (Fang, Wolters et al. 1999).  Activation of pro-MMPs 2 
and 9 is decreased in mice deficient in mast cell chymase-4 (Tchougounova, 
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Lundequist et al. 2005).  MMP-1 is activated by many serine proteases such as 
trypsin, cathespin G, neutrophil elastase, chymase, and tryptase (Saunders et 
al., 2005).  
1.8.4.2.7 Oxidative Control 
Oxidants are generated by leukocytes.  Oxidative control can inactivate or 
activate MMPs.  Activation occurs by oxidation of the pro-domain thiol leading to 
and autolytic cleavage (Ra and Parks 2007).  Reactive oxygen species (ROS) 
activate a number of pro-MMPs.  Pro-MMPs 1, 7 and 9 are activated by 
hypochlorous acid (HOCl) (Fu, Kassim et al. 2001) and pro-MMPs 1, 2 and 9 are 
activated by peroxynitrate (Okamoto, Akaike et al. 1997).  High concentrations of 
HOCl also inactivate the enzyme (Fu, Kao et al. 2004).  HOCl may plays a role in 
MMPs activity regulations in an inflammatory setting (Ra and Parks 2007).  
1.8.4.2.8 Compartmentalisation  
In diseases such as chronic inflammation or cancer, all MMPs are 
expressed, however selectivity is conferred by compartmentalization and enzyme 
affinity (Ra and Parks 2007).  Some substrates are degraded by some enzymes 
better than others.  For example, type 4 collagen is degraded better by MMPs 2 
and 9 in comparison to the other MMPs (Mackay, Hartzler et al. 1990).  MMPs 
are selective catalysts in tissue, where they regulated by enzyme concentration, 
substrate concentration, and affinity. 
The location as well as means by which an MMP will be released into the 
pericellular environment is important in the proteolysis specificity.  This is called 
‗compartmentalisation‘.  For instance, the α2β1 Integrin is binding to the MMP-1 
(Dumin, Dickeson et al. 2001), αvβ3 Integrin to the MMP-2 (Brooks, Stromblad et 
al. 1996), proteoglycans to the MMP-7 (Yu and Woessner 2000), CD44 to the 
MMP9 (Yu and Stamenkovic 2000).  This may play a role as an enzyme 
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activation mediator and the recruitment of the substrate which leads to increase 
in the proteolysis (Ra and Parks 2007). 
 1.8.4.3 Tissue inhibitors of metalloproteinases (TIMPs) 
TIMPs are specific inhibitors for MMPs.  The family of TIMPs consists of 
four members;TIMP-1, TIMP-2, TIMP-3 and TIMP-4 (Ronco and Chatziantoniou 
2008).  The common feature in the TIMP family is that all have 12 cysteine 
residues that form 6 disulphide bonds.  Three of these bonds are in the N-
terminal domain, while the other three are in C-terminal domain.  The 
responsibility of N-terminal domain is to form tight but non-covalent binding with 
the active form of MMPs in a 1:1 stoichiometry. 
TIMPs 1, 2, and 4 are secreted and act in the extracellular space, whereas 
TIMP3 is bound to the ECM.  TIMPs roles are inhibiting MMP activity, stimulating 
proliferation of several cell types (Gomez, Alonso et al. 1997, Brew, 
Dinakarpandian et al. 2000, Clark, Swingler et al. 2008) and stimulating 
production of progesterone by steroidogenic cells (Boujrad, Ogwuegbu et al. 
1995, Nothnick 2003).  Regulation of proteolytic activity is made by a balance 
between active MMPs and TIMPs.  Inhibition of MMPs by excess TIMPs is 
believed to underlie tissue scarring & fibrosis (Johnson, Haylor et al. 2002).  
TIMPs also have important effects in cell proliferation, anti-apoptotic processes, 
and anti-angiogenesis.  Many of these are independent from the MMP activity 
(Brew and Nagase 2010).   
Most of ADAM and ADAMTS families are inhibited by TIMP-3 (Murphy 
2008).  TIMP-3 is different from the rest of TIMPs by it is property of tightly 
binding to the ECM (Pavloff, Staskus et al. 1992).  The rest of TIMPs have a 
limited role in inhibiting ADAMs and ADAMTS.  ADAM10 and 12 are inhibited by 
TIMPs 1 and 2 respectively (Amour, Knight et al. 2000, Jacobsen, Visse et al. 
2008).  ADAMs17 and 28 are inhibited by N-TIMP4, along with TIMP-3 
(Mochizuki, Shimoda et al. 2004, Lee, Rapti et al. 2005). 
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TIMPs have an N-terminal domain of  125 amino acids and a C-terminal 
domain of  65 amino acids.  Most of the biological functions of these proteins are 
attributable to the N-terminal domain, though the C-terminal domain mediates 
interactions with the hemopexin domains of MMP 2, 9 and with the catalytic 
domains of some MMPs (Brew, Dinakarpandian et al. 2000).  The N-terminal 
domain folds like a separate unit and is able to inhibit MMP activity (Murphy, 
Houbrechts et al. 1991).  TIMPs and their inhibitory effects are shown in (Table 
1.2) (Ahmed 2009).  The four types of TIMPs are described below. 
1.8.4.3.1 Tissue inhibitor of metalloproteinase-1 (TIMP-1) 
TIMP-1 (28 KD) was discovered in the 1970‘s and was at first considered to 
be a collagenase inhibitor (Bauer, Stricklin et al. 1975). Its name was changed to 
‗Tissue inhibitor of metalloProteinases‘ because it was found that it is inhibiting 
interstitial collagenases, proteoglycanase as well as gelatinases (Cawston, 
Galloway et al. 1981).  It is a 184 amino acid residue glycosylated protein, 
however glycosylation is not essential for activity (Schultz, Silberman et al. 1988).  
It is produced by inflammatory cells and all mesenchymal tissues (Ahmed 2009).   
1.8.4.3.2 Tissue inhibitors of metalloproteinase-2 (TIMP-2) 
The molecular weight for TIMP-2 is 21 KD.  Thirty eight percent of TIMP-2‘s 
amino acid sequence is similar to that of TIMP-1.  In addition to the role of TIMPs 
in inhibiting metalloproteinase activity, TIMP-1 and TIMP-2 have other significant 
biological functions.  TIMP-1 and TIMP-2 have cell growth–promoting activities 
(Hayakawa, Yamashita et al. 1992, Hayakawa, Yamashita et al. 1994) and 
erythroid-potentiating activity (Stetler-Stevenson, Bersch et al. 1992) 
1.8.4.3.3 Tissue inhibitors of metalloproteinase-3 (TIMP-3) 
TIMP-3 (24 KD) differs from the other members of the TIMP family by its 
potential inhibitory properties.  TIMP-3 inhibits A Disintegrin and 
Metalloproteinase-17 (ADAM-17 (TACE)) (Amour, Slocombe et al. 1998), ADAM-
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10 (Amour, Knight et al. 2000) , ADAM-12 (Loechel, Fox et al. 2000), and the 
aggrecanases (ADAMTS-4 and ADAMTS-5) (Kashiwagi, Tortorella et al. 2001).  
It has been found by kinetic studies that TIMP-3 is a better inhibitor for 
aggrecanases and ADAM-17 than for MMPs.  Another unique characteristic of 
TIMP-3 is that it attaches tightly to sulfated glycosaminoglycans (Yu, Yu et al. 
2000). 
1.8.4.3.4 Tissue inhibitors of metalloproteinase-4 (TIMP-4) 
TIMP-4 (26KD) is the most recent TIMP to be discovered.  TIMP-4 is 
structurally similar to TIMP-2 and TIMP-3 (Leco, Apte et al. 1997).  TIMP-4 binds 
with proMMP-2 in a similar way to that of TIMP-2 (Bigg, Shi et al. 1997). 
TIMPS Inhibitory effect 
TIMP-1  All the latent proMMPs and active MMPs. Does not inhibit MMP-14, MMP-
16, and MMP-24.Poor inhibitor for MMP-19 and a number of MT-MMPs. 
TIMP-2  All the latent proMMPs and active MMPs 
TIMP-3  All the latent proMMPs and active MMPs. Inhibits A Disintegrin and a 
Metalloproteinase (ADAMs), as well as the matrix-associated ADAM with a 
a thrombospondin like motif (ADAM-TS) 
TIMP-4  MMP-1, MMP-2, MMP-3, MMP-7, MMP-9 
Table 1.2 Different types of TIMPs with their inhibitory effects 
Inhibitory profile for TIMP-1, TIMP-2, TIMP-3, and TIMP-4.  From Ahmed, A.K.H. 2009 (Ahmed 2009). 
1.8.4.4 ADAMTS   
The A Disintegrin And Metalloproteinase with Thrombo Spondin motifs 
(ADAMTS) is a unique family of ECM proteases.  ADAMTS are present in 
invertebrates and mammals.  There is similarity a between A Disintegrin And 
Metalloproteinase (ADAM) and ADAMTS is their involvement in proteolytic 
processing of cell surface molecules (Wolfsberg, Straight et al. 1995).  The 
difference is that the ADAM family lacks the binding motif for the catalytic zinc to 
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several proteins.  That is why ADAM has lack in any catalytic activity.  The 
ADAMTS interact with some components of ECM for example, procollagen 
(Jones and Riley 2005).  Different ADAMTS degrade different ECM components.  
The known actions of ADAMTS are illustrated in (Table 1.3), however some 
actions of ADAMTS are unknown (Porter, Clark et al. 2005).           
ADAMTS Degradation 
1, 4, 5, 8, 9 and 15 (known as proteoglycanases)  proteoglycans aggrecan, brevican, and 
versican (Apte 2009). 
2 and 3 pro-collagens I, II and III N-propeptides.    
13 von Willebrand factor (Zheng, Chung et al. 
2001) 
15 aggrecan (Sugimoto, Takahashi et al. 1999).   
Table 1.3 Different ADAMTS targets within the ECM 
ADAMTS have a specific but wide range of proteolytic targets. 
1.8.4.5 The Plasmin system 
The plasmin system has an important role in the coagulation and fibrinolysis 
cascades in the blood.  The precursor plasminogen is activated to plasmin by two 
main activators named tissue-type plasminogen activator (tPA) and urokinase 
type plasminogen activator (uPA).  The inhibitors of plasmin are α2-
macroglobulin and α2-antiplasmin.  The tPA and uPA activities are regulated by 
plasmin activator inhibitors 1 and 2 (PAI-1 and PAI-2). 
1.8.4.5.1 Plasminogen 
The serine protease plasmin has a pro-enzyme precursor called 
plasminogen.  Human plasminogen is a single chain, 90kDa, multidomain 
glycoprotein that is mainly produced in the liver (Forsgren, Raden et al. 1987).  
There are two forms of the plasminogen called Lys-Plasminogen and Glu-
Plasminogen (Violand and Castellino 1976).  The two main activators tPA and 
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uPA (physiological activators) cleave plasminogen to plasmin for activation 
(Dano, Andreasen et al. 1985). 
1.8.4.5.2 Function of plasmin 
 Plasmin has several functions. The main function is the cleavage at 
specific sites of insoluble fibrin polymers to produce soluble fragments (Walker 
and Nesheim 1999).  Plasmin also plays an important role as a proteolytic factor 
in many physiological processes including degradation of the ECM, tissue repair, 
angiogenesis, wound healing embryogensis as well as pathogen and tumour cell 
invasion (Strickland, Reich et al. 1976, Gross, Moscatelli et al. 1983, Ossowski 
and Reich 1983, Dano, Andreasen et al. 1985, Schafer, Maier et al. 1994). 
Plasmin degrades ECM proteins such as collagens, laminins, and 
fibronectin (Bonnefoy and Legrand 2000, Nakagami, Abe et al. 2000, Netzel-
Arnett, Mitola et al. 2002).  Plasmin also degrades blood proteins such as von 
Willebrand factor, factor FVa, and thrombospondin (Hamilton, Fretto et al. 1985, 
Bonnefoy and Legrand 2000, Zeibdawi and Pryzdial 2001).  The other function of 
plasmin is activation of signalling pathways via protease activated receptors.  
Plasmin also plays a role in nicotine reward regulation (Nagai and Yamada 2008). 
1.8.4.5.3 Activators of plasminogen 
The main physiological activators of plasminogen are tPA and uPA.  They 
are multi-domain serine proteases.  They catalyse the same reaction i.e. 
plasminogen is activated to plasmin through Arg561-Val562 peptide bond.  The 
difference is in their biological roles.  tPA has a role in fibrin polymer dissolution 
by plasmin as part of vascular haemostasis, whereas uPA has role in the 
pericellular plasmin activity generation, for example, in degradation of the ECM 
(Schaller and Gerber 2011). 
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1.8.4.5.4 Plasmin Inhibitors 
1) α-2 Antiplasmin 
α-2 antiplasmin (67kDa) is a single-chain plasma glycoprotein.  It is the 
main physiological plasmin inhibitor and is synthesised predominantly in the liver 
(Saito, Goodnough et al. 1982, Sumi, Ichikawa et al. 1989).  It is a member of the 
serpin family.   
2) Plasmin Activator Inhibitor 1 (PAI-1) 
PAI-1 (50kDa) is a single chain plasma glycoprotein from the serpin family 
of proteases.  It is produced by various cells such as liver, endothelial, and 
smooth muscle cells (Alessi, Peiretti et al. 1997).  It is the main inhibitor for both 
activators of plasminogen.  Other serine proteases, such as trypsin and thrombin, 
are inhibited by PAI, but at very low rates, (Hekman and Loskutoff 1988, 
Lawrence, Strandberg et al. 1989, Keijer, Linders et al. 1991).   
The excessive accumulation of collagen in the ECM is determined by an 
increase in the collagen synthesis rate and/or decrease in the collagen 
degradation rate by proteolytic activities.  The uPA/tPA and plasmin play 
important roles in the ECM proteolytic degradation that is required to maintain 
tissue ECM homeostasis.  The activities of plasmin-dependent MMPs, tPA, uPA, 
and thus plasmin depend partly on the activity of PAI-1.  In normal physiological 
conditions, the proteolytic activities of plasmin-dependent MMPs, tPA, uPA, and 
plasmin are controlled by PAI-1 which leads to maintains the tissue homeostasis.  
In contrast to the above (in the pathologic conditions), there are excessive 
collagen accumulation as well as other ECM proteins in the wound area due to 
excessive PAI-1.  This will lead to scarring preservation (Ghosh and Vaughan 
2012). 
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PAI-1 and tPA are involved in fibrogenesis of several organs and they are 
produced by MCs.  PAI1 and t-PA were produced by HPMC in an in vitro study in 
response to glucose based peritoneal dialysis solutions (Katsutani, Ito et al. 
2007).  Peritoneal fibrosis in a mouse model showed that tPA exacerbates 
peritoneal fibrosis, peritoneal inflammation and neoangiogenesis (Kurata, 
Maruyama et al. 2009).  It is not clear whether plasminogen is playing a role in 
the EPS development or not, but it had been shown that MCs express PAI-1 and 
PAI-2 under the effect of TGF-β (Rougier, Guia et al. 1998, Holmdahl, Kotseos et 
al. 2001).  This inappropriate balance of fibrin deposition against breakdown will 
lead to increase in the probability of fibrous adhesion formation which may play a 
role in the EPS development (Moinuddin, Summers et al. 2014). 
3) Plasminogen Activator Inhibitor 2 (PAI-2) 
PAI-2 is a serpin protease produced by keratinocytes, monocytes, 
macrophages, and epithelial cells (Webb, Collins et al. 1987, Wohlwend, Belin et 
al. 1987).  PAI-2 is a  single chain and is poorly secreted (von Heijne, Liljestrom 
et al. 1991) which is why PAI-2 accumulates intracellularly as a non-glycosylated 
protein with molecular size of a 47kDa  (Genton, Kruithof et al. 1987).  PAI-2 has 
the ability to be secreted, but in small quantities as a plasma glycoprotein with 
size of a 60kDa (Belin, Wohlwend et al. 1989).  It inhibits both activators of 
plasminogen (Ny and Mikus 1997), can inhibit apoptosis, change gene 
expression, and affect cell proliferation and differentiation (Schaller and Gerber 
2011).  
4) Neuroserpin 
Another serpin protease is neuroserpin which is expressed mainly in the 
brain (Hastings, Coleman et al. 1997, Schrimpf, Bleiker et al. 1997).  It is a single 
chain,  55kDa glycoprotein (Osterwalder, Contartese et al. 1996, Hastings, 
Coleman et al. 1997, Yazaki, Liepnieks et al. 2001) and is an inhibitor for both 
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activators of Plasminogen and plasmin (Hastings, Coleman et al. 1997, Ricagno, 
Caccia et al. 2009). 
5) α2-Macroglobulin 
α2 macroglobulin is a large glycoprotein, and is found in both vertebrates 
and invertebrates as well as reptile eggs (Buresova, Hajdusek et al. 2009, 
Raymond, Su et al. 2009, Ma, Wang et al. 2010).  It is the main anti-proteinase in 
the plasma of vertebrates.  It is the only inhibitor that has ability to inhibit almost 
all proteinases (Rehman, Ahsan et al. 2013).  It inhibits cysteine-, aspartic-, 
serine-, metalloproteinases, fibrinolysis and coagulation (De Boer, Creasey et al. 
1993).  The mechanism of inhibition of fibrinolysis and coagulation is by inhibiting 
plasmin and inhibiting thrombin respectively.   
1.9 Simple peritoneal sclerosis and encapsulating peritoneal 
sclerosis biomarkers and diagnostic tools 
In summary, peritoneal dialysis is a successful renal replacement therapy 
that can be used alone or in conjunction with haemodialysis in patients with end-
stage renal failure.  PD has particular benefits including: it can be performing at 
home with increase mobility of the patient and less dietary and fluid restriction.  
However the long term use of peritoneal dialysis is restricted by sclerosis of the 
peritoneum and an increasing risk of encapsulating peritoneal sclerosis (EPS) 
where fibrotic tissue encapsulates the bowel, leading to obstruction and 
potentially death.  The availability of dialysis fluid from PD patients gives us a 
unique opportunity to get materials from the site of disease both for routine 
screening and investigation of the disease pathobiology.  By characterising 
changes in ECM related molecules it may be possible to develop noninvasive 
biomarkers that may predict EPS onset or how advanced PS is reached.   
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There is disagreement as to whether EPS represents the severe end of a 
continuum of peritoneal sclerosis (PS) or they are entirely two different 
pathological entities.  Irrespective, it would seem sensible to assume that 
systems involved in normal extracellular cellular matrix (ECM) homeostatic 
balance that are altered in fibrotic disorders in other organs may well be 
implicated in PS and EPS.  This would include the  down regulation of enzyme 
systems involved in ECM breakdown such as matrix metalloproteinases (MMPs) 
and plasmin, or over expression of the natural inhibitors of these enzymes such 
as tissue inhibitors of matrix metalloproteinases (TIMPs) and plasmin activator 
inhibitors (PAIs), as well as excess production of  ECM components.  EPS is 
associated with severe morbidity and mortality and this complication cause 
strong negative view of the PD value as a long-term therapy.  Moreover, 
peritoneal cellular study and it is link to ECM is important area to be studied.  
Last but not least, proteomics analysis of PDE samples to find the proteins that 
behave differently between EPS and control groups are also of high value.   
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1.9.1 Hypothesis 
This thesis proposes the hypothesis that there are proteins present in the 
peritoneal dialysis effluent that will inform on the rate of simple peritoneal 
sclerosis and whether the patient is likely to subsequently develop encapsulating 
peritoneal sclerosis.  These proteins are likely to be those involved in tissue 
remodeling or fibrosis.  This overarching hypothesis is subdivided into 3 mini 
hypotheses that will be addressed individually 
1. ECM proteolysis:  Aberrations in systems involved in ECM regulation are 
already known to play role in numerous fibrotic diseases with perturbations in the 
MMP and TIMP leading to lower ECM clearance particularly prevalent.  It is 
therefore likely that they may also underlie the development of PS and the switch 
to EPS.  Therefore this thesis will test the hypothesis that changes in the MMP 
system in the peritoneum underlie PS &/or the switch to EPS and may have 
values as non-invasive prognostic markers or as diagnostic tools.   
2. Peritoneal cellular changes with long duration of PD therapy: It is 
recognised that ECM processing is very dependent on the cells types present 
and there is some evidence that the cell population in the peritoneum changes 
during PD.  This thesis will also test the hypothesis that changes in the peritoneal 
cell population will change with time on PD and in patients with EPS and that 
these will influence ECM processing 
3. The proteomics proteins: Proteomic interrogation of PDE will reveal protein 
profiles that will link individual protein changes in PDE samples to the 
development of PS or EPS and these proteins can developed as biomarkers or 
diagnostic tools 
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1.9.2 Aims 
To test the above hypotheses, Three cohorts of PDE samples; 2 from the 
Sheffield kidney institute and the global fluid study were used.  The aims were 
divided to: 
1.9.2.1 ECM proteolytic 
1. Measure total MMP and plasmin activity in PDE samples from PD patients 
to establish any abnormal levels of ECM proteolysis and their relations with 
PS and EPS. 
2. Determine the contributions of individual proteolytic enzymes and their 
natural inhibitors by ELISA 
3. Determine the value of  any identified enzyme or inhibitor in predicting EPS 
development 
4. The rate of transfer of proteins of known molecular weight that are not 
produced in the peritoneum will be calculated.  If TIMP and MMP levels in 
PDE samples have a potentially higher transfer rate this will indicate local 
production is occurring. 
1.9.2.2 Peritoneal cellular changes with long duration of PD therapy 
1. Cells will be isolated from overnight bags. 
2. Cells will be stained for different peritoneal cell markers. 
3. These will be quantified by cell counting and then comparing each of the 
peritoneal cells in 3 groups based on time on PD (<1 year, 1-3 years, and 
>3 years). 
1.9.2.3 The proteomics proteins 
The aim is to determine if identified proteins by proteomics are biomarkers 
of, or have diagnostic value in PS and EPS.   
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CHAPTER TWO 
Materials and methods 
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2.1 Patient Cohorts 
Three cohorts of PD patients were consented into the studies presented in 
this thesis. The three patient groups were termed:- 
a) Sheffield Kidney Institute PD cohort 1 (SKI-1), 
b) Sheffield Kidney Institute PD cohort 2 (SKI-2), 
c) Global Fluid Study (GFS). 
For the two Sheffield cohorts (a&b), clinical data was obtained from both the 
patient record system (Proton) and the peritoneal dialysis database (PDDB) at 
the Sheffield Kidney Institute (SKI), Northern General Hospital, Sheffield, UK.  
PD patients in the SKI-1 cohort were subdivided into groups, based on their 
duration on PD.  Both Sheffield PD cohorts were included in the UK EPS 
Registry and DNA Bank.  For the GFS cohort, patient samples were obtained 
from 4 centers from the UK wing of the Global Fluid Study.  The Global Fluid 
Study consists of approximately 2,000 peritoneal dialysis patients, consented 
from a variety of centers worldwide. The GFS was designed to collect samples at 
3-6 monthly intervals for the duration of renal replacement therapy by peritoneal 
dialysis. The GFS represents the largest PD patient group in the world available 
for clinical studies.  Samples of peritoneal dialysis effluent (PDE) were collected 
in a different manner for each patient cohort:- 
a) SKI-1 - single PDE samples were collected when patients consented 
for the EPS registry at a convenient time for the patient.   
b) SKI-2 - single PDE samples were collected during the patient‘s visit 
to hospital for a peritoneal equilibrium test (PET), 
c) GFS - PDE samples were collected sequentially but at irregular 
intervals. 
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2.1.1 Sheffield Kidney Institute PD Cohort 1 (SKI-1) 
2.1.1.1 Ethics  
The UK EPS and DNA Bank Study received national ethics approval on 
12th July 2006 (REC reference number: 06/Q1407/94).  Local ethics approval for 
Sheffield Hospitals Trustees was received on 6th December 2006.  National 
ethics was extended in July 2011.  PDE samples were collected at the Sheffield 
Kidney Institute, Northern General Hospital, Sheffield, UK.  The appropriate 
consent forms (version 4), study protocol (version 4), and participant information 
sheet (PIS) (version 5) are attached in Appendix 2.  
Informed, written consent was obtained for all those PD patients who 
agreed to participate in the study.  The PIS sheet was given to all participants in 
advance of the study.  Withdrawal from the study was permitted at any time, 
without requiring the patient to give any reason or explanation.  The decision by 
any PD patient to withdraw from this study had no effect on the standard of care 
received within the renal unit.   
2.1.1.2 Patients 
Thirty-one patients on PD at the Sheffield Kidney Institute were consented 
into this cohort.  PDE samples were collected from December 2007 to January 
2011.  The inclusion criteria included any patient on PD aged 18 years or over.  
The major exclusion criteria were a diagnosis of peritonitis in the two month 
period prior to sample collection and patients who were too ill to consent.  
Samples were collected from a range of patients; from those just starting on PD 
to patients who had been on PD for a period of up to 6 years.  The study was 
cross sectional.     
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2.1.1.3 Sampling and clinical data 
Single PDE sample was collected from each patient.  PDE samples (20mL) 
were aliquoted into smaller volumes (10 x 1mL, 40 x 250 μL), and stored at -
80oC.  Aliquoted samples were used once for each assay to avoid the possibility 
of protein degradation by freeze/thaw cycles.  Dwell times were not recorded for 
this cohort and unlike the SKI-2 cohort, samples were not collected during a 
peritoneal equilibrium test (PET).  D/P creatinine (D/Pcr), 24hr urine output and 
UF data were also unavailable on the day of the samples were taken.  Clinical 
data were therefore obtained on a date, as close as possible to the date of 
sample collection.  The other data collected were age, gender, ethnicity, duration 
on PD, renal and peritoneal Kt/V, type of PD mode on the day of PDE sample, 
and number of peritonitis episodes.  Samples collected when line flushing 
occurred were not differentiated from samples without and thus some differences 
could occur in sample dilution.  Samples collected with line flushing were 
inevitably more dilute, leading to artificially low measurements of the 
concentration of different proteins in the PDE samples as determined by ELISA.  
The line flush samples would have the effect of diluting the samples by about 
10% (a 200 mL flush in a 2 litre bag of dialysate), but it could be less or more 
than 10%.   
2.1.1.4 Sample Grouping 
Only 1 of the 31 samples collected in the SKI-1 cohort was taken from a PD 
patient after a diagnosis of EPS.  PD patients contributing the other 30 samples 
of PDE were grouped according to their duration on PD.  Patients providing 
samples within 1 month of starting PD formed a separate group because 
inflammation and other changes were expected during the first month on PD.  An 
alternative view for separating this group is because it represents a more normal 
biology of Peritoneum. 
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2.1.2 Sheffield Kidney Institute PD Cohort 2 (SKI-2) 
2.1.2.1 Ethics  
The ethics and the study design were similar to the first Sheffield PD cohort, 
with a slight change in protocol (i.e. version 6 of protocol was followed).  PDE 
samples were collected at the Sheffield Kidney Institute, Northern General 
Hospital, Sheffield, UK. The appropriate consent forms (version 6), study protocol 
(version 6), and participant information sheet (PIS) (version 6) are attached in the 
Appendix 3.  Protocol amendment to version 6 was received on 23 March 2011 
(STH ref: STH14477).  PD patients consented into SKI-1 and SKI-2 were 
subsequently included within the UK EPS Registry and DNA Bank sponsored by 
Central Manchester and Manchester Children‘s University Hospital (CMMC).  
Version 6 of the ethical approval allowed collecting an increased volume of PDE 
sample (a whole PD bag).  It also allowed repeat sample collection, cell recovery 
and plasma sample collection to measure molecules that might give information 
about the causes of EPS.    
2.1.2.2 Patients 
Fifty-one patients on PD at the Sheffield Kidney Institute were consented to 
the specified ethics and utilised for this cohort.  Plasma and PDE samples were 
collected from April 2011 to July 2012.  The inclusion criteria and the exclusion 
criteria were same as SKI-1.  PDE samples were collected from patients ranging 
from those just started PD to patients who had been on PD for more than 10 
years.  This was a cross sectional study. There were no EPS patients in this 
cohort, but detailed clinical data was collected to help in identifying the peritoneal 
membrane status. 
2.1.2.3 Samples and clinical data 
Serial PDE samples were collected from each patient.  PDE samples were 
collected from 4 different dwell times (0, 2hr, 4hr, overnight).  Large volumes of 
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samples were aliquoted and stored at -80oC.  All samples were collected during a 
PET (Figure 2.1).  A plasma sample was also collected at the 2 hour dwell time.  
All PDE at 2hr dwell time were samples collected without a line flush.  Clinical 
data collected included, age, gender, ethnicity (race), data on 24hr urine output, 
duration on PD, last year glucose exposure, UF, D/P creatinine at 2hr and 4hr, 
D/D0 glucose at 2hr and 4hr, renal and peritoneal Kt/v, number of peritonitis 
episodes, eGFR, drain time, peritoneal and renal creatinine clearance, residual 
volume (RV) and type of PD mode on the day of PDE sample.  The glucose 
calculation was used to estimate the last year glucose exposure before the date 
of the PDE sample.   
 
 
Figure 2.1 Sheffield Kidney Institute Cohort 2 PD and plasma sample collection 
Far left, Aliquots of complete peritoneal dialysis effluent (PDE), blood and plasma samples collected to 
send to UK EPS registry in Manchester. Middle: overnight peritoneal dialysis bag before centrifuge.  Far 
right, PDE samples (complete and cell free PDE samples) at dwell times of zero, 2hr, 4hr, and ON with 
2hr plasma samples for Sheffield.  Complete samples were collected before centrifuge, while cell free 
samples were collected after centrifuge. 
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2.1.3 The Global Fluid Study PD Cohort (GFS) 
The Global Fluid Study (GFS) is an international biorepository of PDE and 
plasma samples.  GFS was approved and supported by the British Renal Society 
(BRS) and the International Society for Peritoneal Dialysis (ISPD). 
2.1.3.1 Ethics  
The ethics approval for longitudinal evaluation of peritoneal membrane 
function, inflammation, and structural integrity in PD was given by the Multi-
Centre Research Ethics Committee for Wales (Research protocol: MREC 
02/9/14) on 16 April 2002.  PDE and plasma samples were collected at multi-
centres.  PDE without plasma samples were utilized for this study.  Informed 
consent was taken from all patients locally.  Participants were free to withdraw 
from the study at any time.  The ethical approval is attached in the Appendix 4. 
2.1.3.2 Patients 
Samples from fifty-four patients on PD were sent to Sheffield Kidney 
Institute for analysis.  PDE and plasma were collected from June 2002 to August 
2008.  Inclusion criteria and exclusion criteria were same as SKI-1 and SKI-2.  This 
was a longitudinal cohort 
2.1.3.3 Samples and clinical data 
For the purposes of this study in Sheffield, 201 samples from the UK arm of 
the GFS were made available which comprised of sequential samples from 54 
patients collected at 4 centres.  Approximately 2 to 3 mL of peritoneal dialysis 
effluent (PDE) from each patient was supplied to Sheffield, 400 ul of material was 
removed for this study & PDE aliquoted into smaller volumes (20 μL).  PDE 
samples were stored at -80oC freezer.  Samples were used once for every 
experiment to avoid freeze/defrosting cycle.  Samples consisted of four hour 
dwell times with a few additional overnight samples available.   
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All clinical data pertaining to the patients was exported from the GFS 
database onto an Excel spread-sheet by the GFS team in Cardiff and Stoke.  
The clinical data  included; age at the date of PDE sample,  gender, data on 
duration on PD, 24hr urine output, UF, D/P creatinine at 4hr, renal and peritoneal 
Kt/v, renal and peritoneal CrCl, number of peritonitis episodes, peritoneal and 
renal creatinine clearance, reason for stopping PD, systolic and diastolic blood 
pressure (BP), Pulse pressure (PP), Mean atrial pressure (MAP), weight, height, 
BMI, type of PD mode on the day of PDE sample, daily UF, UF capacity, daily 
H20 removal, Glucose exposure rate, 24hr peritoneal protein loss, protein 
clearance, plasma level of Albumin, Cholesterol, TG‘s, and HDL.   
2.1.3.4 Sample Grouping 
GFS samples were classified into two groups.  The first group, designated 
as the control group, included 42 patients who did not subsequently develop 
EPS.  The second group contained 12 patients that ultimately developed EPS 
(EPS diagnosis according to ISPD criteria).  The EPS & control groups are 
matched for time on PD, number of samples, gender, age, diabetes, and centre. 
2.2 Peritoneal equilibrium test (PET)    
This is a semi-quantitative test to assess the permeability of the peritoneal 
membrane (Pannekeet, Imholz et al. 1995, Teitelbaum and Burkart 2003) and to 
monitor peritoneal transport (Ram 1994).  It was initially described by 
Twardowski et al (1989) to evaluate peritoneal function by assessing the 
movement of solute.  The status of the peritoneal membrane can be grouped into 
4 categories; high transporter, high average transporter, low transporter or low 
average transporter using the PET score (Twardowski, Nolph et al. 1987) 
(Appendix 5).  Population data suggests progression to high solute status 
correlates with the time spent on PD.  This change in transport status may be 
due to a change in the structure of the peritoneal membrane resulting in  
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ultrafiltration and/or technical failure (Davies, Phillips et al. 1998).  Rather than 
using categories the D/Pcr, it is often displayed as a continuous variable. 
Ultrafiltration failure may result in increased mortality and morbidity, fluid 
overload, cardiovascular disease and death.  Minimizing glucose exposure by 
using an appropriate dwell length is an important protection against UF failure.  
For example, PD patients using short dwell times, icodextrin at day time, and 
utilizing amino acids at night.  There is evidence that using icodextrin and APD in 
anuric patients over two years better preserves UF (Davies, Brown et al. 2005).  
The PET is used to determine the best mode of PD (Table 2.1), calculate 
predicted clearance for a given PD regime, measure residual volumes (Appendix 
6) and measure UF (Twardowski 1987, Ho-dac-Pannekeet, Atasever et al. 1997). 
BASELINE PET PROGNOSTIC VALUE 
Solute Transport Predicted Response to CAPD Preferred Dialysis 
 UF Dialysis  
High Poor Adequate CCPD dry day or CAPD dry night 
High Average Poor-Medium Adequate Standard CAPD or APD 
Low Average Good Adequate Standard CAPD 
Low Average Good Inadequate High Dose PD or APD 
Low Very good Inadequate High Dose PD or Haemodialysis 
Table 2.1 Prescription schedules 
Best PD mode for different transport status of peritoneal membrane according to PET results (Twardowski 
1989). 
2.3 Sample collection   
In the SKI-2 cohort, PDE samples were collected at four time points for 
each patient during the visit for a PET (9am – 2pm).  A sample from the prior 
overnight dwell was collected, followed by, 0hr, 2hr and 4hr samples from the 
PET.  Blood samples from patients were also taken at the 2hr dwell time.  During 
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PET, a 2L of 2.27% Dianeal bag (Baxter Castlebar, Ireland) was warmed to body 
temperature.  The overnight dwell (8-12 hours) was drained over 20 minutes.  
The patient must be in a vertical position (sitting or standing).  Drained volume 
was measured and recorded.  120 mL of overnight sample (60 mL before 
centrifuge, and 60 mL after centrifuge) was collected, aliquoted, and stored at -
80oC (Figure 2.2).  For each sample a unique SKI study identification number 
was generated.  Samples were also sent for PET i.e. for clinical chemistry 
laboratory for analysis for urea, creatinine and glucose.   
Fresh solution was infused in a rate of 200 mL/minute (i.e. total infusion 
time = 10 minutes).  The patient lies in a supine position and rolls from side to 
side after 400, 800, 1200, 1600, and 2000 mL have been infused to ensure 
solution mixing.  The 0hr dwell sample was collected at completion of infusion.  .  
Subsequent dialysate samples were collected at 2 and 4 hours dwell times.    
Samples 0, 2 and 4 hr dwell samples were sent for analysis for urea, cr and 
glucose (PET).  Samples were also taken for UK EPS DNA study.  They were 
aliquoted and stored at -80oC.  Drain volume was weighed and recorded.  
Sample volumes were added to give the total drain volume.  In addition to the 
above, 8 slides per patient were prepared for cell staining by cytospining cells 
recovered from generation of a cell free PDE (Figure 2.3).  At 2 hour dwell time, 
venous blood samples were also drawn.  For PET, blood samples were sent for 
analysis of urea, creatinine, and glucose, while for UK EPS DNA study, plasma 
samples were aliquoted and stored in -80oC (Figure 2.4).  PET measures the 
D/Pcr and D/D0 glucose.   PDE samples, blood samples, slide preparation, and 
clinical data collection was performed by me, but the PET was performed by 
nurses with some help from Dr Dina Abdellatif specially in measuring hydrostatic 
intra peritoneal pressure (IPP) (cm). 
Hydrostatic IPP measurement started by connecting the disconnect system 
at the extension tubing.  The patient was placed by lying in supine position in a 
strictly horizontal plane.  Then, zero level of the scale was adjusted on the medial 
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axillary line.  A blue clamp stopped the infusion.  The drainage bag was hung up 
on the stand.  The extension catheter was opened and the drainage line was 
filled with the dialysis fluid.  After that, waiting started until the level was 
stabilized.  The patient was advised to breathe normally and hydrostatic IPP was 
recorded during inspiration and expiration.  After readings, the drainage bag was 
lowered and drainage occurs as usual.  The drainage volume was recorded too.
 
 
Figure 2.2  Processing of the PDE samples in SKI-2 
Peritoneal dialysis effluent (PDE) samples were processed before and after centrifuge in Sheffield Kidney 
Institute PD Cohort 2 (SKI-2).  In addition to that, cells were obtained from spun PDE for cytospin slide 
preparation. 
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Figure 2.3 Processing PDE samples for cytospin slide preparation & cell 
staining in the  SKI-2 cohort 
 (A) PDE samples were centrifuged with using a swing out rotor for 8 minutes, at 2000 g and 4ºC. (B) 
The pellet was suspended in 2ml of PDE and 300 μL loaded onto a cytospin. (C) Slides were spun for 10 
minutes. (D) Four slides were obtained in each cycle.  (E & F) Cells were fixed in acetone for 10 minutes 
at -20
o
C. (G) Slides were then left to dry at room temperature for 15 minutes. (H) Slides were labeled 
with a pencil & stored at -20
o
C prior to staining. 
 
Figure 2.4 Processing blood samples in the SKI-2 cohort 
 (A) Heparin containing vacutainers were used for collecting blood sample to prevent blood clotting. (B) 
The tubes were balanced with another tube filled with water & centrifuged using an Eppendorf  5702 
centrifuge for 10 minutes at 1100 g. (C) Plasma was separated into eppendorf microfuge tubes & stored 
at– 80 
o
C.   
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2.4 Healthy volunteers 
Data on plasma samples from healthy volunteers was retrieved from studies 
performed under ethics application12/YH/0297, a parallel study looking at the 
natural history of diabetic and non-diabetic chronic kidney disease.  Data from 
plasma samples from 18 consented healthy individuals was used in this study 
along with demographic data including age (at the date of plasma sample 
collection), gender and ethnicity.  Plasma samples were aliquoted into smaller 20 
µl volumes, were stored at -80oC and samples thawed just once for analysis to 
avoid protein degradation by freeze/defrosting cycle. 
2.5 Peritoneal dialysis database (PDDB) 
The patient record system (Proton) and the peritoneal dialysis database 
(PDDB) were used for collecting clinical data for the two Sheffield cohorts. In 
particular PDDB is easily used to facilitate quick access to the information on 
patients on PD (Figure 2.5).  PDDB (developers are Prof Nick Topley, Prof Simon 
Davies, Dr Kit Huckvale and Dr James Chess) has a unique timeline feature that 
gives an easy, clear, direct view of the patients‘ renal replacement history.  
PDDB has the ability to identify patients who have consented into the UK EPS 
Study and those who have not.  It contains a collection of information on PD 
patients in one place.  It calculates Kt/V to ensure that all sites across the UK will 
be using same, standard calculation.  
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2.6 Calculations  
2.6.1 Glucose exposure in last year 
Glucose exposures for all patients in the SKI-2 cohort were calculated as 
illustrated in (Table 2.2).   This example shows that this patient had different 
peritoneal regimes in the last year before donating sample for UK EPS DNA 
study.  Therefore glucose exposure was calculated in each period.  After that the 
sum of all glucose exposures in the last year was calculated.   
 
Figure 2.5 Screen print of PDDB 
This screen print shows the timeline feature at the top of the entering area.  Patient‘s name and hospital 
number is obscured for confidentiality reason.  It is reproduced by permission of the UK EPS Registry & 
DNA Bank, 2008. 
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Mode [Glucose] (g/L) Volume (L) From To Glucose exposure (g) 
APD 13.6 5.75 19/04/2010 30/04/2010 860.20 
APD 13.6 5.0 30/04/2010 26/05/2010 1,768.00 
APD 13.6 6.9 26/05/2010 10/08/2010 7,131.84 
APD 13.6 5.55 10/08/2010 02/09/2010 1,736.04 
APD 13.6 6.9 02/09/2010 29/10/2010 5,348.88 
APD 13.6 5.1 29/10/2010 04/11/2010 416.16 
APD 22.7 3.4 29/10/2010 04/11/2010 463.08 
APD 13.6 6.0 04/11/2010 18/11/2010 1,142.40 
APD 22.7 4.0 04/11/2010 18/11/2010 1,271.20 
APD 13.6 8.0 18/11/2010 07/03/2011 11,859.20 
APD 22.7 2.0 18/11/2010 07/03/2011 4,948.60 
APD 13.6 4.0 07/03/2011 19/04/2011 2,339.20 
APD 22.7 6.0 07/03/2011 18/04/2011 5,720.40 
Glucose exposure in the last year = 45005.20 g 
Table 2.2 Glucose exposure in the last year 
An example of method of calculating glucose exposure in one of the patient in the last year before donating 
PDE sample to the UK EPS and DNA bank study. 
2.7 Demographic and clinical characteristics of Cohorts 
2.7.1 Demographic and clinical characteristics in SKI-1 patient cohort 
Thirty one patients (19 males and 12 females) donated samples in this 
cohort.  Twenty six patients in this cohort had UO ≥ 200 mL/day, while four of the 
patients had UO < 200 mL/day and it was not recorded for one patient.  Episodes 
of peritonitis for patients in this cohort varied from patients without a history of 
peritonitis to those who had up to 4 episodes.  Twenty nine patients were from a 
Caucasian background, while one was African, and another Asian.  Any patient 
with diagnosis of peritonitis in the two months period prior to sample collection 
was excluded from this cohort.  The summary of baseline clinical characteristics 
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for the SKI-1 cohort is shown in (Table 2.3).  The primary renal diagnosis for 
patient in the SKI-1 cohort is shown in (Figure 2.6).  
 
Variables Number with 
data available 
Mean ± SD Median (IQR) Median (Range) 
Age at sample (year)  31 56 ± 20 57 (42 - 74) 57 (22 – 88) 
Duration on PD (year)  31 2 ± 2 1.3 (0.3 – 3.1) 1.3 (0.003 – 6.9) 
Peritonitis episodes  31 0.6 ± 1.1 0 (0 – 1) 0 (0 – 4) 
D/Pcr  18 0.72 ± 0.11 0.72 (0.63 – 0.82) 0.72 (0.53 – 0.93) 
UF (mL) 17 185 ± 97 200 (113 – 255) 200 (0 – 400) 
Peritoneal Kt/V 28 1.26 ± 0.37 1.3 (1.01 – 1.56) 1.3 (0.51 – 2.17) 
Renal Kt/V  29 1.02 ± 0.77 1.07 (0.24 – 1.52) 1.07 (0 – 2.97) 
Total Kt/V  28 2.32 ± 0.7 2.31 (1.7 – 2.8) 2.31 (1.3 – 4.16) 
Table 2.3 Clinical characteristics in the SKI-1 cohort 
Clinical parameters recorded in SKI-1 cohort.  Abbreviations: peritoneal dialysis (PD), dialysate-to-plasma 
ratio of creatinine (D/Pcr), ultrafiltration (UF).  K - peritoneal clearance of urea, t - dialysis time, and V - 
volume of distribution of urea (Kt/V). 
 
Figure 2.6 Primary renal 
diseases in SKI-1 
Seven patients were diagnosed 
with diabetic renal disease.  PCKD-
adult and GN including IGAN were 
affecting five patients each.  Four 
patients were with unknown primary 
renal diagnosis.  The rest were 
affected by other various primary 
renal diseases.  Abbreviations: 
PCKD (polycystic kidney disease), 
GN (Glomerulonephritis), IGAN (IgA 
nephropathy), SLE (Systemic lupus 
erythematosus). 
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2.7.2 Demographic and clinical characteristics in SKI-2 cohort 
Fifty one patients (29 males and 22 females) were included in this cohort.  
All patients were from white ethnic backgrounds.  The summary of baseline 
clinical characteristics in the SKI-2 is given in (Table 2.4).  Episodes of peritonitis 
for patients in this cohort were various from patients without history of peritonitis 
to others who had up to 4 episodes of peritonitis.  Sixteen patients were on 
CAPD during PDE sampling, while thirty five patients were on APD.  Any patient 
with diagnosis of peritonitis in the two months period prior to sample collection 
was excluded from this cohort.  There were wide ranges of primary renal 
diagnosis in second Sheffield cohort (Figure 2.7). 
 
 
Figure 2.7 Primary 
renal diseases in the 
SKI-2 patient cohort 
Approximately 1/3 of patients 
were with unknown primary 
renal diagnosis. Diabetic renal 
disease was among one of the 
common diagnosis. 
Abbreviations: PCKD 
(polycystic kidney disease), 
GN (Glomerulonephritis), 
IGAN (IgA nephropathy), SLE 
(Systemic lupus 
erythematosus). 
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Variables  Number of 
patients with 
data available 
Mean ± SD Median (IQR) Median (Range) 
Age at sample (year)  51 59 ± 16 62 (46 - 72) 62 (20 – 85) 
Duration on PD (year)  51 1.8 ± 1.9 1.1 (0.2 – 2.8) 1.1 (0.1 – 9.1) 
Peritonitis episodes  51 0.6 ± 1 0 (0 – 1) 0 (0 – 4) 
D/Pcr at 2hr  51 0.53 ± 0.1 0.53 (0.46 – 0.6) 0.53 (0.3 – 0.8) 
D/Pcr at 4hr  51 0.73 ± 0.1 0.74 (0.66 – 0.79) 0.74 (0.46 – 1) 
D/D0 glucose at 2hr  51 0.55 ± 0.1 0.55 (0.48 – 0.6) 0.55 (0.27 – 0.92) 
D/D0 glucose at 4hr  51 0.34 ± 0.1 0.34 (0.28 – 0.4) 0.34 (0.12 – 0.62) 
UF capacity (mL)  48 73 ± 213 128 (-94 – 200) 128 (-475 – 500) 
Peritoneal Kt/V  51 1.15 ± 0.4 1.18 (0.85 – 1.3) 1.18 (0.54 – 2.22) 
Renal Kt/V  51 1.41 ± 0.93 1.38 (0.64 – 1.98) 1.38 (0 – 4.6) 
Total Kt/V  28 2.56 ± 0.8 2.36 (2.03 – 2.92) 2.36 (1.23 – 5.22) 
Peritoneal Crcl (l/wk/1.73 m
2
)  51 28.1 ± 11 25.7 (19.5 – 33.8) 25.7 (12.5 – 57.5) 
Renal Crcl 51 69.8 ± 43.9 66.5 (32.2 – 101.6) 66.5 (0 – 187.8) 
Last year glucose exposure 
(g)  
51 22410 ± 16753 24604 (6178 – 
36502) 
24604 (1877 – 67767) 
Urine output  (U.O.) (mL/day)  51 1486 ± 864 1400 (820 – 2130) 1400 (0 – 3840) 
drain time (min)  42 14.5 ± 4.1 15 (10 – 20) 15 (10 – 20) 
residual volume (RV) (mL)  46 279 ± 120 251 (190 – 359) 251 (80 – 590) 
eGFR  (mls/min/1.73m
2
)  51 8 ± 4 6 (5 – 12) 6 (3 – 15) 
Intra peritoneal pressure (cm)   35 17 ± 5 16 (13 – 19) 15.5 (10 – 28) 
Serum albumin (g/L)  51 39 ± 4 40 (36 – 42) 40 (28 – 47) 
Table 2.4 Clinical characteristics in the SKI-2 
Mean ± SD, Median (IQR), and (Range) for clinical parameters recorded in SKI-2 cohort.  Abbreviations: 
peritoneal dialysis (PD), dialysate-to-plasma ratio of creatinine (D/Pcr), ratio of dialysate glucose at 4 hours 
dwell time to dialysis glucose at 0 dwell time (D/D0 glucose), ultrafiltration (UF), K - peritoneal clearance of 
urea, t - dialysis time, and V - volume of distribution of urea (Kt/V), creatinine clearance (Crcl), 
estimated glomerular filtration rate (eGFR).  
 
78 
 
2.7.3 Demographic and clinical characteristics in the GFS cohort 
2.7.3.1 Control group (i.e. none EPS) 
Forty two patients (18 males and 24 females) were included in the control 
group of GFS.  A total of 158 PDE samples were collected from these patients. 
Episodes of peritonitis for patients in this cohort were various from patients 
without a history of peritonitis to others who had up to 14 episodes of peritonitis.  
Ninety nine samples were collected during CAPD, while fifty three samples were 
collected during APD.  Termination in the control group was due to peritonitis, 
transplantation, death, or other technique failure without any signs or symptoms 
of EPS.  Baseline clinical characteristics in the control group/GFS are illustrated 
in (Table 2.5).  
2.7.3.2 EPS group 
Twelve patients (6 males and 6 females) were included in the EPS group of 
the GFS cohort.  A total of 43 PDE samples were collected from these patients.  
Episodes of peritonitis for patients in this cohort were various from patients 
without history of peritonitis to others who had up to 6 episodes of peritonitis.  
Thirty samples were collected during CAPD, while eleven samples were 
collected during APD.  Termination of PD in this group was due to EPS, 
transplant, patient choice, UF failure (type 2) or other technique failure, but all of 
them developed EPS ultimately.  Baseline clinical characteristics in the EPS 
group/GFS are illustrated in (Table 2.6).  Comparison of EPS group (GFS), 
control group (GFS), SKI-1, and -2 cohorts is given in (Table 2.7).  One of the 
interesting finding was better residual renal function in SKI-2 in comparison to the 
GFS.  The median value of renal Crcl in SKI-2, GFS (control), and GFS (EPS) 
were 66.5, 23.4, and 11.7 respectively.  
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Variables Number of 
patients with 
data available 
Mean ± SD Median (IQR) Median (Range) 
Age at sample (year)  42 55 ± 15 54 (44 - 66) 54 (18 – 84) 
Duration on PD (year)  42 2.8 ± 3 1.7 (0.5 – 4.8) 1.7 (0.02 – 12.7) 
Peritonitis episodes  42 1.3 ± 2.8  0 (0 – 1.3) 0 (0 – 16) 
D/Pcr at 4hr  42 0.72 ± 0.14  0.72 (0.62 – 0.81) 0.72 (0.47 – 1.06) 
Ultrafiltration (UF) capacity (mL)  42 428 ± 272  432 (279 – 582) 432 (-100 – 1610) 
Daily UF (mL)  42 911 ± 655 829 (460 – 1406) 829 (-940 – 2485) 
Daily water removal (mL)  42 1780 ± 716 1838 (1303 – 2254) 1838 (224 – 3039) 
Peritoneal Kt/V  42 1.64 ± 0.48 1.53 (1.34 – 1.9) 1.53 (0.86 – 3.41) 
Renal Kt/V  42 0.71 ± 0.73  0.51 (0.12 – 1.22) 0.51 (0 – 2.59) 
Total Kt/V  42 2.4 ± 0.8  2.2 (1.8 – 2.7) 2.2 (1.4 – 4.7 ) 
Peritoneal Crcl (l/wk/1.73 m
2
)  42 51.4 ± 14 48.1 (42.3 – 58) 48.1 (31.5 – 101.5 ) 
Renal Crcl  42 38.5 ± 41.5  23.4 (6.7 – 64.1) 23.4 (0 – 175.2) 
Glucose exposure rate (g/day)  41 133 ± 39  127 (109 – 145) 127 (61 – 261) 
Urine output  (U.O.) (mL/day)  42 870 ± 746 742 (177 – 1434) 742 (0 – 2466) 
Serum albumin (g/L)  42 36 ± 6  37 (32 – 40) 37 (23 – 46) 
Weight (Kg)  42 70 ± 15 70 (57 – 83) 70 (45 – 92.5) 
Height (m)  42 1.66 ± 0.08 1.64 (1.61 – 1.71) 1.64 (1.52 – 1.89) 
Body mass index (BMI) (Kg/ m2)  42 25.2 ± 4.4 24.2 (21.9 – 29.3) 24.2 (18 – 33.9) 
Table 2.5 Baseline clinical characteristics in the control group/GFS 
Clinical parameters recorded in the control group/GFS.  Abbreviations: peritoneal dialysis (PD), dialysate-to-
plasma ratio of creatinine (D/Pcr), K - peritoneal clearance of urea, t - dialysis time, and V - volume of 
distribution of urea (Kt/V), creatinine clearance (Crcl). 
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Variables Number of 
patients with 
data available 
Mean ± SD Median (IQR) Median (Range) 
Age at sample (year)  12 50 ± 14 51  (40 - 62) 51 (22 – 71) 
Duration on PD (year)  12 3 ± 3.2 2.6  (0.5 – 4.3) 2.6 (0.02 – 11.4) 
Peritonitis episodes 11 1 ± 1.5 1 (0 – 1) 1 (0 – 5) 
D/Pcr at 4hr  12 0.8 ± 0.16 0.78 (0.7 – 0.92) 0.78 (0.52 – 1.07) 
Ultrafiltration (UF)  capacity 
(mL)  
12 312 ± 141 345 (165 – 440) 345 (81 – 473) 
Daily UF (mL)  12 1124 ± 511 1270 (733 – 1500) 1270 (40 – 1698) 
Daily water removal (ml)  12 1532 ± 700 1576 (968 – 1771) 1576 (408 – 2752) 
Peritoneal Kt/V  12 1.76 ± 0.35 1.75 (1.43 – 1.94) 1.75 (1.38 – 2.48) 
Renal Kt/V  12 0.39 ± 0.45 0.22 (0 – 0.74) 0.22 (0 – 1.27) 
Total Kt/V  12 2.15 ± 0.26 2.14 (1.9 – 2.34) 2.14 (1.87 – 2.67) 
Peritoneal Crcl (l/wk/1.73 m
2
)  11 60.5 ± 17.4 58.1 (48.9 – 78.7) 58.1 (29 – 83.9) 
Renal Crcl  12 21.1 ± 24.8 11.7 (0 – 42) 11.7 (0 – 69) 
Glucose exposure rate (g/day)  12 175.8 ± 76.7 173.6 (113.4 – 
222.3) 
173.6 (65.3 – 358.7) 
Urine output  (U.O.) (mL/day) 12 409 ± 522 179 (0 – 771) 179 (0 – 1482) 
Serum albumin (g/L)   10 38 ± 2.3 38 (37 – 39) 38 (32 – 40) 
Weight (Kg)  12 71 ± 14 69 (59 – 80) 69 (52 – 95) 
Height (m)  12 1.65 ± 0.11 1.67 (1.57 – 1.73) 1.67 (1.44 – 1.78) 
Body mass index (BMI) (Kg/ 
m2) 
12 26.1 ± 3.9 26.4 (22.5 – 29.1) 26.4 (19.8 – 33.1) 
Table 2.6 Baseline clinical characteristics in the EPS/GFS 
Mean ± SD, Median (IQR), and (Range) for baseline clinical parameters recorded in the EPS group/GFS.  
Abbreviations: peritoneal dialysis (PD), dialysate-to-plasma ratio of creatinine (D/Pcr), K - peritoneal 
clearance of urea, t - dialysis time, and V - volume of distribution of urea (Kt/V), creatinine clearance (Crcl). 
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Variables SKI 1 SKI 2 GFS control GFS EPS 
N (male) 31 (19) 51 (29) 42 (18) 12 (6) 
Age (year) 57 (22 – 88), n=31 62 (46 - 72), n=51 54 (18 – 84), n=42 51  (40 - 62), n=12 
Duration on PD (year) 1.1 (0.003 – 6.9), 
n=31 
1.1 (0.1 – 9.1), 
n=51 
1.7 (0.02 – 12.7), n=42 2.6  (0.5 – 4.3) , n=12 
Peritonitis episodes 
 
0 (0 – 1), n=31 0 (0 – 1), n=51 0 (0 – 1.3), n=42 1 (0 – 1), n=11 
D/Pcr at 4hr 0.72 (0.63 – 0.82), 
n=18 
0.74 (0.66 – 0.79), 
n=51 
0.72 (0.62 – 0.81), 
n=42 
0.78 (0.7 – 0.92), 
n=12 
D/D0 gluc at 4hr  0.34 (0.28 – 0.4), 
n=51 
  
UF capacity (mL) 200 (113 – 255), 
n=17 
128 (-94 – 200), 
n=48 
432 (279 – 582), n=42 345 (165 – 440), 
n=12 
Daily UF (mL)   829 (460 – 1406), n=42 1270 (733 – 1500), 
n=12 
Daily water removal (mL)   1838 (1303 – 2254), 
n=42 
1576 (968 – 1771), 
n=12 
Peritoneal Kt/V 1.3 (1.01 – 1.56), 
n=28 
1.18 (0.85 – 1.3) , 
n=51 
1.53 (1.34 – 1.9), n=42 1.75 (1.43 – 1.94), 
n=12 
Renal Kt/V 1.07 (0.24 – 1.52) 
, n=29 
1.38 (0.64 – 1.98) 
, n=51 
0.51 (0.12 – 1.22), 
n=42 
0.22 (0 – 0.74), n=12 
Total Kt/V 2.31 (1.7 – 2.8) ), 
n=28 
2.36 (2.03 – 2.92)  
, n=51 
2.2 (1.8 – 2.7), n=42 2.14 (1.9 – 2.34), 
n=12 
Peritoneal Crcl (l/wk/1.73 
m
2
) 
 25.7 (19.5 – 33.8), 
n=51 
48.1 (42.3 – 58), n=42 58.1 (48.9 – 78.7), 
n=11 
Renal Crcl  66.5 (32.2 – 
101.6), n=51 
23.4 (6.7 – 64.1), n= 42 11.7 (0 – 42), n=12 
Last year glucose 
exposure (g)  
 24604 (6178 – 
36502), n=51 
  
Urine volume (mL)  1400 (820 – 
2130), n=51 
742 (177 – 1434), n=42 179 (0 – 771), n=12 
drain time (min)   15 (10 – 20), n=42   
RV (mL)   251 (190 – 359), 
n=46 
  
eGFR  (mls/min/1.73m
2
)   6 (5 – 12), n=51   
Hydrostatic intra 
peritoneal pressure (cm)  
 16 (13 – 19), n=35   
Serum albumin (g/L)   40 (36 – 42), n=51 37 (32 – 40), n=42 38 (37 – 39), n=10 
Weight (Kg)   70 (57 – 83), n=42 69 (59 – 80), n=12 
Height (m)   1.64 (1.61 – 1.71) , 
n=42 
1.67 (1.57 – 1.73), 
n=12 
BMI (kg/ m
2
)   24.2 (21.9 – 29.3) , 
n=42 
26.4 (22.5 – 29.1), 
n=12 
 
Table 2.7 Baseline Comparison between the 3 patient cohorts 
Comparison of EPS and control groups from GFS with SKI-1 and -2 cohorts.  Median (IQR) for all variables, 
except Age of the patients and duration on PD Median (range). 
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2.7.3.3 PDE samples distribution in the GFS Cohort 
PDE samples from the GFS were not collected at intervals of 3-6 months as 
planned.  Most patients also did not have samples in the last year before 
diagnosis of EPS.  Only two EPS patients had samples within 3 months of EPS 
diagnosis.  Subsequently PDE samples were grouped in intervals of 200 days to 
developing EPS in EPS group or technique termination of PD in the control 
group.  In the last 200 days, there was further subdivision to every 100 days and 
this was helpful by facilitating a better look at late changes.  The sample 
distribution is illustrated in (Figure 2.8).  It is shows variation in sample numbers 
in each interval.  Twelve EPS patients and forty-two control patients were 
included.  Two samples of the 12 EPS patients were obtained in the last 100 
days compared to 10 in the control group. 
 
 
Figure 2.8 PDE samples collection with time in the GFS cohort 
GFS sample distribution by time to development of EPS or termination of PD in control group in GFS 
cohort.  PDE samples were grouped into intervals of 200 days (100 days in the last 200 days) either 
prior to the development of EPS in EPS group or termination of PD without developing EPS in the 
control group. 
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2.8 Experimental laboratory Methods 
Various experimental methods were applied on peritoneal dialysis effluent 
(PDE), plasma samples and cell cytospins.  Experiments methods performed in 
this study were: 
a) Protein measurement 
b) Enzyme activity assays (MMP activity and plasmin activity assays) 
c) Enzyme-linked immunosorbent assays (ELISAs) 
d) Cell staining 
2.8.1 Protein measurement  
Protein concentration was measured in PDE fluid samples using the 
Thermo Scientific™ Pierce™ 660nm protein assay.  It is a fast and ready-to-use 
colorimetric method to measure total protein quantitation.  The assay is claimed 
to more linear and rapid compared to coomassie-based Bradford assays by the 
manufacturer.  Total protein assay methods show some variability toward 
different proteins.  This variable response is due to the variability in amino acid 
sequence, protein structure, isoelectric point, and the presence of certain side 
chains or prosthetic groups. 
Purified protein for the main protein being assayed is the ideal protein for 
standard in any protein assay.  If there is protein that produces similar assay 
response to that of the assayed protein, then it provides the most accurate 
standard.  BSA (Bovine Serum Albumin) and BGG (Bovine Gamma Globulin) are 
the two protein standards used in protein assays.   
A standard curve (0, 0.4, 0.8, 1.2, 1.6, and 2 mg/mL) was prepared from a 
10 mg/mL BSA stock in PBS (phosphate buffered saline).  Each well of a 96 well 
EIA/RIA plate (Corning Incorporated, NY 14831, USA) was loaded with 10 µl of 
standard or sample (suitably diluted) in duplicate.  150 µl of Pierce 660 nm 
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protein assay reagent (Cat# 22660, Thermo Scientifc Pierce Protein assay) was 
subsequently added to each well.  After application of an adhesive plate sealer, 
the plate was mixed on a Stuart plate shaker at  400 RPM for 1 minute.  After 5 a 
minute incubation at room temperature, optical density of each well was read at 
660 nm on 96 well microplate reader using software called Thermo Labsystems 
Multiskan Ascent plate reader (Labsystems, UK). 
2.8.2 Enzyme activity assays 
2.8.2.1 MMP activity assay 
2.8.2.1.1 Rationale for measuring MMP activity 
The ENZchek Gelatinase/Collagenase Assay Kit (E-12055) was used to 
measure MMP activity in PDE.  DQ Gelatin was used as substrate (E-12055, Life 
Technologies - Molecular Probes) (formerly Invitrogen and Applied Biosystems).  
The assay was used to determine the effect of the MMP versus TIMP balance on 
ECM breakdown.  E-12055 cleavage provides high sensitivity, fast, and 
convenient way for measuring gelatinase or collagenase activity in a high-
throughput format. 
2.8.2.1.2 Principle of assay 
DQ labeled gelatin consists of a gelatin molecule (heated Collagen) heavily 
labeled with both a fluorochrome (FITC) and a quenching agent (QA).  The close 
proximity of the fluorochrome and quencher prevents fluorescence.  ECM 
proteases in the sample will breakdown collagen releasing the fluorophore and 
quenching molecules.  The increased space between the quencher and 
fluorochrome allows fluorescence which can then be detected and monitored 
with a fluorescence microplate reader or standard fluorometer (Figure 2.9).  ECM 
proteolytic activity can be assessed by measuring the change in fluorescence 
over time with the proteolytic activity proportional to increase in fluorescence.  
While the majority of ECM proteolytic activity is a result of MMP activity, the use 
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of a broad spectrum but specific MMP inhibitor such as 1,10-Phenanthroline, 
monohydrate can be used to determine which proportion of the activity relates to 
MMPs. 
 
 2.8.2.1.3 Experimental protocol of Gelatinase/Collagenase Activity 
2.8.2.1.3.1 Materials 
The EnzChek Gelatinase/Collagenase Assay Kit consists of the following 
components: 
1) DQ gelatin: Isolated from pig skin and fluorescein conjugate.  Each vial 
contains 1 mg substrate lyophilized from 1 mL of PBS, pH 7.2. 
2) 10X Reaction Buffer:  It consists from 50 mL of 0.5 M Tris-HCl, 50 mM 
CaCl2, 1.5 M NaCl, 2 mM sodium azide, pH 7.6. 
 
Figure 2.9 Principle of the MMP activity assay using DQ labelled substrates 
ENZchek gelatinase/collagenase assay (Molecular probes) using a DQ Gelatin substrate.  MMPs 
cleave collagen causing the release of the fluorophore from the quenched ECM protein.  Excitation of 
the Fluorophore generates a change in fluorescence per unit time that is proportional to the rate of 
breakdown by MMPs and other ECM proteases. 
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3) 1,10-Phenanthroline, monohydrate: MW = 198.2,  a general inhibitor for 
metalloproteinase. 
4) Collagenase Type IV: This is from Clostridium histolyticum.  One unit is the 
amount of enzyme which is required to release 1 µmole of L-leucine 
equivalents from collagen in duration of 5 hours at 37°C with pH 7.5.  
EnzChek Gelatinase/Collagenase Assay Kit contains collagenase purified 
from Clostridium histolyticum to serve as a control enzyme.  100 µg/mL DQ 
gelatin with 2 hours incubation period, the MMP activity assay can be detected 
as low as a final concentration of 0.002 U/mL (7 ng protein/mL).  One unit is the 
amount of enzyme which is required to liberate 1 µmole of L-leucine equivalents 
from collagen in 5 hours at 37°C with pH 7.5.  24 hours incubation can increase 
the sensitivity approximately 10 fold.  Incubation times of 15 minutes are enough 
for high enzyme concentrations such as a final concentration of 0.2–0.4 U/mL.  
 2.8.2.1.3.2 Reagent Preparation 
1) DQ gelatin: The concentration of the stock solution of DQ gelatin was 1.0 
mg/mL.  It was prepared by adding 1.0 mL of deionized water (dH2O) to 
each vial DQ gelatin.  The stock solution was agitated in an ultrasonic 
water bath for approximately 5 minutes and heated to 50°C to help 
dissolution.  The DQ gelatin stock solution should never be frozen 
because it may lead to increase background fluorescence of the 
substrates with freezing and thawing.  Reconstituted DQ gelatin may be 
used fresh or stored in the dark at 4°C.  Sodium azide will be added to a 
final concentration of 2 mM for longer storage.  
2) 10X Reaction Buffer: 1X Reaction Buffer was prepared by diluting 1 mL of 
the 10X Reaction Buffer in 9 mL dH2O.  
3) 1,10-Phenanthroline, monohydrate: 9.9 mg of the 1,10-Phenanthroline, 
monohydrate was dissolved in 25 µL ethanol.  After that 10 µL of this 
solution was added to 2 mL of 1X Reaction Buffer to prepare a 10 mM 
working solution.   
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4) Collagenase Type IV: 1000 U/mL of stock solution was prepared by 
dissolving 500U of Clostridium collagenase in the 0.5 mL dH2O. The stock 
solution can be used for at least 6 months, if it is aliquoted and stored at -
20°C.  
2.8.2.1.3.3 Assay procedure  
MMP activity was assayed on PDE using the ENZchek 
gelatinase/collagenase assay kit with a DQ gelatin substrate according to 
manufactures instruction.  Each well of a 96 well of BD Falcon 96-Well Multiwell 
Micro Plate was loaded with final assay volume of 200 μl as follows:   
100 µl of standard or sample was loaded in duplicate.  For each assay, the 
standard curve was (0, 0.003125, 0.00625, 0.0125, 0.0250, 0.05, 0.1 U/mL) of 
clostridium collagenase using 1X reaction buffer as the diluent.   Samples were 
loaded neat.  80 ul of reaction Buffer was added to each well.  After that, 20 ul of 
a 12.5 µg/mL solution of DQ gelatin was added to each well to complete the final 
volume of 200 μl.  All steps were repeated when assays using 
Gelatinase/Collagenase inhibitors were run except   70 ul of reaction Buffer was 
added + 10 ul of 1,10-phenanthroline monohydrate instead of 80 ul of reaction 
Buffer..  Fluorescence was then measured at room temperature with protection 
from light.  The measurements were taken every 15-20 min in first 3 hours, and 
then the measurements were less frequent for up to 48 hours.  Excitation was set 
at 495 and emission at 515 nm on a Fluorimeter, typically the Varioskan™ Flash 
Reader from Thermo Scientific. 
All assays was performed with and without the general inhibitor of  
metalloproteinase (10 μl 1,10-Phenanthroline, monohydrate) to calculate the 
extent of the proteolytic activity due to MMP activity only.  The rate of reaction 
with MMP inhibitor was subtracted from the rate without to calculate the MMP 
specific cleavage of the substrate.  The reason of measuring fluorescence at 
multiple points was to get good linear reaction rate for all samples.   
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2.8.2.1.3.4 Development and validation of EnzCheck assay for PDE 
Assay protocol was established by testing PDE at different dilutions (1:1, 
1:2, 1:5, 1:10, and 1:20) to determine the best sample dilution to position 
readings in the middle of the standard curve These test runs showed that no 
PDE samples dilution was required as PDE did not affect assay activity & 
because MMP activities were towards the bottom of the standard curve in all 
samples.  The inter assay precision was obtained by repeatedly assaying one of 
the samples in every plate.  The inter‐assay coefficient was below 10%. 
2.8.2.2 Plasmin activity assay 
2.8.2.2.1 Rationale for measuring plasmin activity 
Measuring plasmin activity in PDE samples were used to determine the 
overall effect of the plasmin activity in the samples.  A colorimetric substrate 
V0882 (sigma) was used for measuring the plasmin activity. 
2.8.2.2.2 Principle of assay 
The plasmin activity assay is a colorimetric activity assay using substrate 
V0882 (sigma).     
N-L-valine-L-leucine-L-lycine (Val-Leu-Lys) peptide structure is the 
functional unit of V0882.  (Val-Leu-Lys) is attached to a p-nitroaniline (pNA) 
molecule (Figure 2.10).  Plasmin  willcomplex and cleave the colorimetric 
substrate V0882 releasing the the pNA from the Val-Leu-Lys peptide.  After  
clevage, free pNA part will give a yellow colour to the sample which can be 
measured at 405nm which is proportional to its release and thus plasmin activity. 
D-Val-Leu-Lys-pNa Plasmin> D-Val-Leu-Lys + p-Nitroanilide (El-Shabouri, Hussein 
et al. 1989)  
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The optical density of each well was read at 405 nm on 96 well microplate 
reader (Thermo Labsystems Multiskan Ascent.) with curve fit and analysis 
performed using Genesis software. 
 
2.8.2.2.3 Experimental protocol 
Plasmin activity was assayed in peritoneal dialysis effluent (PDE) using 
cleavageof substrate V0882 (sigma).  100ul of the substrate V0882 (D-Val-Leu-
Lys-pNa substrate 3mM) was added to 100ul of standard or PDE samples in a 96 
well plate.  The absorbances were measured at 405nm at 0,30,60,90 and 120 
minutes on the microplate reader using software called Thermo Labsystems 
Multiskan Ascent plate reader (Labsystems, UK).  The plate was incubated in the 
dark at 37°C during incubation periods.  Plasmin from human plasma (P1867 
(sigma)) was used to obtain for a standard curve (0, 1.25, 2.5, 5, 10, 20 µg/mL) in 
which zero was distilled water.  
 
Figure 2.10  Principle of the plasmin activity assay 
Plasmin activity assayed using cleavage of plasmin substrate V0882 (sigma).  N-L-valine-L-leucine-L-
lycine (Val-Leu-Lys) is the functional unit of V0882. Val-Leu-Lys is attached to a p-nitroaniline (pNA) 
molecule.  Plasmin forms a complex with substrate V0882.  This will lead to cleavage in the bond 
between the pNA and the Val-Leu-Lys structure.  pNA part will be free and  give a yellow colour to the 
sample which can be read at 405nm.  It is reproduced by permission from transfer report, 2011 given 
by John Atkinson. 
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2.8.2.2.4 Development and validation of assay  
Similar to the MMP activity above, the assay protocol was established by 
testing samples at different dilutions.  Neat samples produced the optimal assay.  
The inter‐assay coefficient was always below 10%. 
2.8.3 ELISAs 
 ELISAs (Enzyme-linked immunosorbent assays) are commonly used for 
the quantitative and qualitative assessment of chemokines, cytokines, 
phosphorylated targets, growth factors, immunoglobulins in addition to the other 
immunological markers.  ELISAs are also used for detecting and quantification of 
protein analytes from biological sample such as plasma, serum, cell culture 
supernatants, cell lysates, urine, PDE.  ELISAs are valuable tools in drug 
development because they are widely used for biomarker profiling of healthy 
individuals versus diseases and in toxicity profiling.  Various commercial 
―sandwich‖ ELISAs (pre-coated ELISA or coat-It-Yourself ELISA) were used in 
this study.  ELISA kits were bought from different companies according need.  
The following ELISA kits were used. 
1. Human MMP-1,-2,-3,-9 from R/D system.  MMP-13 from abcam. 
2. Human TIMP-1,-2, and -3 from R/D system. 
3. Human MMP-1/TIMP-1 complex from R/D system. 
4. Human Transferrin and Albumin from AssayPro 
5. Human IgG from Mabtech 
6. Human Beta 2 microglobulin from abcam 
7. Human intelectin-1 from USCN 
8. Human collagen (1) I from USCN 
9. Human dermatopontin I from USCN 
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2.8.3.1 Human MMP-1,-2,-3,-9, TIMP-1,-2,-3, and MMP-1/TIMP-1 Complex 
ELISA Kits (R&D systems Duoset system) 
2.8.3.1.1 Materials 
The standard, capture antibody, and detection antibody are summarized in 
(Table 2.8.A and B).  Streptavidin-HRP (Part 890803, 1 vial) was used same for 
all ELISA.  The streptavidin conjugated to horseradish-peroxidase should be 
stored at a 2 - 8° C for not more than 6 months after opening and never frozen.  
Streptavidin-HRP was diluted 1:200 in R&D reagent diluent.  Other solutions 
required are summarised in (Table 2.9).  In all assays the blocking  solution was 
same as reagent diluent except in Human MMP-1 /TIMP-1 Complex DuoSet 
(DY1550) where 1% BSA in PBS.  Reagent diluent is 0.15 M NaCl, 10 mM 
CaCl2, 50 mM Tris, 0.05% Brij 35, pH 7.45-7.55. 
ELISA Standard Capture Antibody Detection Antibody 
Human 
TIMP-1 
DuoSet 
(DY970) 
80 ng/mL of recombinant 
human TIMP-1 after adding 
0.5 mL of RD to 1 vial. A 7 
point standard curve with two-
fold serial dilutions in RD with 
high standard of 2000 pg/mL. 
360 µg/mL of mouse anti-
human TIMP-1 after 
reconstituted with 1 mL of 
PBS. Working 
concentration is 2 µg/mL 
in PBS. 
9 µg/mL of biotinylated goat 
anti-human TIMP-1 after 
reconstituted with 1 mL of 
RD. Working concentration is 
50 ng/mL in RD. 
Human 
TIMP-2 
DuoSet 
(DY971) 
70 ng/mL of recombinant 
human TIMP-2 after adding 
0.5 mL of RD to 1 vial. A 7 
point standard curve with two-
fold serial dilutions in RD with 
high standard of 2000 pg/mL. 
360 µg/mL of mouse anti-
human TIMP-2 after 
reconstituted with 1 mL of 
PBS. Working 
concentration is 2 µg/mL 
in PBS. 
9 µg/mL of biotinylated goat 
anti-human TIMP-2 after 
reconstituted with 1 mL of 
RD. Working concentration is 
50 ng/mL in RD. 
Human 
TIMP-3 
DuoSet 
(DY973) 
90 ng/mL of recombinant 
human TIMP-3 after adding 
0.5 mL of RD to 1 vial. A 7 
point standard curve with two-
fold serial dilutions in RD with 
high standard of 4000 pg/mL. 
360 µg/mL of mouse anti-
human TIMP-3 after 
reconstituted with 1 mL of 
PBS. Working 
concentration is 2 µg/mL 
in PBS. 
360 µg/mL of biotinylated 
mouse anti-human TIMP-3 
after reconstituted with 1 mL 
of RD. Working concentration 
is 2 µg/mL in RD. 
Table 2.8.A Materials required in TIMP ELISA kits 
Standard, capture antibodies, and detection antibodies used for performing R&D ELISAs, for human TIMP-
1,-2, and -3 duosets (R&D systems). 
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ELISA Standard Capture Antibody Detection Antibody 
Human 
MMP-1 
DuoSet 
(DY901) 
180 ng/mL of recombinant 
human MMP-1 after adding 
0.5 mL of diH2O to 1 vial. A 7 
point standard curve with two-
fold serial dilutions in RD, with 
high standard of 10,000 
pg/mL.  
360µg/mL of goat anti-
human MMP-1 after 
reconstituted with 1 mL of 
PBS. Working 
concentration is 2 µg/mL 
in PBS. 
18 µg/mL of biotinylated goat 
anti-human MMP-1 after 
reconstituted with 1 mL of 
RD. Working concentration is 
100 ng/mL in RD. 
Human 
MMP-2 
DuoSet 
(DY902) 
2100 ng/mL of recombinant 
human MMP-2 after adding 
0.5 mL of diH2O. A 7 point 
standard curve with two-fold 
serial dilutions in RD with high 
standard of 20 ng/mL. 
360 µg/mL of mouse anti-
human MMP-2 after 
reconstituted with 1 mL of 
PBS. Working 
concentration is 2 µg/mL 
in PBS. 
90 µg/mL of biotinylated 
mouse anti-human MMP-2 
after reconstituted with 1 mL 
of RD. Working concentration 
is 500 ng/mL in RD. 
Human 
MMP-3 
DuoSet 
(DY513) 
90 ng/mL of recombinant 
human MMP-3 after adding 
0.5 mL of diH2O. A 7 point 
standard curve with two-fold 
serial dilutions in RD with high 
standard of 2000 pg/mL. 
144 µg/mL of goat anti-
human MMP-3 after 
reconstituted with 1 mL of 
PBS. Working 
concentration is 0.8 µg/mL 
in PBS. 
36 µg/mL of biotinylated goat 
anti-human MMP-3 after 
reconstituted with 1 mL of 
RD. Working concentration is 
100 ng/mL in RD. 
Human 
MMP-9 
DuoSet 
(DY911) 
50 ng/mL of recombinant 
human MMP-9 after adding 
0.5 mL of diH2O. A 7 point 
standard curve with 2-fold 
serial dilutions in RD with high 
standard of 2000 pg/mL.  
180 µg/mL of mouse anti-
human MMP-9 w after 
reconstituted with 1 mL of 
PBS. Working 
concentration is 1 µg/mL 
in PBS. 
36 µg/mL of biotinylated goat 
anti-human MMP-9 after 
reconstituted with 1 mL of 
RD. Working concentration is 
100 ng/mL in RD with 2% 
heat inactivated normal goat 
serum (prepare 1-2 hrs prior 
to use). 
Human 
MMP-
1/TIMP-1 
Complex 
DuoSet 
(DY1550) 
90 ng/mL of recombinant 
human TIMP-1 after adding 
0.5 mL of RD. A 7 point 
standard curve with 2-fold 
serial dilutions in RD with high 
standard of 4000 pg/mL. 
288 µg/mL of goat anti 
human MMP-1 after 
reconstituted with 1 mL of 
PBS. Working 
concentration is 1.6 µg/mL 
in PBS. 
18 µg/mL of biotinylated goat 
anti-human TIMP-1 after 
reconstituted with 1 mL of 
RD. Working concentration is 
100 ng/mL in RD. 
Table 2.8.B Materials required in MMP and MMP-1 /TIMP-1 complex ELISA kits 
Standard, capture antibodies, and detection antibodies used for performing R&D ELISAs, for human MMP-
1,-2,-3, -9, and MMP-1 /TIMP-1 complex duosets (R&D systems). 
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Solution Composition 
PBS 1.5 mM KH2PO4, 2.7 mM KCl, 8.1 mM Na2HPO4, 137 
mM NaCl, pH 7.2 - 7.4. 
Wash Buffer 0.05% Tween  20 in PBS  
Reagent Diluent 1% BSA in PBS 
Substrate Solution  
 
Colour Reagent A (H2O2) & Colour Reagent B 
(Tetramethylbenzidine) 1:1 
Stop Solution  2 N H2SO4 
 
Table 2.9 Solutions required in Human MMPs and TIMPs ELISAs 
Solutions and their composition which are required for MMPs and TIMPs ELISAs 
2.8.3.1.2 Assay procedure 
Specific ELISA kits were used to measure different MMPs, TIMPs, and the 
MMP-1/TIMP-1 complex in PDE fluid.  The assays were performed according to 
manufacturer‘s instructions in all cases.  Commercial DuoSet ELISA kits (R&D 
systems) were used in all assays except MMP-13.  MMP-13 was from abcam 
(MMP-13 Human ELISA/ab100605). 
In all commercial DuoSet ELISA kits, the capture antibodies were coated 
and covered with an adhesive strip overnight at room temperature prior to 
running the assay.  Next day, aspiration and washing of each well was performed 
using washing buffer for three times (0.05% Tween 20 in PBS).  After that, 300 
µL of reagent diluent was added to each well and covered with a new adhesive 
strip to block the plate at room temperature for a minimum of 1 hour.  Then, 
aspirate and wash 3x with 0.05% Tween 20 in PBS.  After that, the plates were 
ready for the addition of samples and standards.  One hundred µL of samples or 
standards in reagent diluent were added per well and covered with a new 
adhesive strip and incubated for 2 hours at room temperature. 
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 After that, repeat the aspiration & washing step prior to 100 µL of the 
detection antibody diluted in reagent diluent being added to each well.  The plate 
was covered with a new adhesive strip and incubated for 2 hours at room 
temperature.  Following a repeat aspiration & wash, 100 µL of the working 
dilution of Streptavidin-HRP was added to each well and covered with a new 
adhesive strip and incubated for 20 minutes at room temperature in a dark place.  
Then, repeat the aspiration & wash step prior to 100ul of Substrate Solution [1:1 
mixture of Colour Reagent A (H2O2) and Colour Reagent B 
(Tetramethylbenzidine)] being added to each well and incubated for 20 minutes 
at room temperature avoiding direct light.  After that, 50 µL of Stop Solution (2 N 
H2SO4) was added to each well.  Gently tap the plate to ensure thorough mixing.  
The optical density of each well was read at 450 nm on 96 well microplate reader 
using Ascent Genesis software on a Thermo Labsystems Multiskan Ascent plate 
reader. 
2.8.3.2 Human MMP13 ELISA Kit (abcam) 
Unlike the rest of the MMP and TIMP ELISA, the MMP13 Human Elisa Kit 
was bought from abcam (ab100605).   
2.8.3.2.1 Materials and solutions 
The materials and solutions of (ab100605) should be at room temperature 
prior to use (Table 2.10).  There are other materials which are not provided with 
kits, but they are required including microplate reader with ability to measure at 
450 nm, precision pipettes, Adjustable 1-25 mL pipettes as this required for 
reagent preparation, cylinders, tubes for standard and sample preparation, 
distilled water, absorbent paper, and computer and software for ELISA data 
analysis. 
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Item Amount Notes 
MMP13 Microplate  (pre-coated) 1 X 96 wells  
Recombinant Human MMP13 
Standard 
2 vials A 7 point standard curve was 
prepared according to manufacturer‘s 
procedure (0, 8.2, 24.69, 74.1, 222.2, 
666,7, 2000 pg/mL) 
Biotinylated anti-Human MMP13 2 vials 1X Biotinylated MMP13 Detection 
Antibody (Ab) was prepared by 
spining the vial of Biotinylated anti-
Human MMP13 for few seconds. 
Then, add 100 μL of 1X Assay Diluent 
into the vial and mix it gently. The 
detection Ab was diluted 80-fold by 1X 
assay diluent before use in the Assay. 
20X Wash Solution 
25 mL It was diluted to 1 X wash solution in 
diH2O 
5X Assay Diluent 15 mL It was diluted to 1 X assay diluent in 
diH2O 
HRP-Streptavidin Concentrate 200 µL It should be diluted 35000-fold by 1X 
assay diluent 
Substrate Reagent (TMB One-Step) 12 mL  
Stop Solution 8 mL  
 
Table 2.10 Materials and solutions required in MMP13 human ELISA Kit 
Materials and solutions with their amounts, dilutions and preparations according to the manufacturer‘s 
instructions (ab100605).  
2.8.3.2.2 Assay procedure 
An antibody pre-coated 96-well plate is used for this assay. All materials are 
brought to room temperature prior to use.  100 μL of each standard and PDE 
samples (neat) were loaded in wells.  The plate was covered and incubated for 
2.5 hours with gentle shaking at room temperature.  If MMP13 is present in any 
samples, then it will bound to the wells via the immobilized antibody.  The 
samples/standards were then discarded & wash with 1X Wash Solution (4 times).  
100 μL of 1X Biotinylated MMP13 Detection Ab was added to each well & 
incubated for 1 hour with gentle shaking at room temperature.   
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After that unbound biotinylated Ab was washed away.  100 μL of 1X HRP-
Streptavidin solution was added to each well & incubated for 45 minutes with 
gentle shaking at room temperature.  Post washing, 100 μL of TMB One-Step 
Substrate Reagent was added to each well.  It was incubated for 30 minutes in 
the dark with gentle shaking at room temperature.  50 μL of stop Solution was 
added to each well.  Finally, optical density of each well was read at 450 nm on 
96 well microplate reader as previously. 
2.8.3.3 Human albumin and transferrin ELISA Kits (AssayMax) 
Commercially available sandwich ELISAs were used for measuring albumin 
and transferrin in samples.  These kits were AssayMax Human Albumin ELISA 
Kit, catalog No. EA3201-1, Lot No. 02021212 and AssayMax Human Transferrin 
ELISA Kit, catalog No. ET3105-1, Lot No. 04721227. 
2.8.3.3.1 Principal of the Assays 
Human albumin and transferrin ELISA kits were used for quantifying 
albumin and transferrin respectively.  Each was a quantitative sandwich enzyme 
immunoassay.  Specific polyclonal antibodies for human albumin or transferrin 
had been pre-coated onto a 96-well plate allowing albumin or transferrin to be 
sandwiched between the capture antibody and biotinylated secondary polyclonal 
antibodies. Secondary antibody was detected by a streptavidin-peroxidase 
conjugate using a TMB substrate.  The developed colour was stopped.  After 
that, the colour intensity was measured. 
2.8.3.3.2 Materials 
All reagents should be brought to the room temperature before use.  The 
standard, antibodies, and other materials are summarized in (Table 2.11).  The 
kit components were either stored at -800C or -200C upon arrival.  
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Materials Albumin Transferrin 
96-well polystyrene 
microplate 
Coated with polyclonal antibodies 
for human albumin 
Coated with polyclonal antibodies 
for human transferrin 
Sealing Tapes 3 pre-cut tapes 3 pre-cut tapes 
Standard Human albumin in a buffered 
protein base (800 ng, lyophilized) 
Human transferrin in a buffered 
protein base (1 μg, lyophilized) 
Biotinylated Antibody Biotinylated Human Albumin 
Antibody. It is 80-fold concentrated 
antibody (100 μL) 
Biotinylated Human Albumin 
Antibody. It is 100-fold 
concentrated antibody (80 μL) 
MIX Diluent 
Concentrate 
10-fold concentration of the 
buffered protein base (30 mL) 
10-fold concentration of the 
buffered protein base (30 mL) 
Wash Buffer 20-fold concentration of the 
buffered surfactant (60 mL) 
20-fold concentration of the 
buffered surfactant (60 mL) 
Streptavidin-
Peroxidase Conjugate 
100-fold concentration (80 μL) 100-fold concentration (80 μL) 
Chromogen Substrate Tetramethylbenzidine (8 mL).  It is 
a stabilized peroxidase chromogen. 
Tetramethylbenzidine (8 mL).  It 
is a stabilized peroxidase 
chromogen. 
Stop Solution 0.5 N hydrochloric acid (12 mL) 0.5 N hydrochloric acid (12 mL) 
Table 2.11 Materials and solutions required in human albumin and transferrin 
ELISA Kits 
Materials and solutions with their amounts and dilutions according to the manufacturer instructions from 
AssayMax. 
2.8.3.3.3 Reagent Preparation  
1) Diluent Concentrate (10-fold):  Mix the diluent concentrates gently to 
dissolve any crystals that have been formed prior to dilution in 1:10 with reagent 
grade water after which it can be stored for up to 1 month at 2-8 oC.2). 
2) Standard Curve: Reconstitute the 800 ng of Albumin or 1 μg of 
Transferrin standard with 4 and 2.5 mL of diluent respectively to make a standard 
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solution of 200 ng/mL of albumin and 400 ng/mL of transferrin (stock solutions).  
The standards were agitated gently for 10 minutes before making dilutions.  For 
both albumin and transferrin, duplicate standard points were prepared by serially 
diluting of the stock solutions.  Eight points standard curve for albumin were 
made.  These were 200, 100, 50, 25 12.5, 6.25, 3.125 and 0 ng/mL, while the 
standard curve for transferrin were 100, 50, 25, 12.5, 6.25, 3.125, 1.563 and 0 
ng/mL.  The mix diluents were used as diluents. 
3) Biotinylated human albumin antibody (80-fold) or biotinylated 
transferrin antibody (100-fold): The antibodies were spun down briefly and 
then they were diluted to the desired amount of the antibody (1:80 for albumin 
and 1:100 for transferrin) with diluent.  The remaining solutions were stored at -
20 C. 
4) Wash Buffer Concentrate (20-fold): If crystals have been formed in the 
wash buffer concentrate, then mix gently until the crystals have been dissolved 
completely.  It was diluted by 1:20 with reagent grade water. 
5) Streptavidin-Peroxidase Conjugate (100-fold): It was spun down 
briefly and then diluted 100 times with diluent.  The remaining solutions were 
stored at -20 C. 
2.8.3.3.4 Assay Procedure  
The assay procedures were similar for albumin and transferrin.  All 
reagents, working standards and solutions were prepared as instructed.  All 
reagents (either albumin or transferrin reagents) were brought to the room 
temperature before use in the experiments and the assays were performed at 
room temperature between 20-30 0C.  50 μL of standard or sample were loaded 
per well.  The wells were covered with a sealing tape.  The incubation period was 
1 hour and 2 hours in albumin and transferrin assays respectively. 
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The solutions were discarded from the wells and washed out manually 
using 1X wash buffer (5 times).  50 μL of biotinylated human albumin or 
transferrin antibodies were loaded into each well for an incubation period of 30 
minutes.  After that, the plate was washed 5 times and 50 μL of streptavidin-
peroxidase conjugate added & incubated for 30 minutes at.  Wash the microplate 
again as described above and add 50 μL of chromogen substrate for 15 minutes 
for albumin and 10 minutes for transferrin.  The plates were tapped gently to 
ensure thorough mixing50 μL of the stop solutions was added to each well and 
the optical density read at 450 nm as previously.   
2.8.3.4 Human beta 2 microglobulin (B2M) ELISA kit (abcam) 
The kit must be stored immediately at the -20°C upon the receipt, (product 
code ab99977). 
2.8.3.4.1 Materials and reagent preparation  
The contents of the kit and methods of the reagent preparation are 
illustrated in (Table 2.12). 
2.8.3.4.2 Assay procedure 
All reagents, working standards and solutions were prepared as instructed.  
All reagents were brought to the room temperature before use in the experiment 
and the assay was performed at room temperature.  Antibody specific for Human 
B2M were pre-coated onto a 96-well plate.  100 μL of standards and samples 
were loaded into the wells for two and half hours.  The solutions were discarded 
from the wells and washed out manually using 1X wash buffer (4 times).  100 μL 
of biotinylated B2M detection antibody were loaded to each well for an incubation 
period of 1 hour.  After washing away unbound biotinylated antibody in a similar 
to the previous wash step (4 times), HRP-conjugated streptavidin (100 μL) was 
loaded into each well and incubated for 45 minutes.  The wells were again 
washed, and then a TMB substrate solution (100 μL) was added for 30 minutes.  
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The Stop solution (50 μL) was added.  Optical density of each well was read at 
450 nm on 96 well microplate reader as previously.   
Materials Reagent preparation 
B2M microplate (96 wells) (1 plate)  
Assay diluent A (2 x 30 mL)  
Assay diluent B (5-fold) (15 mL) Assay diluent B was diluted 1:5 with distilled water. 
Wash buffer concentrate (20-fold) 
(25 mL) 
If the crystals have been formed in the wash buffer 
concentrate, then mix gently until the crystals have been 
dissolved completely. It was diluted by 1:20 with distilled 
water.  
Recombinant human B2M standard 
(2 vials) 
Standard was prepared immediately before using in the 
assay (fresh preparation). The vial was spun briefly and 
400 μL Assay Diluent A (for plasma) was added or 400 
μL 1X Assay Diluent B (for PDE) was added to prepare 
50 ng/mL B2M Stock Standard.  Eight points standard 
curve for B2M were made.  These were 1000, 500, 250, 
125, 62.5, 31.25, 15.6 and zero pg/mL. 
Biotinylated anti-human B2M  
(2 vials) 
A vial of biotinylated anti-Human B2M was spun briefly. 
100 μL of 1X Assay Diluent B was added into the vial to 
make a detection antibody oncentrate. Then, pipette up 
and down to mix gently. It is important to store the 
concentrate either at 4°C for 5 days or it needs to be 
aliquoted and frozen at -20°C for up to 2 months). The 
detection antibody concentrate was diluted 1:80 with 1X 
assay diluent B before using it in the assay procedure. 
HRP-streptavidin concentrate (300-
fold) (200 μL) 
A vial of the 300X HRP-streptavidin concentrate was 
spun briefly. HRP-streptavidin concentrate were diluted 
1:300 with 1X assay diluent B before using it in the assay 
procedure. 
TMB (substrate reagent) (12 mL)  
Stop solution (8 mL)  
Table 2.12 Materials and solutions required in human beta 2 microglobulin ELISA 
Kit 
Materials and solutions with their amounts and dilutions according to the manufactures instructions. 
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2.8.3.5 Human IgG ELISA kit (Mabtech) 
The standard vial was stored at the -20°C upon receipt, while the capture 
and detection antibodies were stored at 4-8 0C. (Product code 3850-1AD-6). 
2.8.3.5.1 Materials and reagent preparation 
The kit consists of the following: 
 Incubation buffer: PBS with 0.05% Tween 20 (PBS-Tween) containing 
0.1% BSA.  It is used not only as block solution, but also as diluent.  The 
same buffer was used for dilution and blocking. 
 Monoclonal capture antibody (MT145): Supplied in sterile-filtered PBS (0.2 
µm) with sodium azide (0.02%).  The volume was 300 µL at a, 
concentration of 0.5 mg/mL. 
 ALP-conjugated detection antibody (MT78-ALP).  Supplied in Tris-buffer 
(0.1 M) with 0.15% Kathon and 1% BSA. 
 Lyophilized human IgG standard.  11 points for a standard curve were 
prepared ranging from 0.2 to 100 ng/mL using incubation buffer  as diluent 
to prepare the curve.  The preparation of the standard was started by 
adding 500 μl PBS to the vial which made up a stock solution of 50 μg/mL.  
This stock solution must be used immediately or stored in aliquots at -20°C 
for any future uses. 
 Substrate were not included and bought separately.  High sensitivity pNPP 
substrate was used because it is suitable for ELISA assays with alkaline 
phosphatase (ALP).  The substrate was supplied in diethanolamine buffer 
and it is ready-to-use solution.  A soluble yellow product was produced 
after adding the substrate which is measured at 405 nm.  The substrate 
can be bought from Sigma-Aldrich or Mabtech.  
 Washing buffer PBS-Tween: 0.05% Tween 20 in PBS, pH 7.2-7.4. 
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2.8.3.5.2 Assay procedure 
The ELISA plate was coated with MT145 antibody after diluting the antibody 
to 2 μg/mL in PBS pH 7.4.  100 μl of this antibody was placed in each well and 
incubated overnight at 4-8°C.  The following day, the plate was washed twice 
with washing buffer (200 μl/well) & 200 μL of block solution (Incubation buffer) 
added & incubated for 1 hour at room temperature.  After 1 hour, the plate was 
washed out five times with washing buffer & 100 μL of standard or samples 
diluted in incubation buffer loaded into each well followed by incubation for 2 
hours at room temperature.  After the incubation period, the plate was washed 
out five times with washing buffer & 100 μL of MT78-ALP diluted 1:1000 in 
incubation buffer added.  After incubation for 1 hour at room temperature, the 
plate was washed out five times with washing buffer.  100 μL p-nitrophenyl-
phosphate (pNPP) was loaded on each well.  After a suitable development time 
(30 minutes), optical density of each well was read at 405 nm on 96 well 
microplate reader as before.   
2.8.3.6 ELISAs from USCN for the detection of intellectin-1, dermatopontin 
and collagen 1(I) 
1. E90933Hu 96 Tests, Enzyme-linked Immunosorbent Assay Kit For 
Omentin, Organism: Homo sapiens (Human), USCN 
2. E92432Hu 96 Tests, Enzyme-linked Immunosorbent Assay Kit For 
Dermatopontin, Organism: Homo sapiens (Human), USCN 
3. E90350Hu 96 Tests, Enzyme-linked Immunosorbent Assay Kit For 
collagen (1) I, Organism: Homo sapiens (Human), USCN 
The 96-well plate must be stored at -20 C, while the rest of the kit must be 
stored at 4 OC. 
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2.8.3.6.1 Materials and reagents preparation  
The contents of the kits and methods of the reagent preparations are given 
in (Table 2.13). 
Materials Reagent preparation 
Pre-coated and ready to use 96-well 
plate for either intelectin-1, COL1a1 or 
DPT 
 
Standard Diluent  
Assay Diluent A (2-fold) for either 
intelectin-1, COL1a1 or DPT 
6mL of Assay Diluent A concentrate (2×) was diluted with 6mL of 
distilled water to made 12 mL of Assay Diluent A.  
Assay Diluent B (2-fold) for either 
intelectin-1, COL1a1 or DPT 
6mL of Assay Diluent B concentrate (2×) was diluted with 6mL of 
distilled water to made 12 mL of Assay Diluent B.  
Wash buffer (30-fold) Distilled water was used to dilute wash buffer concentrate to get 
wash buffer (1×) 
Lyophilized standard (lyophilized) for 
either intelectin-1, COL1a1 or DPT 
Standard for intelectin-1, COL1a1 or DPT were reconstituted with 
1.0mL of standard diluent and it was kept for 10 minutes at room 
temperature with shake gently.  The concentrations of the 
standard in the stock solution were 500pg/mL for intelectin-1, 
80ng/mL for COL1a1 and 40ng/mL for DPT. 
Series concentration of standard were produced for intelectin-1 
(500, 250, 125, 62.5, 31.2, 15.6, 7.8 and 0 pg/mL), for COL1a1 
(20, 10, 5, 2.5, 1.25, 0.625,0.312 and 0 ng/mL), and for DPT (10, 
5, 2.5, 1.25, 0.625,0.312, 0.156 and 0 ng/mL). 
Detection Reagent A for either 
intelectin-1, COL1a1 or DPT 
Stock of detection A was spun briefly prior to use. It was diluted to 
the working concentration (1:100) using working Assay Diluent A. 
Detection Reagent B for either 
intelectin-1, COL1a1 or DPT 
Stock of detection B was spun briefly prior to use. It was diluted to 
the working concentration (1:100) using working Assay Diluent B. 
Plate sealer for 96 wells  
TMB Substrate  
Stop Solution  
Table 2.13 Materials and solutions required in human intelectin-1, collagen type I 
alpha 1, and dermatopontin  ELISA Kits 
Materials & solutions with their amounts and dilutions according to the manufactures instructions from 
USCN. 
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2.8.3.6.2 Assay procedure 
All reagents, working standards and solutions were prepared as instructed 
& brought to the room temperature before use.  100μL standard (intelectin-1, 
COL1a1 or DPT) or sample was added to each well with incubation for 2 hours at 
370C.  After 2 hours, the liquid in the wells were removed, but not washed.  
100μL of prepared detection reagent A (detection reagent A for intelectin-1, 
COL1a1 or DPT) was added to each well & incubated for 1 hour at 370C.  After, 
the plate was washed out three times with washing buffer.  100μL of prepared 
detection reagent B was added to each well & incubated for 30 minutes at 370C.  
The plate was washed out three times with washing buffer.  90μL of substrate 
solution was added to each well and incubated for 20 minutes at 370C.  The plate 
was protected from light.  50μL of stop solution was added to each well & optical 
density of each well was read at 450 nm as previously   
2.8.3.7 Precision for all ELISA kits 
Inter-assay Precision (Precision between assays): 1-3 samples were always 
repeat tested in all ELISAs to calculate CV. The target inter-Assay CV was 
always below 10%. 
2.8.3.8 Technical hints for all ELISA kits 
When performing ELISAs, the use of high quality BSA for the reagent 
diluent is important for the ideal performance of the assays.  Impurities in BSA 
preparations can interfere with the detection of certain analytes.  The wash 
technique is crucial for proper assay performance.  Wash buffer should be 
removed forcefully and completely from the wells via decanting or aspiration.  
Any remaining wash buffer can be removed by inverting and blotting the plate 
against clean paper towels.  Microbial contamination of buffers and reagents 
should be avoided because it may interfere with the assay sensitivity.  Bubbling 
and foaming should be avoided during reconstituting or mixing components.  The 
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plate should be properly covered in incubation period.  It is very important to 
briefly spin down the standard vial because the powder may fall from the cap 
during opening the standard vial, if it is not spun down.  Lyophilizedilised 
materials must be dissolved thoroughly and gently during reconstituting without 
vortex.  Vortex may lead to protein destabilization of the standard.  It is also 
important to keep special care about the microplate strips.  It is important to 
remove and store the excess microplate strips from the plate frame immediately 
by returning them to the foil pouches provided by company which contain 
desiccant inside.  Then, reseal the pouch tightly to minimize exposure to water 
vapor and store in -20 C.  It is important to avoid mixing reagents or materials 
between the ELISA kits even if they are all for detecting same protein and they 
were purchased from same company.  The other important technical hint is that 
residual substrate solution should not be dumped back into the main vial.  Any 
solution with crystals needs to be warmed at room temperature by mixing the 
solution vial gently until the crystal dissolved completely.  Another important 
technical point is to be ensured that calibration of the pipettes is accurate.  TMB 
Substrate must be protected from light.  It is also advised to remove fingerprint or 
drop of water on the bottom of the 96 wells plate and ensure there are no 
bubbles on the liquid surface.  Finally, it is essential to run the microplate reader 
immediately after stopping the substrate in the plates. 
2.8.4 Cell staining 
Immunohistchemistry (IHC) is a staining technique used for identification of 
protein expression or antigen in cell samples by using a specific antibody that 
binds to it.  The antibody allows visualization of the protein under a microscope.  
With IHC it is possible to determine specific cell component localisation and 
distribution. IHC has many applications including diagnosis of illnesses, 
development of medications and for biological research purposes. 
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The processes of PD cytospin for slide preparation are described in (section 
2.3).  In the SKI-2 patient cohort, overnight bags were used for slide preparation.  
PD fluids with suspended cells were centrifuged using a centrifuge for 8 minutes, 
at 2000 g and 4ºC.  The pellet was suspended in 2mL of PD fluid and 300 μL 
loaded onto a cytospin.  Cytospin was performed at 1200g for 10 minutes.  Eight 
slides were obtained for each patient.  Cells were fixed in acetone for 10 minutes 
at -20oC.  Slides were then left to dry at room temperature for 15 minutes.  Slides 
were labelled with a pencil & stored at -20oC until used for immunocytochemistry.   
In the day of cell staining, the endogenous peroxidase activity was 
quenched by immersing in a solution of 3% hydrogen peroxide in methanol for 20 
minutes after that rinsed in dH2O.  Slides were rinsed in PBS, then blocked with 
serum from the Impress Kit (catalog number was MP-7500 from Vector 
laboratories). The slides were incubated with primary antibody for 1 hour at room 
temperature (Type of primary antibody is different according to the cell of interest 
to be stained).  Trial staining runs were conducted to find the optimum dilution.  
Dilutions were made up in sterile PBS.  Slides were washed again with stirring in 
PBS for 5 minutes (x2).  Slides were incubated with the secondary biotinylated 
antibody from the Impress Kit.  Slides washed for 5 minutes with stirring in PBS.  
Meanwhile, diaminobenzidine (DAB) was prepared as per kit instructions (5 mL 
dH2O plus 2 drops of buffer, 4 drops of DAB solution and 2 drops of peroxide). 
Slides were incubated in chromagen, viewing the colour development under 
microscope.  The reaction was stopped by dH2O. After that, counterstain for 15-
30 seconds in Haematoxylin, blue with Scotts‘ Tap water.  Slides were 
coversliped in consul mount and dried overnight. 
2.8.4.1 Primary antibody 
All four primary antibodies used were bought from Dako.  Monoclonal 
mouse anti-human CD68 Clone PG-M1 was used for macrophages, monoclonal 
mouse anti-human CD45 leukocyte common antigen (Clone 2B11 + PD7/26) was 
used for leukocyte, monoclonal mouse anti-human mesothelial cell clone HBME-
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1 was used for mesothelial cells, and polyclonal rabbit anti-human S100A4 was 
used for fibroblasts as shown in (Table 2.14). 
Targeted cell (cell marker) Primary antibody (Dilution)  Source  
Macrophages (CD68) Monoclonal mouse Anti-Human CD68 Clone PG-
M1, (1:100) 
(Dako, 
M0876, UK)  
Leukocytes (CD45) Monoclonal Mouse Anti-Human CD45 Leukocyte 
Common Antigen (Clone 2B11 + PD7/26), (1:50) 
(Dako, 
M0701, UK)  
Mesothelial cells Monoclonal Mouse Anti-Human Mesothelial Cell 
Clone HBME-1, (1:75) 
(Dako, 
M3505, UK)  
Fibroblasts (FSP-1) Polyclonal Rabbit Anti-Human S100A4, (1:200) (Dako,  
A5114, UK) 
Table 2.14 Primary antibodies used for various cell staining 
Primary antibodies used in cell staining with sources and dilutions. 
2.8.4.2 Secondary antibody 
ImmPRESS™ universal reagent, anti-mouse/rabbit IgG was used as 
secondary antibody in the protocol (catalog number was MP-7500 from Vector 
laboratories) being stored at 2 - 8 °C prior to use.  Vector ImmPRESS™ reagent 
is ready-to-use and needs no dilution. The ImmPRESS™ polymerized reporter 
enzyme staining system.  The ImmPRESS™ reagents have a ―micro-polymer‖ of 
very active peroxidase with a mixture of anti-mouse IgG as well as anti-rabbit IgG 
secondary antibodies. The ImmPRESS™ reagent is provided pre-diluted.  
Ready-to-use 2.5% of normal horse serum blocking solution was also included.  
ImmPRESS™ universal kit consisted of the 50 mL ImmPRESS™ Universal anti-
mouse/rabbit IgG Reagent and 50 mL Ready-to-use normal horse serum 
blocking solution.  The peroxidase substrate which is used is Diaminobenzidine 
(DAB). It produced a brown colour. 
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2.8.4.3 DAB Peroxidase Substrate  
Vector® DAB Substrate (3,3‘-diaminobenzidine, catalog number- SK-4100) 
yields a brown reaction product when oxidized by HRP. If nickel chloride is added 
to the substrate working solution, this results in a grey-black colouration.  
Vector® DAB Substrate can be used on cells or tissue sections, or even on 
membranes such as nitrocellulose.  The Vector® DAB Substrate Kit has all of the 
reagents essential to prepare either a DAB or a DAB/nickel substrate working 
solution. These reagents were supplied in convenient dropper bottles (6 mL DAB 
Stock Solution, 6 mL Hydrogen Peroxide Solution, 6 mL Buffer Stock Solution, 6 
mL Nickel Solution).  The substrate was stored at 2 - 8 °C in dark place.   
2.8.4.4 Photomicrography  
An Olympus BX61 microscope with 2CC-12 FW colour digital camera was 
used for taking photographs. Neutral density filters were used when required.  
400X was used as an objective magnification. The capture software was 
Olympus Cell^F image analysis version. 
2.8.4.5 Cell counting  
Fifteen random non-overlapping fields at 400x magnification were captured 
for each slide.  The total number of cells for each slide was counted manually.  
Positive stained cells from the fifteen slides images were counted and divided by 
total cell count (positive and negative cells) for each image to obtain the 
percentage of positive stained cells.  The means were calculated for 15 images 
per slide using Microsoft Excel 2010. 
2.9 Statistical analysis 
Analysis was performed using Microsoft Excel 2010 software, SPSS 
Statistics 21, and Graphpad prism (prism 6.01 for windows). P<0.05 was 
109 
 
considered statistically significant.  Continuous data with normal distribution were 
expressed as means±SD or SE, while those with skewed distribution were 
expressed as median (IQR) or (range).  Various tests had been used according 
to the need (Table 2.15).  G*Power 31.3 was used for calculating sample size.  
The correlations run between various data and they were examined by Pearson 
correlation coefficient.  Guidelines for interpreting correlations (Pearson‘s r) were: 
r = +.70 or higher.  It means very strong positive relationship  
r= +.40 to +.69.  It means strong positive relationship  
r= +.30 to +.39.  It means moderate positive relationship  
r= +.20 to +.29.  It means weak positive relationship  
r= +.01 to +.19.  It means no or negligible relationship  
r= -.01 to -.19.  It means no or negligible relationship  
r=-.20 to -.29.  It means weak negative relationship  
r= -.30 to -.39.  It means moderate negative relationship  
r= -.40 to -.69.  It means strong negative relationship  
r= -.70 or higher.  It means very strong negative relationship 
2.10 Copyright permission 
Permission was obtained for figures obtained from other sources as shown 
in the legend of the figures and appendix 7. 
 
110 
 
Statistical tests Reasons of use 
Unpaired t test 
 
Unpaired data with Gaussian distribution, and 
equal SDs (two groups) 
Unpaired t test with Welch's correction 
 
Unpaired data with Gaussian distribution, and 
unequal SDs (two groups) 
Mann Whitney test Unpaired data with non-Gaussian distribution 
(two groups). 
One way ANOVA Unpaired data with Gaussian distribution (three 
or more groups) 
Kruskal-Wallis test 
 
Unpaired data with non-Gaussian distribution 
(three or more groups) 
Friedman test Each row represents matched data with non-
Gaussian distribution (three or more groups). 
Post-hoc comparisons using the Tukey's 
multiple comparisons test 
Compare the mean of each column with the 
mean of every other column 
The correlation test (Compute Pearson 
correlation coefficient). 
Gaussian distribution of the data 
Table 2.15 Statistical tests 
Various statistical tests had been used with the reasons of using them. 
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CHAPTER THREE 
Changes in ECM proteolytic 
systems in peritoneal dialysis 
effluent and plasma  
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3.1 Introduction 
Numerous fibrotic disease mechanisms are known to be conserved across 
multiple organ systems.  It is therefore reasonable to assume that systems 
involved in normal extracellular matrix (ECM) homeostatic balance that are 
altered in fibrotic disorders in other organs, may well also be implicated in PS 
and EPS.  This would include the down regulation of enzyme systems involved in 
ECM breakdown (eg. matrix metalloproteinases (MMPs) and plasmin), the over 
expression of the natural inhibitors of these enzymes (eg. tissue inhibitors of 
matrix metalloproteinases (TIMPs) and plasminogen activator inhibitors (PAIs)), 
or excess production of ECM components.   
MMPs are shut down in numerous fibrotic states resulting in the failure to 
clear ECM in the face of either continuing or accelerated deposition.  MMPs and 
TIMPs are thought to play an important role in fibrosis in many organs such as 
the kidney (Johnson, Haylor et al. 2002), lung (Selman, Ruiz et al. 2000) and 
liver (Nie, Duan et al. 2004).    It is possible that one or many members of the 
MMP family may have reduced expression or activation in PS & EPS.  More 
likely is that there is over expression of the natural inhibitors of these enzymes 
such as TIMPs.  TIMP-1 is particularly elevated in renal scarring (Johnson, 
Haylor et al. 2002) as well as other types of tissue scarring (Wang, Tu et al. 
2011).  There is study which showed that MMP-2 may be useful as a marker of 
increased solute transport, peritoneal injury or progression to EPS (Hirahara, 
Inoue et al. 2007).  This serves to demonstrate the importance of understanding 
the ECM processing profile on an individual disease basis. 
MMPs and TIMPs are produced by many cells (Figure 3.1) (Gibson, Cullen 
et al. 2009) including monocytes, (Zhang, McCluskey et al. 1998).  Connective 
tissue destruction in chronic inflammatory lesions is due to infiltration by 
Monocyte/macrophages which secrete huge amounts of various MMPs 
degrading the connective tissue (Borden and Heller 1997).  MMPs are also 
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produced by other inflammatory cells such as neutrophils and wound cells such 
as fibroblasts, endothelial  and epithelial cells (Gibson, Cullen et al. 2009).  It is 
already known that MMP-2 is produced by macrophages, endothelial cells, and 
myofibroblasts in the peritoneum (Hirahara, Umeyama et al. 2002, Hirahara, 
Ogawa et al. 2004, Hirahara, Kusano et al. 2006, Hirahara, Inoue et al. 2007). 
 
 
Figure 3.1 MMP production, activation, and inhibition 
A summary of MMPs & TIMPs production and pathways of MMP activation and inhibition.  
Abbreviations, MMP: matrix metalloproteinase, MT-MMP: membrane type MMP, and TIMP: tissue 
inhibitor of metalloproteinase. It is reproduced by permission of the Wounds International (Gibson, 
Cullen et al. 2009). 
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Human peritoneal mesothelial cells (HPMC) have a role in controlling ECM 
accumulation by secreting MMPs such as MMP-2, MMP-3, and MMP-9.  In 
Culture, TIMPs are also produced through HPMC.  MMP and TIMP secretion by 
HPMC is mainly regulated by inflammatory cytokines.  This process is important 
in the maintenance of the peritoneal membrane integrity in healthy individual and 
in the changes that happen after prolonged PD (Martin, Yung et al. 2000). 
Proteolytic enzymes have various roles in inflammation such as ECM and 
basement-membrane proteins degradation.  The MMP and plasmin systems are 
the two most important ECM proteolytic enzyme systems.  TIMPs and plasmin 
activator inhibitors are key regulators of proteolytic activity, moderating MMP and 
plasmin activities respectively.  The MMP to TIMP balance plus the regulation of 
tPA and uPA by plasmin activator inhibitors regulate ECM turnover. 
In wound healing, MMPs play important and beneficial roles.  They can 
remove of bacteria and damaged ECM (inflammation healing phase), degrade 
capillary basement membrane allowing angiogenesis (proliferation healing 
phase), encourage epidermal cells migration (proliferation healing phase), and 
regulate ECM scar contraction and remodeling (remodeling healing phase).  All 
these are significant roles of the MMPs in normal or aberrant wound healing such 
as fibrosis.  Importantly, high MMP activity for prolonged periods can create  
problems by causing excessive protein destruction  leading to tissue damage or 
impairment of the healing process (Gibson, Cullen et al. 2009).  For example, 
MMP-2 activation in rats can cause peritoneal injury during PD (Hirahara, Ogawa 
et al. 2004). 
TIMP-1 and MMP-2 levels in the peritoneal effluent are known to mirror the 
small solute transport rate (Hirahara, Inoue et al. 2007).  Regression analysis 
showed that serum levels of TIMP-1 and MMP-7 are predictors of heat shock 
protein (Hsp) 27 concentrations in patients on chronic dialysis (automated 
peritoneal dialysis and hemodialysis).  Hsp27 is a marker of cellular stress in 
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children on long term dialysis (Musial and Zwolinska 2012).  Mast cells are 
increased in number in PD patients (Alscher, Braun et al. 2007).  Mast cell 
tryptase is defined as a serine protease which is involved in fibrosis and 
angiogenesis (Kondo, Kagami et al. 2001, Alscher, Braun et al. 2007) 
The Plasmin system also plays an important role in fibrosis alongside the 
MMP system.  They work together to breakdown most ECM components.  In 
addition to that several pro-MMPs are activated by the plasmin system (Galis and 
Khatri 2002) such as MMPs-1, 3, 7, 9, 10 and 13 (Amalinei, Caruntu et al. 2007).  
MMP and Plasmin system are described in detail in section 1.8 in chapter one.  
Taken together, it appears that the MMP and plasmin systems either 
directly or through their endogenous inhibitors of activity (TIMP) or activation 
(PAI) have a major role in ECM remodeling and homeostasis.  Further those 
perturbations in either would have a dramatic effect on normal function in any 
organ especially when under stress. 
3.2 Hypothesis 
Given the importance of the MMP and plasmin systems in ECM regulation 
and their known role in other fibrotic diseases it is likely that similar changes in 
their normal function also underlie the development of PS and the switch to EPS.  
This chapter therefore proposes to test the hypothesis that changes in the MMP 
and plasmin system activity in the peritoneum underlies PS &/or the switch to 
EPS.  Further that changes in these systems may be detectable in the PD 
effluent and that they may have values as non-invasive prognostic markers or as 
diagnostic tools for PS and EPS. 
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3.3 Aims 
To test this hypothesis this chapter aims to gain an insight into the 
contribution of the MMP and plasmin systems to the pathology of PS and EPS.  
To do this, the following studies will be undertaken: 
1. Measure MMP and plasmin activity in PDE samples from PD patients to 
establish any abnormal levels of ECM proteolysis 
2. If there are changes in activity, determine the contributions of individual 
proteolytic enzymes and their natural inhibitors by ELISA kits 
3. Determine the value of  any identified enzyme or inhibitor in predicting 
EPS development 
3.4 Methods 
3.4.1 Activity assays 
MMP activity in PDE samples was measured using the ENZchek 
Gelatinase/Collagenase Assay Kit (E-12055) (section 2.8.2.1).  Various 
concentrations of MMP activity were used and then changes of fluorescence 
were measured with time at room temperature.  From this, standard curve was 
created for fluorescence changes/hr to MMP units/mL (Figure 3.2).  All PDE 
samples were loaded neat. 
Plasmin activity in PDE samples was assessed by using cleavage of the 
V0882 substrate (sigma) (section 2.8.2.2).  Various concentrations of plasmin 
activity were used and then changes of optical density at 405 nm were measured 
with time at room temperature.  From this, standard curve was created for optical 
density changes/hr to plasmin activity µg/mL (Figure 3.3).  All PDE samples were 
loaded neat or 1:2 /1.3.   
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Figure 3.2  Rate of reaction and standard curve of MMP activity assay 
Rate of reaction (A) is showing changes of fluorescence within first  120 minutes for various 
concentrations of MMP activity.  Standard curve (B) is showing fluorescence changes/hr to MMP 
activity U/mL. 
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Figure 3.3  Rate of reaction and standard curve of plasmin activity assay 
Rate of reaction (A) is showing changes of optical density at 405 nm within first  150 minutes for 
various concentrations of plasmin activity.  Standard curve (B) is showing optical density at 405 nm 
changes/hr to plasmin activity µg/mL.  
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3.4.2 Protein assay 
Protein in PDE samples was measured using Thermo Scientific™ Pierce™ 
660nm protein assay (section 2.8.1) because protein concentration was used for 
correcting TIMPs and MMPs in SKI-1.  All PDE samples were loaded neat or 1:2 
/1.3.  Various concentrations of BSA (Bovine Serum Albumin) were prepared 
from a stock concentration of BSA in PBS (phosphate buffered saline).  Each of 
the standard curve point was calculated from the average value of the duplicate 
readings.  Then the curve was generated by plotting the measured protein 
concentrations on the x–axis, while the corresponding mean 660 nm absorbance 
on the y-axis.  After that either straight line or the best fit curve was obtained from 
the points.  The standard curve and the calculating equation can be performed 
either by using Excel or Thermo Lab systems Multiskan Ascent plate reader 
software (Figure 3.4). 
 
 
Figure 3.4 Standard curve for protein 
The protein concentrations are plotted on the x-axis, while the absorptions are plotted on the y-axis. 
Optical density changes were measured in the 96 well microplate reader at 660 nm. Standard curve 
is made for protein either by using Microsoft Excel or Thermo Labsystems Multiskan Ascent plate 
reader software. 
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3.4.3 ELISAs 
Individual TIMPs and MMPs in these 2 cohorts and the GFS patients was 
measured using standard commercial ELISAs (sections 2.8.3.1 and 2.8.3.2).   
Two examples of standard curves (TIMP-1 and MMP-2) are given as examples 
for TIMPs and MMPs standard curve (Figure 3.5).  The SKI-1 cohort consists of 
overnight PDE samples only.  The GFS cohort consists of 4 hour dwell time PDE 
samples only.  The SKI-2 cohort has PDE samples obtained from patients 
undergoing PET at 0, 2, 4 hour, and overnight with a plasma samples at 2 hour.  
During ELISA, samples were diluted to ensure measurements were within the 
most accurate range of the ELISA.  MMP-1, MMP-9, MMP-13, TIMP-3, and 
MMP-1/TIMP-1 complex were measured in PDE samples in a dilution of 1:1 
(neat samples).   
TIMP-1, TIMP-2, MMP-2, and MMP-3 were measured in PDE and plasma 
samples.  They required dilutions as the concentrations of TIMP-1, TIMP-2, 
MMP-2, and MMP-3 are high in PDE samples.  The dilutions were very variable 
depending on subtype of MMP or TIMP; for example TIMP-1 needed more 
dilution than the rest of TIMPs and MMPs.  Sample dilutions were also affected 
by dwell times as overnight samples required higher dilution than others.  
Flushed samples needed less dilution because they are diluted.  All efforts were 
made to ensure measurements were within the most accurate range of the 
ELISA.  TIMP-1, TIMP-2, MMP-2, and MMP-3 concentrations were higher in 
plasma samples in comparison to PDE samples, requiring a higher dilution.  The 
dilutions were approximately 1:400, 1:700, 1:75, and 1:80 for measuring plasma 
levels for TIMP-1, TIMP-2, MMP-2, and MMP-3 respectively.   
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Figure 3.5 Standard curves for TIMP-1 and MMP-2 
The TIMP-1 (A) and MMP-2 (B) concentrations are plotted on the x-axis, while the absorptions are 
plotted on the y-axis. Optical density changes were measured in the 96 well microplate reader at 
450 nm. Standard curves are made for TIMP-1 and MMP-2 either by using Microsoft Excel or 
Thermo Labsystems Multiskan Ascent plate reader software. 
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3.5 Results 
3.5.1 MMP activity in SKI-1 and SKI-2 
MMP activity (i.e. MMP-TIMP balance) was measured in SKI-1 and SKI-2 
patient cohorts.  To see if there was any change in MMP activity with time on PD,  
SKI-1 and SKI-2 patient cohort samples were divided into 3 groups based on 
time on PD (<1 year, 1-3 years, and >3 years).  In SkI-1, there was one EPS 
patient (SKI-120), but this sample was collected over 9 months after an EPS 
diagnosis was made.   
There was no or very little MMP activity in any of Sheffield PDE samples 
tested from either SKI-1 or SKI-2 cohorts irrespective of duration on PD or EPS 
development even after 48 hours incubation (Figure 3.6).  Given the low values, 
to validate the assay was working correctly, MMP activity was measured in a 
CKD patient urine sample  and was found to be high as predicted (25.5 u/L).  
During statistical analysis, PDE sample from one EPS patient and urine sample 
from one CKD patient were excluded from analysis. 
The finding of such low MMP activity compared to other biological fluids 
was marked and could clearly be associated with a pro-fibrotic phenotype.  Thus 
to establish the reasons behind this low or undetected MMP activity in PDE 
samples, ELISA for various TIMPs and MMPs was performed on PDE samples 
to understand the relative MMP-TIMP balance.  
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Figure 3.6  MMP activity in the 
PDE samples 
MMP activity (u/L) in PDE samples from 2 
separate Sheffield cohorts was measured 
by the change in fluorescence from 
cleavage of DQ gelatin. (A) In the SKI-1 
cohort samples were divided into 3 
groups based on time on PD (<1 year, 1-
3 years, and >3 years) and an EPS 
patient.  One urine sample of CKD patient 
was used as control +ve. (B) In the SKI-2 
cohort samples were again divided by 
time on PD (<1 year, 1-3 years, and >3 
years).  The data represent mean with 
SD. Abbreviations: PDE: peritoneal 
dialysis effluent.  Note: SKI-1 and SKI-2 
PDE samples were from overnight dwells 
and collected after a line flush.  
GraphPad Prism 6 used for statistical 
analysis (Kruskal-Wallis test).  One EPS 
patient and one urine sample of CKD 
patient were excluded from statistical 
analysis because it is a single sample.  
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3.5.2 Plasmin activity in SKI-1 and SKI-2 cohorts 
In addition to the MMP activity assay, plasmin activity assay was measured 
in PDE samples.  Plasmin plays an important role in activating pro-MMPs to 
MMPs and MT-MMPs (Figure 3.1) and in ECM degradation.  The gradient (Δ 
optical density at 405 nm/hr) for each PDE sample was calculated to show the 
plasmin activity with time.  A plot of change in optical density for SKI-125 with 
time is shown as an example (Figure 3.7).   
 
In comparison to MMP activity, plasmin activity in PDE samples in both SKI-
1 and SKI-2 cohorts was readily detectable using changes in the optical density 
due to cleavage of substrate  V0882  (Figure 3.8).  Overall there seemed to be a 
decrease in plasmin activity in patients on PD for long duration (3 years or more).  
In the SKI-1 patient cohort the mean plasmin activity was lower in the 3 years PD 
 
Figure 3.7 Example of changes in optical density with time in a PDE 
sample 
Changes in the optical density at 405 nm for SKI 125 are plotted on the y-axis, while times in 
minutes are plotted on the x-axis. The curve is made by using Microsoft excel. 
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group compared to shorter PD periods but never reached significance.  However 
in the SKI-2 cohort, mean plasmin activity for those on PD for more than 3 years 
was 50% lower than the less than 1 year group and 33% lower than the 1 to 3 
year group, with significant difference between the three groups (p=0.004). 
 
 
 
 
Figure 3.8  Plasmin activity in the 
PDE samples 
Plasmin activity (µg/mL) in PDE samples from 2 
separate Sheffield cohorts was measured.by 
the change in optic density at 405 nm using the 
V0882  as a substrate. (A) In the SKI-1 cohort 
samples were divided into 3 groups based on 
time on PD (<1 year, 1-3 years, and >3 years) 
and an EPS patient. (B) In the SKI-2 cohort 
samples were again divided by time on PD (<1 
year, 1-3 years, and >3 years).  GraphPad 
Prism 6 used for statistical analysis (One way 
ANOVA test) p=0.004. Post-hoc comparisons 
using the Tukey's multiple comparisons test 
indicated that <1year was significantely 
different from >3 years (p=0.003).  1-3 years did 
not differ significantely from either <1year    or  
>3 years.  EPS was excluded from statistical 
analysis. The data represent mean with SD. 
Abbreviations: PDE: peritoneal dialysis effluent.  
SKI-1 and -2: Sheffield Kidney Institute PD 
cohort 1 and 2 respectively.  Note: SKI-1 PDE 
samples were from overnight samples collected 
with a flushed line. SKI-2 PDE samples were 
from 2hr dwell time without a line flush which 
gives a more precise level of plasmin activity.  
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In the SKI-2 cohort, the plasmin activity at the 2 hour dwell time was 
negatively correlated to the duration on PD (r= -0.4, p=0.004, n=51 samples), 
and to the last year glucose exposure during PD (r= -0.51, p=0.0001, n=51 
samples) (Figure 3.9). 
 
To ascertain the most representative dwell time for measuring plasmin 
activity in, PDE samples from the same patient with increasing dwell times were 
analysed.  This was to allow identification of the earliest time plasmin activity 
could be assayed and the linearity in the changes of plasmin activity with dwell 
time.  PDE samples from 6 patients were collected prior to tube flushing during a 
PET at all-time points (zero, 2hr, 4hr, and overnight).  All the 6 samples showed 
an increase of plasmin activity with dwell time (Figure 3.10).  2 hour dwell times 
 
Figure 3.9 Correlation between 
plasmin activity with duration 
on PD and glucose exposure 
Plasmin activity (µg/mL) in PDE samples 
from Sheffield Kidney Institute PD cohort-2 
(SKI-2) at 2 hour dwell times was 
measured.by the change in optic density 
at 405 nm with using V0882 as a 
substrate. Plasmin activity is negatively 
correlated to (A) the duration on PD and 
(B) the last year glucose exposure to the 
peritoneal membrane in PD patients (B).  
GraphPad Prism 6 was used to perform 
the correlation test (Compute Pearson 
correlation coefficient). 
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appear suitable for analysis for all 51 PDE samples in the SKI-2 cohort because 
samples were collected prior to a line flush at 2 hour dwell time.  In 4 hour dwell 
times, due to the dilution of collected samples with a line flush, samples are more 
diluted so less plasmin activity was present.  This lead to inaccurate and variable 
results; for example plasmin activity in PDE sample SKI-143 (4hr) dwell was 
measured before  and after a line flush were 2 and 1.5 µg/mL respectively.  The 
presence of plasmin activity in the time zero samples may have been due to 
residual overnight plasmin activity in the samples.  
 
 
Figure 3.10 Effect of dwell times on measuring plasmin activity 
Plasmin activity level was measured in PDE samples of six PD patients in the SKI-2 cohort with each 
having samples collected at 0, 2 and 4 hour and overnight dwell times.  GraphPad Prism 6 used for 
statistical analysis (One way ANOVA) (P<000.1). Post-hoc comparisons using the Tukey's multiple 
comparisons test indicated that zero was significantely different from 4hr and overnight with p=0.005 and 
<0.0001. 2hr was also significantely different from overnight with p=0.006. The rest comparison did not 
differ significantely from eachothers. The data represent mean with SD. Abbreviations: PDE: peritoneal 
dialysis effluent.  SKI-2: Sheffield Kidney Institute PD cohort 2.  
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3.5.3 Measurement of individual MMPs and TIMPs in PDE samples from 
patient cohort SKI-1  
Given the lack of MMP activity in PDE, then it is reasonable to assume that 
this would affect ECM clearance and thus lead to a pro-fibrotic environment in 
the peritoneum.  It was therefore important to ascertain why there was this lack of 
activity; a failure to make MMPs, an overproduction of TIMPs or combinations of 
the two are potential options. 
3.5.3.1 Measurement of MMP-1, MMP-2, MMP-3, MMP-9 and MMP-13   
The exact dwell times for SKI-1 samples are unknown and the degree of 
line flushing that can lead to sample dilution was also unknown. To compensate 
correction has been performed to total protein concentration in PDE samples.  
MMP-1, -9, and -13 were low or undetected in most samples in the SKI-1 cohort 
(Figure 3.11).  In comparison, MMP-2 level was considerably higher and 
detectable in all PDE samples with a cohort mean (±SD) of 33±24 ng/mL.  MMP-
2 level in the single EPS patient was higher than other groups.  MMP-3 was also 
detectable but the level was lower than MMP-2 (Figure 3.12). 
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Figure 3.11  MMP-1,-9 &-13 levels 
in PDE from the SKI-1 cohort 
PDE samples were divided by time on PD 
(<1 year, 1-3 years, and >3 years) or EPS 
development.  They were assayed by 
commercial ELISA for A) MMP-1 B) MMP-9 
& C) MMP-13. All PDE samples were from 
overnight dwell with a line flush and as such 
all values were corrected for protein. 
GraphPad Prism 6 used for statistical 
analysis (Kruskal-Wallis test).  The EPS 
sample was excluded from all statistical 
analysis because it is a single patient. The 
data represent mean with SEM. 
Abbreviations: PDE: peritoneal dialysis 
effluent, MMP: matrix metalloproteinases, 
SKI-1: Sheffield Kidney Institute PD cohort 
1, and EPS: encapsulating peritoneal 
sclerosis.  
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3.5.3.2 Measurement of TIMP-1, and the MMP-1/TIMP-1 complex 
TIMP-1 was high in all Sheffield PDE samples from the start of PD.  TIMP-1 
in the SKI-1 cohort (Mean±SD) was 110±89 ng/mL.  TIMP-1 in the single EPS 
patient in SKI-1 was particularly high (224 ng/mL), which when corrected to the 
amount of protein in the sample was clearly elevated (Figure 3.13.A).  MMP-1/ 
TIMP1 complex was also measured, Like MMP-1, the MMP-1/TIMP-1 complex 
was low or undetected in Sheffield PDE samples most likely due to very little or 
no MMP-1 in PDE samples.(Figure 3.13.B).   
 
Figure 3.12 MMP-2 &-3 levels in 
PDE from the SKI-1 cohort 
PDE samples were divided by time on PD 
(<1 year, 1-3 years, and >3 years) or EPS 
development.  They were assayed by 
commercial ELISA for A) MMP-2 and B) 
MMP-3. All PDE samples were from 
overnight dwell with a line flush and as such 
all values were corrected for protein.  
GraphPad Prism 6 used for statistical 
analysis (One way ANOVA test).  The EPS 
sample was excluded from all statistical 
analysis because it is a single patient. The 
data represent mean with SEM. 
Abbreviations: PDE: peritoneal dialysis 
effluent, MMP: matrix metalloproteinases, 
SKI-1: Sheffield Kidney Institute PD cohort 
1, and EPS: encapsulating peritoneal 
sclerosis.  
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3.5.3.3 Measurement of TIMP-2 and TIMP-3  
TIMP-2 was detectable in all in Sheffield PDE samples in the SKI-1 cohort, 
from the start of PD with a mean±SD value of 17.2±12.4 ng/mL, which is 7 fold 
less than TIMP-1 in the same PDE samples.  Of note was that the single EPS 
 
 
Figure 3.13 TIMP-1 & MMP-
1/TIMP-1 complex levels in PDE 
from the SKI-1 cohort 
PDE samples were divided by time on PD 
(<1 year, 1-3 years, and >3 years) or EPS 
development.  They were assayed by 
commercial ELISA for A) TIMP-1 and B) 
MMP-1/TIMP-1 complex. All PDE samples 
were from overnight dwell with a line flush 
and as such all values were corrected for 
protein.  GraphPad Prism 6 used for 
statistical analysis (One way ANOVA test 
for TIMP-1 (P=0.03). Post-hoc comparisons 
using the Tukey's multiple comparisons test 
indicated that <1 year was significantely 
different from >3 years (p=0.027).  1-3 
years did not differ significantely from either 
<1 year  or  >3 years. Kruskal-Wallis test 
was used for MMP-1/TIMP-1 complex.  The 
EPS sample was excluded from all 
statistical analysis because it is a single 
patient. The data represent mean with 
SEM. Abbreviations: PDE: peritoneal 
dialysis effluent, MMP: matrix 
metalloproteinases, TIMP: tissue inhibitor 
metalloproteinase, SKI-1: Sheffield Kidney 
Institute PD cohort 1, and EPS: 
encapsulating peritoneal sclerosis. 
132 
 
patient reached 39.3 ng/mL, which was the maximum value seen.  TIMP-2 was 
corrected for protein in the PDE samples to normalize for dilution, with the level 
in the EPS sample was clearly elevated (67.8 ng/mg) (Figure 3.14 A).  TIMP-3 
had the lowest level among the three TIMPs measured in this cohort averaging 
244 pg/mL in none EPS patients (Figure 3.14 B). However TIMP-3 in the EPS 
patient was also high (1392 pg/mL) compared to all other samples.  After 
correction for protein, TIMP-3 in the EPS PDE remained higher than any other 
sample measured. 
TIMP-2 was very strongly positively correlated to TIMP-1 (r=0.8, p < 
0.0001).  TIMP-2 was less strongly positively correlated to TIMP-3 (r=0.65, p < 
0.0001) with the correlation between TIMP-1 and TIMP-3 weak (r=0.37, p= 0.04).  
Together this demonstrates differential regulation of the TIMPs in PDE and low 
level of TIMP-3 in PDE may be due to binding to ECM. 
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3.5.4 MMPs and TIMPs in PDE and plasma samples in SKI-2  
MMPs and TIMPs measured again in Plasma and PDE samples in the 
second Sheffield Kidney Institute PD cohort 2 (SKI-2) for two reasons.  Firstly, to 
validate the data above in a more rigoursly collected cohort and and secondly, to 
compare plasma levels of TIMP-1, TIMP-2, MMP-2, and MMP-3 in PD patients 
versus their levels in plasma of 18 healthy individuals. 
 
Figure 3.14 TIMP-2 &-3 levels in 
PDE from the SKI-1 cohort 
PDE samples were divided by time on PD 
(<1 year, 1-3 years, and >3 years) or EPS 
development.  They were assayed by 
commercial ELISA for A) TIMP-2 and B) 
TIMP-3. All PDE samples were from 
overnight dwell with a line flush and as such 
all values were corrected for protein.  
GraphPad Prism 6 used for statistical 
analysis (One way ANOVA test).  The EPS 
sample was excluded from all statistical 
analysis because it is a single patient. The 
data represent mean with SEM. 
Abbreviations: PDE: peritoneal dialysis 
effluent, TIMP: tissue inhibitor 
metalloproteinase, SKI-1: Sheffield Kidney 
Institute PD cohort 1, and EPS: 
encapsulating peritoneal sclerosis. 
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TIMP-1, TIMP-2, MMP-2, and MMP-3 were easily detectable in SKI-1, and 
thus it seemed logical to restrict to these 4 proteins & confirm these findings in 
the second Sheffield cohort, SKI-2, where there were known dwell times, the line 
flush controlled and detailed clinical information available.    TIMP-1, TIMP-2, 
MMP-2, and MMP-3 were also measured in plasma of healthy individuals and & 
PD patients to ascertain if any changes in PDE were simply related to systemic 
levels. 
3.5.4.1 Correlations of protein, MMPs and TIMPs in PDE samples with 
clinical data in the SKI-2  
A set of correlations were run between protein, MMP-2, MMP-3, TIMP-1, 
and TIMP-2 against various clinical data (D/Pcr, D/D0 glucose and UF). 
3.5.4.1.1 Correlations of protein, MMPs and TIMPs in PDE samples against 
D/Pcr and D/D0 glucose.  
Peritoneal solute transport rate may be useful for evaluating peritoneal 
membrane injury.  This is assessed during PET by D/Pcr and D/D0 glucose.  
These clinical data were analysed to establish any link to the MMP family 
proteins.  D/D0 glucose at 2hr was negatively correlated to overall protein in PDE 
samples at 2hr (r= -0.57, p < 0.0001).  It was also negatively correlated to TIMP-1 
(r= -0.57, p < 0.0001), TIMP-2 (r= -0.58, p < 0.0001), MMP-2 (r= -0.61, p < 0.0001) 
and MMP-3 (r= -0.57, p < 0.0001) in PDE samples at 2 hr, n=51.   D/Pcr at 2hr 
was positively correlated to protein in PDE samples at 2hr (r=0.7, p < 0.0001), 
n=51.  It was also positively correlated to TIMP-1, TIMP-2, MMP-2 and MMP-3 in 
PDE samples at 2hr (Figure 3.15).   
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3.5.4.1.2 Correlation of protein, MMPs and TIMPs in PDE samples against 
UF in PDE samples in the SKI-2 patient cohort. 
Ultrafiltration failure (UFF) is an important cause of long-term failure of PD.  
UF was negatively correlated to protein in PDE samples at 2hr (r= -0.46, p = 
0.001), n=48.  It was also negatively correlated to TIMP-1, TIMP-2, MMP-2 and 
 
 
Figure 3.15 Correlations between 
D/Pcr at 2hr against TIMP-1, TIMP-2, 
MMP-2, and MMP-3 in PDE samples 
in SKI-2 
TIMPs and MMPs in PDE were assayed 
by commercial ELISA.  D/Pcr at 2hr was 
positively correlated to A) TIMP-1, B) TIMP-2, C) 
MMP-2, and D) MMP-3.  All TIMPs and MMPs 
were measured in PDE samples at 2h dwell time.  
GraphPad Prism 6 was used to perform the 
correlation test (Compute Pearson correlation 
coefficient). Abbreviations: D/Pcr: dialysate-to-
plasma ratio of creatinine, PDE: peritoneal 
dialysis effluent, MMP: matrix 
metalloproteinases, TIMP: tissue inhibitor 
metalloproteinase, and SKI-2: Sheffield Kidney 
Institute PD cohort 2. 
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MMP-3 in PDE samples at 2hr specially to TIMP-1 which shows the best 
negative correlation (r= -0.64, p < 0.0001) (Figure 3.16).   
 
 
Figure 3.16 Correlation between UF 
with TIMP-1, TIMP-2, MMP-2, and 
MMP-3 in PDE samples in patient 
cohort SKI-2 
TIMPs and MMPs were assayed by 
commercial ELISA.  UF was negatively correlated 
to A) TIMP-1, B) TIMP-2, C) MMP-2, and D) MMP-
3.  All TIMPs and MMPs were measured in PDE 
sample at 2hr dwell time.  GraphPad Prism 6 was 
used to perform the correlation test (Compute 
Pearson correlation coefficient). Abbreviations: 
UF: ultrafiltration, PDE: peritoneal dialysis effluent, 
MMP: matrix metalloproteinases, TIMP: tissue 
inhibitor metalloproteinase, and SKI-2: Sheffield 
Kidney Institute PD cohort 2. 
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3.5.4.2 Effect of dwell time on TIMP and MMP levels in PDE samples from 
patient cohort SKI-2 
Increases in dwell times had an effect on the TIMP-1,-2 and MMP-2,-3 
levels in PDE samples.  In SKI-2 cohort, most of the samples had multiple dwell 
times.  18 of them were collected prior to tube flushing in PET at zero, 2hr, and 
4hr and they showed an increase in TIMPs and MMPs levels in the samples with 
longer dwell times (Figure 3.17) in what appeared to be a linear manner. 
 
 
Figure 3.17 Effect of dwell times on TIMP & MMP levels in PDE samples/SKI-2 
cohort 
PDE samples were collected during a PET test after 0, 2 & 4hr dwell times and assayed by commercial 
ELISA for TIMPs and MMPs.  Graph Pad Prism 6 was used for statistical analysis (Friedman test). The 
data represent mean with SD. 
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3.5.4.3 Plasma level in healthy volunteers compared to PD patients in SKI-2 
To understand if there was more systemic MMP and TIMPs in PD patients 
than healthy individuals, MMP & TIMPs levels in plasma were measured in both 
populations.  Healthy volunteers had an age ranging from 22 – 49 years old 
(mean±SD was 35±9.  The female : male ratio was 7 :  11).  PD patients had an 
age ranging from 26 – 78 years old (mean±SD was 60±14 The female : male 
ratio was 19 :  27).  TIMP-1, TIMP-2, MMP-2, and MMP-3 were lower in plasma 
of healthy volunteers compared to PD patients.  TIMP-1 median (IQR) in plasma 
was 126 (107–144) ng/mL in healthy group, but the median is more than double 
in PD patients and median (IQR) was 276.5 (253.8–347) ng/mL (Figure 3.18 A).  
TIMP-2 median (IQR) in plasma was 79.5 (74.7–93.8) ng/mL in healthy 
individuals, but it rises to approximately double at 150.5 (135.5–172.3) ng/mL in 
patients on PD (Figure 3.18 B).  MMP-2 Median (IQR) in plasma was 165 
(150.7–208.6) ng/mL in healthy, but it is higher at 302.1 (242.5–370.8) ng/mL in 
patients on PD (Figure 3.18 C).  MMP-3 median (IQR) in plasma was 10.8 (6.9–
13.2) ng/mL in healthy individuals, but it rises to triple at 32.7 (25–48.8) ng/mL in 
patients on PD (Figure 3.18 D).   
3.5.5 TIMPs and MMPs in PDE samples (SKI-1 and SKI-2) in patient with 
various history of peritonitis 
Patients were grouped in SKI-1 (Figure 3.19) and SKI-2 (Figure 3.20) 
according to the history of peritonitis to (0, 1-2, and 3-4 attacks).  Most patients 
were without history of peritonitis.  Even those with history of peritonitis, PDE 
samples dates were not close to the peritonitis attacks dates as it is clarified in 
method that patients with history of peritonitis in the two months period prior to 
sample collection were excluded from this cohort.  It seems from figure 3.19 and 
figure 3.20 that there is no constant relationship between TIMPs and MMPs 
versus history of peritonitis.   
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Figure 3.18 Plasma level of TIMPs and MMPs in healthy volunteers and patients 
on PD 
TIMPs and MMPs were assayed in plasma samples by commercial ELISA.  Plasma levels of A) TIMP-1, 
B) TIMP-2, C) MMP-2, and D) MMP-3 in healthy volunteers and PD patients from SKI-2. GraphPad 
Prism 6 used for statistical analysis (Unpaired t test with Welch's correction).  Box and Whisker Plots 
show median, 25th Percentile, 75th Percentile, and the range. Abbreviations: MMP: matrix 
metalloproteinases, TIMP: tissue inhibitor metalloproteinase, and SKI-2: Sheffield Kidney Institute PD 
cohort 2.   
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Figure 3.19 TIMPs & MMPs levels in PDE in patients with different history of 
peritonitis from the SKI-1 cohort 
PDE samples were divided by number of peritonitis (0, 1-2, and 3-4).  They were assayed by commercial 
ELISA for A) MMP-2, B) MMP-3, C) TIMP-1, and D) TIMP-2.  All PDE samples were from overnight dwell 
with a line flush and as such all values were corrected for protein.  GraphPad Prism 6 used for statistical 
analysis (One way ANOVA test) for MMP-2 (P=0.002), MMP-3 (p=0.5), TIMP-1 (p=0.09), and TIMP-2 
(p=0.009). The data represent mean with SEM. Abbreviations: PDE: peritoneal dialysis effluent, MMP: 
matrix metalloproteinases, TIMP: tissue inhibitor metalloproteinase, SKI-1: Sheffield Kidney Institute PD 
cohort 1. 
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Figure 3.20 TIMPs & MMPs levels in PDE in patients with different history of 
peritonitis from the SKI-2 cohort 
PDE samples were divided by number of peritonitis (0, 1-2, and 3-4).  They were assayed by commercial 
ELISA for A) MMP-2, B) MMP-3, C) TIMP-1, and D) TIMP-2.  All PDE samples were from 2hr dwell time 
without a line flush.  GraphPad Prism 6 used for statistical analysis (One way ANOVA test) for MMP-2 
(P=0.04), MMP-3 (p=0.13), TIMP-1 (p=0.01), and TIMP-2 (p=0.04). The data represent mean with SEM. 
Abbreviations: PDE: peritoneal dialysis effluent, MMP: matrix metalloproteinases, TIMP: tissue inhibitor 
metalloproteinase, SKI-2: Sheffield Kidney Institute PD cohort 2. 
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3.5.6 Global Fluid Study (GFS) Samples 
Data from SKI cohorts 1 and 2 demonstrated low MMP activity in PDE that 
appeared to be due to high TIMP levels with only MMP2 having significant 
presence.  Further the high level of TIMP-1, TIMP-2 and MMP-2 in the 1 EPS 
patient in SKI-1 and the positive correlation of TIMP-1, TIMP-2 and MMP-2 with 
D/Pcr and negative correlation with UF suggested they may be involved in PS or 
in the switch to EPS.  To explore this, TIMPs and MMPs required to be measured 
in the sequential samples and material from those developing EPS such as those 
present in the GFS.  However, limited materials were available from the GFS and 
as this is an extremely valuable resource, only proteins where we easily detect 
proteins in a very small volume of PDE could be investigated.  TIMP-1, TIMP-2 
and MMP-2 were chosen to be measured in PDE samples.  In the GFS, 
individual patients had their TIMP-1, TIMP-2, and MMP-2 levels measured in 4 hr 
dwell samples and these were plotted with time on PD for control and EPS 
groups.  In the control group, there were 158 samples that were taken from 43 
patients (periodic sampling from each patient).  In the EPS group, there were 43 
samples that were taken from 12 patients. 
3.5.6.1 TIMP-1 
TIMP-1 level was plotted for individual control and EPS patients as 
spaghetti plots (Figure 3.21).  In the control group, nearly all of the 158 samples 
remained bunched and below 155 ng/mL with only 5 (or 3% ) with values higher 
than155 ng/mL at some point randomly on PD that always returned to within this 
―normal‖ range.  These 5 samples (3%) had D/Pcr at 4hr (0.8 or more).  
Importantly in the EPS group, all of the samples stayed within the range of 25-
155ng/mL with the exception about the EPS samples within last 100 days of EPS 
diagnosis because they had a rapid increase in the level of TIMP-1.  The median 
(IQR) (ng/mL) for the control was 48.8 (36.7 - 67.2) with a range (10.1 - 339.5), 
and for the EPS was 62.6 (42.6 – 94) with a range (15.3 – 364).   
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Figure 3.21 Spaghetti plots of TIMP-1 level in PDE samples (control and EPS) 
TIMP-1 was assayed by commercial ELISA in the PDE samples from the GFS in control (i.e. not 
developing EPS) and EPS samples.   (A) TIMP-1 plotted against sample days till PD end in those not 
developing EPS and (B) TIMP-1 plotted against days from sample to EPS diagnosis in the EPS group.  
Abbreviations: TIMP: tissue inhibitor metalloproteinase, PDE:   peritoneal dialysis effluent, GFS: global 
fluid study, and EPS: encapsulating peritoneal sclerosis.  
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Mean TIMP-1 level from non-EPS & EPS developing patients with time on 
PD were subsequently plotted (Figure 3.22).  This clearly demonstrated the late 
divergence in TIMP-1 level between control and EPS in the last 100 days in the 
EPS group.  That said, in patients that ultimately developed EPS, TIMP1 level 
were not dissimilar to controls until this late period where a significant 6 fold 
increase in mean TIMP-1 level occurred.  However this only included samples 
from 2 of the 13 EPS patients being followed compared to 10 in the control group 
at this point (last 100 days).   
This late increase in TIMP-1 could potentially point towards its use as a late 
diagnostic marker as well as a potential pathogenic mechanism.  A cutoff of 3 x 
average of control group (59.4 x 3=178.2) was established to assess how TIMP-1 
could be used diagnostically.  Five samples from control group (158 samples) fall 
above this normal range (i.e. 3% false positive if using this as a diagnostic for 
EPS) but with both EPS samples in the last 100 days higher than this cutoff (plus 
the high TIMP-1 level in the EPS patient from the SKI-1 cohort) then there is a 
high detection rate.    
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3.5.6.2 TIMP-2 
TIMP-2 level was much lower in PDE samples compared to TIMP-1 level.  
TIMP-2 level was below 31 ng/mL in all PDE samples (Figure 3.23).  The median 
(IQR) (ng/mL) for TIMP-2 in the control group was 9.2 (6.3  - 13.1) with a range 
(2.5 – 30.5), and for the EPS group was 11 (8.4 – 13.5) with a range (3.9 – 30.7).    
 
 
Figure 3.22  Mean TIMP-1 concentrations in control and EPS groups (GFS) 
TIMP-1 concentration in PDE samples were grouped into 200 day segments for time before PD stop or 
EPS diagnosis for both EPS and control groups. Greater resolution was achieved in the last 200 days 
before cessation by refining to 100 day groupings. Mean TIMP-1 concentration was then calculated 
within each segment and plotted as mean with SEM with time to EPS diagnosis or PD termination.  
Abbreviations: TIMP: tissue inhibitor metalloproteinase, PDE:   peritoneal dialysis effluent, GFS: global 
fluid study, and EPS: encapsulating peritoneal sclerosis. 
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Figure 3.23 Spaghetti plots of TIMP-2 level in PDE samples (control and EPS) 
TIMP-2 was assayed by commercial ELISA in the PDE samples from the GFS in control (i.e. not 
developing EPS) and EPS samples.   (A) TIMP-2 plotted against sample days till PD end in those not 
developing EPS and (B) TIMP-2 plotted against days from sample to EPS diagnosis in the EPS group.  
Abbreviations: TIMP: tissue inhibitor metalloproteinase, PDE:   peritoneal dialysis effluent, GFS: global 
fluid study, and EPS: encapsulating peritoneal sclerosis.  
147 
 
The mean TIMP-2 level with time on PD was also plotted and showed a relatively 
consistent level throughout the dialysis period irrespective of the patients‘ 
outcome (Figure 3.24). 
 
3.5.6.3 TIMP-1/TIMP-2 ratio 
Of note was that the few samples that were sporadically high in TIMP-1 
were also sporadically high for TIMP2 except those close to EPS diagnosis.  
Thus this raised the concept that if TIMP-1 could have value as a diagnostic tool 
 
Figure 3.24 Mean TIMP-2 concentrations in control and EPS groups (GFS) 
Means TIMP-2 in PDE samples were plotted for every 200 days and every 100 days in the last 200 days 
for EPS and control groups.  There is relatively stable level of TIMP-2 in PDE samples with average of 
10.9 ng/mL. Data represents mean with SEM. Abbreviations: TIMP: tissue inhibitor metalloproteinase, 
PDE:   peritoneal dialysis effluent, GFS: global fluid study, and EPS: encapsulating peritoneal sclerosis. 
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or even late predictive biomarker then could TIMP-2 be used as internal 
reference for TIMP-1 to minimise the number of ―false positive‖ TIMP-1 in 
identifying EPS onset.  TIMP-2 used because it was relatively stable and it was 
minimising the effect of high transport status in the control group by dividing 
TIMP-1 over TIMP-2.  In addition to that, GFS samples are from 4 hour dwell 
time, but it is not recorded whether the samples are diluted or not due to flushed 
line.  Further, could it correct for any variability in sample dilution due to line 
flushing to further tighten the data. 
Individual patients therefore had their TIMP-1/TIMP-2 ratios plotted with 
time on PD (Figure 3.25).  When TIMP-1 level were normalised to TIMP-2 level 
―spikes‖ in the TIMP1 baseline were minimised.  The maximum level of TIMP-
1/TIMP-2 ratio in the non-EPS control group was 18.1, while the TIMP-1/TIMP-2 
ratios in the 2 EPS patients who had samples within last 100 days were 22 and 
46 respectively.  This therefore clearly defined a phenotype in the late EPS 
samples where the TIMP-1/TIMP-2 ratio was higher than those not developing 
EPS.  The median (IQR) (ng/mL) for the control was 5.6 (4.3  - 7.3) with a range 
(1.8 – 18.1), and for the EPS was 5.5 (4.2 – 7.5) with a range (1.7 – 46). 
Mean TIMP-1/TIMP-2 ratio with time on PD was also calculated & plotted 
which unsurprisingly also showed a stable level with a clear late elevation in EPS 
patients (Figure 3.26).  If a cutoff of 3 x of the mean value in the non-EPS control 
group (6.1 x 3=18.3) is used, none of the sample from this (158 samples) rose 
above this cutoff, while just the 2 EPS samples in the last 100 days were higher.  
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Figure 3.25 Spaghetti plots of TIMP-1/TIMP-2 level in PDE samples (control and 
EPS) 
TIMP-1 &-2 was assayed by commercial ELISA in the PDE samples from the GFS in control (i.e. not 
developing EPS) and EPS samples.   (A) TIMP-1/Timp-2 ratio plotted against sample days till PD end in 
those not developing EPS and (B) TIMP-1/Timp-2 plotted against days from sample to EPS diagnosis in 
the EPS group.  Abbreviations: TIMP: tissue inhibitor metalloproteinase, PDE:   peritoneal dialysis 
effluent, GFS: global fluid study, and EPS: encapsulating peritoneal sclerosis.  
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3.5.6.4 MMP-2 
Individual patients also had their MMP-2 level measured and plotted with time on 
PD (Figure 3.27).  The majority of measurements for both groups were less than 
40 ng/mL with only the odd sporadic sample being above this.  The average 
MMP-2 level in the non-EPS control and EPS samples were 23 and 25 ng/mL 
respectively.  The median (IQR) (ng/mL) for the non-EPS control was 21.9 (15.1 - 
28.6) with a range (5.7 – 63.7), and for the EPS was 23.5 (19.5 – 31.1) with a 
range (8.2 – 43.7).   
 
 
Figure 3.26 Mean TIMP-1/TIMP-2 concentrations in control and EPS groups 
(GFS) 
Samples were grouped by time to EPS diagnosis or stopping PD using a 200 day windows with 100 
days close to stopping PD or EPS diagnosis.  The mean TIMP-1/TIMP-2 ratio in all PDE samples within 
each 200 or 100 day window was calculated and plotted chronologically.  Data represents mean with 
SEM.  Abbreviations: TIMP: tissue inhibitor metalloproteinase, PDE:   peritoneal dialysis effluent, GFS: 
global fluid study, and EPS: encapsulating peritoneal sclerosis. 
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Figure 3.27 Spaghetti plots of MMP-2 level in PDE samples (control and EPS) 
MMP-2 was assayed by commercial ELISA in the PDE samples from the GFS in control (i.e. not 
developing EPS) and EPS samples.   (A) MMP-2 plotted against sample days till PD end in those not 
developing EPS and (B) MMP-2 plotted against days from sample to EPS diagnosis in the EPS group.  
Abbreviations: MMP: matrix metalloproteinase, PDE:   peritoneal dialysis effluent, GFS: global fluid 
study, and EPS: encapsulating peritoneal sclerosis.  
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From above spaghetti plots there is no trend in MMP-2 values that suggests any 
value as a predictor or diagnostic for developing EPS.  Mean MMP-2 were 
predictably flat (Figure 3.28). 
 
 
 
 
 
Figure 3.28 Mean MMP-2 concentrations in control and EPS groups (GFS) 
Means MMP-2 in PDE samples were plotted for every 200 days and every 100 days in the last 200 days 
for EPS and control groups.  MMP-2 did not show clear shift in the level of MMP-2 averages between 
control and EPS in last 100 days in EPS group. Data represents mean with SEM.  Abbreviations: MMP: 
matrix metalloproteinase, PDE:   peritoneal dialysis effluent, GFS: global fluid study, and EPS: 
encapsulating peritoneal sclerosis. 
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3.5.7 Statistical analysis after this study 
The statistician was approached to analyse the power of the study using the 
program G*power 31.3.  Sample size required to detect full and half effect shown 
in this study of TIMP-1 in SKI-2 and GFS were performed. Small studies which 
are significant often tend to overestimate the effect, thus half effect used as a 
more cautious approach.  In SKI-2, sample sizes required to detect full effect of 
TIMP-1 correlation against D/Pcr, UF, and D/D0 glucose were 13, 21, and 28 PD 
patients respectively.  Sample sizes required to detect half effect of TIMP-1 
correlation against D/Pcr, UF, and D/D0 glucose were 68, 100, and 127 samples 
respectively. In Sheffield 51 samples were available for these assays. 
In GFS, the statistician regarded the 2 EPS PDE samples from the GFS 
cohort to be acceptable to apply a statistical test on these 2 samples in order to 
compare them to the non EPS samples (10 samples).  This was tested using an 
Exact Mann-Whitney as the sample size was small. TIMP-1 from the two EPS 
PDE samples was significantly higher than those from the control samples at 100 
days (p=0.03).  However, the statistician advised for more samples in any future 
study (16 samples EPS and 16 samples control in the last 100 days).  If at 100 
days the EPS and control behave as in this study with p=0.05 and power 95%, 
then 2 EPS patients and 2 controls are required.  This sample size is too small 
for a study so to get reasonable sample size, then the assumption of drastic 
alternative behavior of the samples in the last 100 day were made.  If all that is 
happening in the two extreme cases, then there may be expectation that EPS is 
averaging about double the controls, and this would give a sample size of 20 (10 
controls and 10 EPS patients), p=0.05 and power=95%.  However, if it is a 
sudden triggered, and then there will be expectation that 50% of the EPS 
patients behave like controls and 50% like EPS patients in the study.  At that time 
a power calculation indicates that with p=0.05 and power=95%, then 16 EPS 
patients and 16 control patients are required in the last 100 days. 
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3.6 Discussion 
The key finding from this chapter is that there is low or undetected MMP 
activity in the PDE samples from the start of PD suggesting that peritoneal 
capacity has limited ECM clearance capacity.  This results from low or 
undetectable MMPs in PDE samples (with the exception of MMP-2 and to a 
lesser extent MMP-3) in compared with very high TIMPs levels, especially TIMP-
1.  There is a suggestion that changes in TIMP reflect membrane status with, 
D/Pcr being positively correlated to TIMP-1, TIMP-2, MMP-2, and MMP-3 while 
UF is negatively correlated to TIMP-1, TIMP-2, MMP-2 and MMP-3.  TIMP-1 and 
TIMP-2 as well as MMP-2 and MMP-3 were higher in plasma of PD patients than 
in healthy volunteers. Finally looking at TIMP-1, 2 and MMP-2 in the larger GFS 
cohort has given some indication that TIMP-1 in PDE could have value as an 
EPS diagnostic tool. 
 Gender distribution differed between the study populations. In both SKI 
cohorts, male patients exceeded the number of female patients while in the GFS 
cohort, the reverse was seen. The majority of patients from SKI-1 cohort, and all 
the patients from the second Sheffield PD cohort were from a white ethnic 
background. Ethnicity was not recorded for the global PD cohort.  These three 
groups of PD patients were used in this study, while none of the cohorts above 
were ideal in isolation, some crucial conclusions could be drawn by combining 
data together. 
The initial assays were performed on samples from the SKI-1 cohort for 
proteins of interest in PDE samples.  Twenty milliliters of PDE sample were made 
available for each patient.  This amount was adequate to develop assays for 
PDE and establish the relative levels moving forward.  One patient within this 
cohort was diagnosed with EPS, but the sample was taken approximately 10 
months after diagnosis of EPS, although proved a useful insight into what may 
change.   
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One of the important limitations of SKI-1 cohort was unrecorded exact dwell 
times which can clearly affect data analysis.  Furthermore, samples were not 
collected during a PET, thus D/P creatinine, UF and other clinical data were not 
available at the precise time of sample collection.  Most of the clinical data was 
recorded from values obtained from a day close to the day PD samples were 
collected. Plasma samples were not collected.  There was also an absence of 
records concerning the flushing or non-flushing of the PDE samples.  This 
affected sample dilution.  While these all impact on the accuracy of data 
obtainable from these samples, the cohort has large sample volumes pre stored 
providing material for early ―first look‖ studies‖ with sufficient material for assay 
development.   
Samples from the SKI-2 cohort were collected as the study progressed.  
There was no EPS patient in the SKI-2 cohort, but recorded clinical parameters 
were available to assess the degree of peritoneal membrane damage which were 
absent in the SKI-1 cohort.  In the SKI-2 cohort, both PDE and blood samples 
were collected and samples were collected without line flushing to remove 
variability on sample dilution.  .   
The GFS has good numbers of EPS patients with sequential sampling, but 
limited materials were available for study, thus the good pilot data from studies in 
Sheffield PD cohorts gave a sound insight into how to use the GFS samples 
wisely and whether robust measurements could be obtained from the limited 
available volume of PDE samples.  The target was to measure any protein of 
interest in 10µL or less of PDE samples.  Based on the preliminary data from the 
Sheffield cohort of fluid samples, all three TIMPs looked to be potential markers 
of EPS, however only TIMPs 1 and 2 had levels sufficiently high enough to be 
measured in a 10 µL aliquot of PDE samples.  MMP-2 and total protein were also 
measured in global fluid study as they also needed low quantity of PDE samples 
for measuring by ELISA kits. 
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GFS were collected from different centres.  Clinical data and PD samples 
were available.  Periodic sample collection provided the facility to study changes 
in the clinical data and laboratory data with time.  The GFS is by far the largest 
and best repository of PD fluid in the world having sequential samples from over 
2000 patients from its UK arm alone.  Samples from 55 patients collected at 4 
centres were made available for this study in Sheffield.  Samples were collected 
at the time of PET so precise clinical data was available as well as information on 
dwell time.  The main limitations of GFS samples were the availability of only 
small fluid samples (100 µl), irregular sample collection, there was also an 
absence of records concerning the flushing or non-flushing of the line at sample 
collection, and for the 12 PD patients in the EPS group, only 2 samples were 
collected within 100 days of EPS diagnosis. 
All assays feasibility and workup studies were performed on the SKI-1 
samples in which sample materials were available in good volume.  From this, 
any changes that looked promising and could be measured on the small amount 
of GFS material available were subsequently investigated in the GFS samples.  
In the end, important assays were applied on SKI-2 samples because they 
weren‘t available in the beginning.  The absence or lack of MMP activity in the 
PDE samples in both SKI-cohorts was predominantly due to very little MMPs 
being present in PDE samples which would be completely inhibited by the huge 
levels of TIMPs present.  This lack of proteolytic decay would clearly lead to the 
classical thickening of the peritoneal membrane as lack of MMP activity which is 
normally used to balance the rate of ECM deposition to maintain a homeostatic 
balance in membrane thickness is missing. 
The primary focus of this chapter was to look at the MMP system, but 
plasmin activity was also measured in PDE samples in SKI-1 and SKI-2.  This is 
because plasmin system is closely related to MMP system.  Plasmin activity is 
also important in activation of proMMPs to MMPs and MT-MMPs (Figure 3.1).  
Plasmin activity were easily detectable in PDE samples and showed a negative 
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correlation with time on PD i.e. longer duration on PD in years was associated 
with less plasmin activity in PDE.   The single EPS sample was low in plasmin 
activity.  Changes in plasmin system have already been associated with post-
operative adhesions (Awonuga, Fletcher et al. 2011) and some pilot publications 
do relate the plasmin system to PS and EPS.  The combination of loss of MMP 
activity early, with diminishing of plasmin activity with time could facilitate PS, 
with and a further drop in MMP activity due to large TIMP-1 level pushing the 
disease into EPS with its extensive scar tissue production.  
The lack of GFS material meant performing MMP activity and plasmin 
activity assays on sequential GFS samples was not possible.  Assaying MMP 
activity in GFS theoretically would have not yielded much valuable data as it was 
clear from the SKI-1 and SKI-2 cohorts that MMP activity is lost early and it is low 
or undetected in all samples.  On the other hand, assaying plasmin activity in 
GFS may have yielded valuable data given plasmin activity with time changes in 
the SKI cohorts.  
In the SKI-1 cohort, TIMPs, MMPs, and MMP-1/TIMP-1 complex were 
corrected to total protein concentration in the PD samples in order to address the 
problem of unknown exact dwell times in the SKI-1 PDE samples and overcome 
the problem of line flushing.  MMP-1, MMP-9, MMP-13 and the MMP-1/TIMP-1 
complex were very low or undetected in all PDE samples of SKI-1.  However, 
TIMP-1, TIMP-2, MMP-2, and MMP-3 were detectable in PDE samples of SKI-1 
and showed interesting changes in the single EPS sample in TIMP-1, TIMP-2 
and MMP-2.  For this reason, it was decided to measure these molecules in SKI-
2 and GFS PDE samples.   
MMP-1, MMP-9, and MMP-13 levels may be below the threshold of 
detection by ELISA in the PDE samples.  MMP-1, MMP-9, and MMP-13 assays 
are sensitive down to 156, 31, and 6 pg/mL respectively.  It is a real possibility 
that there are still these MMPs present in the PDE samples but they simply 
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cannot be measured.  However, MMP-1 was also assayed by ELISA after the 
PDE samples were concentrated by rotary evaporation 10 fold, but MMP-1 
remained low or undetected in PDE samples which suggest levels are extremely 
low.  There are previous published papers that support these findings, for 
example, MMP-9 was undetected in most PDE samples in patients without 
infectious peritonitis (Hirahara, Inoue et al. 2007). This is match with our data as 
peritonitis in the two month period prior to sample was excluded. 
The ELISA for MMP-1 detects total MMP-1 which was low or undetected in 
PDE samples.  ELISA was also performed for the MMP-1/TIMP-1 complex in 
PDE samples.  MMP-1/TIMP-1 complex were low or undetectable too.  There is 
high TIMP-1 level in PDE samples, but low MMP-1 to bind with it.  This means 
that there is genuinely low total MMP-1   in PDE samples and thus there is clear 
shut down of these proteases in PDE samples.  It is thus very likely that MMP-9 
and MMP-13 are also shut down in PDE samples.  This is consistent with a pro-
ECM and hence pro-sclerotic phenotype. 
In the SKI-2 cohort, TIMP-1, TIMP-2, MMP-2 and MMP-3 in PDE samples 
were correlated to the degree of peritoneal membrane damage.  TIMP-1 in PDE 
samples was best negatively correlated to UF (less UF was associated with high 
TIMP-1 in PDE samples).  This observation on TIMP-1 correlation in PDE 
samples was observed in both genders.  The level of TIMP-1 in PDE samples 
was biased by difference in gender in a study made by Hirahara et al (Hirahara, 
Inoue et al. 2011).  The detailed comparison with this study and other similar 
studies are in chapter 7 (General discussion).  TIMP-1, TIMP-2, MMP-2 and 
MMP-3 in PDE samples were positively correlated to D/Pcr and this may reflect 
transporter status i.e. TIMPs and MMPs may simply be markers of transport 
status. 
In the SKI-2 cohort plasma samples were also available.  Given that there is 
no true normal or control for peritoneal levels of proteins in PDE samples, then it 
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was reasoned that this may be a way to see if TIMP and MMP levels are 
changed in the PD peritoneum compared to healthy individuals.  There was a 
clear elevation in TIMPs and MMPs levels in plasma from PD patients.  While 
this is possibly due to impaired renal clearance of these molecules in PD 
patients, it is equally likely this is from elevated peritoneal production of these 
proteins.  Ideally there should have been non-dialysis CKD controls to be sure 
whether elevated plasma levels are due to reduced clearance or increased 
production. 
In the GFS, only TIMP-1, TIMP-2, MMP-2, protein were measured in this 
cohort.  The data clearly shows that TIMP-1 was elevated in EPS close to 
diagnosis, so may have value as a late noninvasive biomarker of EPS (within 100 
days of diagnosis) or in confirmation of EPS diagnosis.  However, it is too early to 
draw that conclusion with any certainty as only 2 EPS samples were close to the 
time of EPS diagnosis, however a similar result was seen with TIMP-1 in PDE 
from the single EPS patient in cohort SKI-1.  As explained previously if an 
arbitrary  cut off of 3 x  baseline is imposed as a ―healthy upper limit‖ for TIMP-1 
then  measurements of TIMP-1 would be  97% accurate in predicting patients 
developing EPS within 100 days which is better than most clinical biomarkers 
used today.  The changes in TIMP-2 from the SKI-1 cohort did not read through 
to the GFS samples, but rather showed a relatively stable level throughout 
dialysis in both groups in GFS.  This allowed in using TIMP-2 as an internal 
reference point.  TIMP-1 in odd samples in non-EPS patients was staying above 
the typical range and these samples were odd during TIMP-2 measurements too.  
A cutoff of 3 x of the mean TIMP-1/TIMP-2 ratio with time on PD was calculated 
in the control group and it was 18.3.  None of the sample from the control group 
rose above this cutoff.  In the EPS group, the 2 EPS samples in the last 100 days 
were higher than 18.3.  Therefore, it is difficult to deliver strong conclusion about 
this ratio based on 2 samples.  Nevertheless, it is an interesting observation that 
needs further validation. 
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Of note was that the 3% non-EPS patients that had TIMP-1 above the 
upper range for the bulk of the patients in the non-EPS control group was 
associated with high D/Pcr (0.8 or more).  It could be reasoned that their high 
TIMP-1 level may result from systemic leakage across a compromised 
membrane.  Calculation of TIMP-1/TIMP-2 ratio would minimise the effect of a 
high transport status in the control group and correct for any sample dilution due 
to line flushing.   
TIMP-1 may have value as a biomarker/diagnostic tool, but it clearly may 
have a pathobiological role.  TIMP-1 is a potent inhibitory effect for all the latent 
proMMPs and active MMPs (Ahmed 2009) and is, therefore, likely to be 
important in contributing to an overall reduction in matrix turnover.  Previous 
study showed that TIMP-1 and MMP-2 are correlated to D/Pcr and they are 
produced locally from the peritoneum (Hirahara, Inoue et al. 2011).  A study 
showed that MMP-2 may be useful as a marker of increased solute transport, 
peritoneal injury or progression to EPS (Hirahara, Inoue et al. 2007).  It is likely 
that combinations of markers may be of far more value than single molecule in 
order to understand the contribution of the MMP and plasmin systems in 
peritoneal membrane damage, but the best predictor identified in this study is 
TIMP-1. 
Fibrosis formation in the peritoneum like in all organs is governed in part by 
a decrease in degradation of ECM.  The MMP2, MMP9 (gelatinases) play a role 
in degrading the ECM components such as fibronectin and collagen IV (Collier, 
Wilhelm et al. 1988).  Experimental studies in EPS showed increase in MMP2 
level in PDEs, and MMP2 inhibition led to less injury in the peritoneum (Hirahara, 
Ogawa et al. 2004, Ro, Hamada et al. 2007, Kurata, Maruyama et al. 2009).  
MMP-2 and MMP9 levels were investigated in a multicentre study in PDEs of PD 
patients with peritoneal injury and EPS patients.  High MMP-9 level was 
observed in PD Patients with infectious peritonitis.  The highest MMP-2 level was 
observed in PD patients with mild peritoneal injury (those had ascites less than 
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100 mL).  The MMP-2 level was between moderate to high level in the EPS 
patients.  Nevertheless, approximately half of PD patients (7 out of 15) with 
MMP-2 more than 600ng/mL ended up with EPS (Hirahara, Inoue et al. 2007).  
HPMC exposed to glucose in an in vitro study revealed that a decrease in the 
MMP-1,-8, and -13 expression as well as an increase in the TIMP expression 
leads to accumulation of the ECM (Kim, Li et al. 2008). 
It seems that MMPs are essential, but in the right amount, duration (time 
frame) and place for peritoneal fibrosis.  MMPs play important roles in debriding 
damaged ECM, re-epithelialisation, angiogenesis, remodelling of scar and wound 
contraction. However, there are clinical evidence which shows that high MMPs 
levels are also prevent wound healing, and treatments which lower MMP 
activities promote wound healing (Cullen, Watt et al. 2002, Veves, Sheehan et al. 
2002, Lobmann, Zemlin et al. 2006, Gibson, Cullen et al. 2009). 
In summary, the negligible MMP activity in PDE results from higher TIMP 
than MMP levels.  This is consistent with a fibrotic phenotype which could 
underlie the development of simple PS.  The elevated TIMP-1 level in PDE may 
have value as a diagnostic tool or late biomarker of EPS, but this requires 
extensive evaluation in more patients in different cohorts.  Various TIMPs and 
MMPs in PDE showed markers of increased solute transport during peritoneal 
dialysis.  Plasma levels of TIMP-1, TIMP-2, MMP-2 and MMP-3 are higher in PD 
patients in compared to healthy individuals.  Plasmin activity will decline in 
patients who have been on PD for a long period (more than 3 years).  
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CHAPTER FOUR 
Local and systemic production of 
TIMPs and MMPs 
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4.1 Introduction 
The data from chapter three showed changes in the MMP system in 
patients on PD and this may play a role in the fibrotic remodeling seen in these 
individuals.  Importantly in chapter 3, levels of TIMPs and MMPs measured in the 
drained dialysate were lower than in their levels in plasma hinting towards the 
source of theses being from the circulation and inappropriate build up in the 
peritoneum.  Therefore the source of the TIMPs and MMPs in peritoneal dialysis 
effluents (PDE) could be important to understanding the pathological processes 
and any value as a diagnostic tool.  It is known that many TIMPs and MMPs are 
found in the blood normally (Hirahara, Inoue et al. 2011) and because of their 
size could easily access the peritoneum, but it also remains possible that levels 
could be regulated locally in response to the presence of PD fluids which typically 
have high glucose which is a known trigger for changes in TIMPs (Kim, Li et al. 
2008).  Albumin, transferrin, β2-microglobulin (B2M), immunoglobulin G (IgG), 
and creatinine were used to generate a standard curve (Molecular weight versus 
dialysate/plasma ratio for these proteins) at 2hr dwell time and start effectively 
assessing the rate of transfer across the peritoneal membrane.  After that, D/P 
ratios of TIMPs and MMPs can be plotted against their molecular weights.  If the 
measured D/P ratios of MMPs and TIMPs are on the positive side (faster 
accumulation) of the standard curve, then that would suggest local production in 
the peritoneum.  The reason why albumin, transferrin, B2M, IgG, and creatinine 
were selected comes from understanding their source and function. 
Albumin (69 kDa) is anionic, non-glycosylated protein. It is regarded as the 
most abundant protein in the serum (Garcovich, Zocco et al. 2009).  Albumin is 
produced in liver.  In normal individuals, a daily amount of 10-15 g of albumin is 
synthesized from liver. This accounts for about 10% of total hepatic protein 
production.  The majority of synthesized albumin will be released into the 
vascular compartment.  A small quantity of albumin is stored in liver (<2g). About 
30-40% of the synthesized albumin will be maintained in the plasma, with 
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remaining amount being located in tissues like skin and muscle (Redman 1969).  
Homeostasis of albumin is kept by balanced catabolism which take place in all 
tissues, mainly in liver, muscle and kidney (Beeken, Volwiler et al. 1962).  One of 
the important functions of albumin is maintaining the colloid oncotic pressure.  
About 60% of intravascular protein is composed of albumin, thus maintaining 
60% of plasma colloid oncotic pressure.  Albumin causes water retention. It 
occurs through attraction of sodium ions by the negative charge on protein 
molecules.  The remaining contribution of albumin to colloid oncotic pressure is 
through the Gibbs-Donnan in which there will be attraction of other active positive 
ions, resulting in further water retention (Nguyen and Kurtz 2006).    Albumin will 
also participate in transporting   metabolites such as bilirubin, thyroxine, fatty 
acids and amino acids (Garcovich, Zocco et al. 2009).  Low serum albumin can 
be found in conditions such as liver cirrhosis and excess excretion through 
the kidneys in patients with nephrotic syndrome.  High level of serum albumin 
can be found in conditions such as dehydration.  Gibbs-Donnan Equilibrium is 
the ionic concentration difference between interstitial fluid and plasma is caused 
by the much higher proteins concentration in the plasma compared to the 
interstitial fluid.  Large molecular weight substances such as proteins are not 
passing the capillary membrane easily.  There is lack in the permeability of 
protein across capillary membranes and this is responsible for causing 
differences in the ionic concentration between the interstitial fluid and plasma and 
this is identified as the Gibbs-Donnan effect (Pitts 1974, Rose 1994, Nguyen and 
Kurtz 2004).  
Transferrin (85 kDa) is an iron-binding plasma glycoprotein which is 
synthesized in the liver. It acts as a major transporter for iron through binding to it 
and transferring it to various cells in the body (Yang, Lum et al. 1984).  Low 
transferrin may be as a result of poor transferrin production by the liver or 
excessive transferrin loss by the kidneys into the urine.  Conditions associated 
with low plasma transferrin are including malignancy and infection, while iron 
deficiency anemia leads to abnormal high level of transferrin. 
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Malnutrition is associated with increase in the morbidity and mortality.  
There is no single effective indicator in the laboratory to identify malnutrition, but 
serum proteins and in particularly serum albumin are commonly used.  There are 
some variables that could affect the levels of serum protein by decreasing their 
effectiveness.  Serum albumin (Alb), prealbumin (PAB), transferrin, and retinol 
binding protein (RBP) are examples of malnutrition parameters or markers of 
nutritional status.  Albumin has a half-life of approximately 14–20 days, which is 
why it has been used as a chronic nutritional status marker.  PAB has a shorter 
half-life (2–3 days) and that is why it is expected to change rapidly with variations 
in the nutrient intake.  Transferrin has a half-life of approximately 8–10 days, 
while RBP has a half-life of approximately 12 hours (Nutrition-support-team 
2006). 
There are several factors which cause an increase in the serum albumin 
level such as marasmus, dehydration, exogenous albumin and blood 
transfusions.  In contrast, there are several factors which cause decreased 
serum albumin level such as  kwashiorkor, over-hydration, ascites, eclampsia, 
infection, inflammation, metabolic, hepatic failure stress, nephrotic syndrome, 
burns, protein losing states, trauma, post-operative states, bed rest, cancer, 
collagen diseases, corticosteroid use, pregnancy, and zinc deficiency (Parrish, 
Krenitsky et al. 2003).   
There are also situations that cause increases in the serum transferrin level 
such as iron deficiency, pregnancy (third trimester), dehydration, chronic kidney 
diseases, oral contraception (estrogens), hepatitis, chronic blood loss, and 
hypoxia.  Decreases in the serum transferrin level can occur due to kwashiorkor, 
zinc deficiency, age, cancer, corticosteroids, protein, severe liver disease 
(hepatic congestion), iron overload (iron dextran therapy), uremia, acute 
catabolic states, nephrotic syndrome (permeability of glomerulus), pernicious 
anemia (B12 deficiency), folate deficiency anemia, anemia of chronic disease, 
chronic infection, and overhydration (Parrish, Krenitsky et al. 2003). 
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In the United States Renal Data System database (USRDS), a fall of 1 g/dL 
of the serum albumin level is associated with increase cardiovascular death risk 
factor by 39% (Fung, Sherrard et al. 2002).  There is linear and incremental 
association between serum albumin level and mortality.  It is unclear as to 
whether hypoalbuminemia in the CKD patients are as a result of inadequate 
protein intake or other disorders related to Protein-energy wasting such as 
comorbidity and inflammation (Friedman and Fadem 2010).  Dialysis patients 
that tolerate the technique well show higher level of the serum albumin with 
better survival rates, while the reverse is true for those with an inferior dialysis 
performance (Lacson, Wang et al. 2009, Lacson, Wang et al. 2009).  Longevity 
has steadily been observed in the CKD patients with a better nutritional status, 
including better appetite, larger muscle mass, higher intake of proteins, and fat 
mass (Kalantar-Zadeh, Cano et al. 2011, Jadeja and Kher 2012). 
B2M (11.8 kDa) is a polypeptide and it is a subunit of the class I major 
histocompatibility antigens which is located on the cell surface.  The B2M 
concentration is regulated by the kidney & it is not surprising to find B2M 
elevated in the plasma of patients with chronic kidney diseases (Lysaght, Pollock 
et al. 1989).  The normal free B2M concentration in the serum is (1–2 mg/L) 
(Rennella, Cutuil et al. 2013).  The other two molecules used to create plasma to 
dialysate transfer rate versus molecular weight as a standard curve were IgG and 
creatinine.  IgG had the highest MW among the five molecules at 150 kDa, while 
creatinine had the smallest MW and it is 0.113 kDa.  IgG molecules are created 
in plasma B cells and released from these cells, while serum creatinine is 
primarily a metabolite of creatine, which is located in mainly in the skeletal 
muscle (Harita, Hayashi et al. 2009) 
4.2 Hypothesis  
TIMPs and MMPs are produced locally in the peritoneum during PD and 
those local levels of production increase with the development of PS and EPS.  
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This local production can be demonstrated by measuring the rate of 
accumulation of TIMPS and MMPs in comparison to proteins of similar molecular 
weight known to be produced only outside the peritoneum. 
4.3 Aims 
To test this hypothesis, the rate of transfer of proteins of known molecular 
weight that are not produced in the peritoneum will be calculated.  If TIMP and 
MMP levels in PD fluid have a potentially higher transfer rate this will indicate 
local production is occurring.  Practically this aim will be addressed by: 
1. Collecting plasma & PDE samples at set time points during PET 
2. Measuring the plasma and drained dialysate levels of TIMPs, MMPs 
3. Measuring the plasma and drained dialysate levels of albumin, 
transferrin, β2-microglobulin and IgG to calculate D/P for these 
proteins.  
4. Obtaining D/P creatinine from clinical data 
5. Constructing plasma to dialysate transfer rate standard curve by 
plotting of creatinine, albumin, transferrin, β2-microglobulin and IgG 
dialysate/plasma (D/P) ratio in a 2hr dwell vs. its molecular weight 
(MW). 
6. Plotting TIMPs and MMPs D/P ratios against their molecular weight 
to calculate whether TIMPs and MMPs are produced locally or not by 
comparing to the plasma to dialysate transfer rate standard curve. 
4.4 Methods  
  All ELISAs measured at optical density (OD) 450 nm in an ELISA reader 
immediately after adding stopping solutions except in IgG, in which an OD of 405 
nm was used after suitable developing time (40 minutes) without adding stopping 
solution.  Examples of the standard curves for the four molecules are illustrated 
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in the Figure 4.1.  The standard curve in beta 2 microglobulin (B2M) was in 
pg/mL, while the standard curves of albumin, transferrin, and IgG were in ng/mL.
  
Figure 4.1 Standard 
curves for albumin, 
transferrin, IgG, and B2M 
The albumin (A) transferrin (B), 
IgG (C), and B2M (D) 
concentrations are plotted on the 
x-axis, while the absorptions are 
plotted on the y-axis. Optical 
density changes were measured 
in the 96 well microplate reader 
at 450 nm (except IgG at 405 
nm). Standard curves are made 
for albumin, transferrin , IgG , 
and B2M either by using 
Microsoft Excel or Thermo 
Labsystems Multiskan Ascent 
plate reader software 
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4.5 Results  
Commercially available sandwich ELISA‘s for measuring albumin, 
transferrin, β2-microglobulin and IgG were used as described in sections 2.8.3.3, 
2.8.3.4, and 2.8.3.5 to measure levels in PDE and plasma samples from SKI-
cohort 2 patients undergoing PET at 0, 2 and 4 hours.  Samples were diluted as 
listed in (Table 4.1) to ensure measurements were within the most accurate 
range of the ELISA. 
Molecules Sample Dilution (plasma / PDE) 
0 Hour 2 Hour 4 Hour Plasma 
Albumin 3000 7000 13000 1500000 
Transferrin 600 1750 2750 250000 
IgG 1000 2500 5000 950000 (in healthy individual) 
550000 (in PD patients) 
Beta-2 Microglobulin 1750 5000 7250 90000 (in healthy individual) 
40000 (in PD patients) 
Table 4.1 Peritoneal dialysis effluent and plasma samples dilutions 
The ideal approximate dilution approached for samples during ELISA, Abbreviations: PDE:   peritoneal 
dialysis effluent, IgG: Immunoglobulin G, and ELISA:  enzyme-linked immunosorbent assay. 
4.5.1 Plasma level in healthy volunteers compared to PD patients in SKI-
2 
Albumin, transferrin, and IgG levels in plasma were higher in healthy 
volunteers compared to PD patients, while B2M level was lower in plasma of 
healthy volunteers.  Albumin Median (IQR) in plasma was 44 (41–45) mg/mL in 
healthy but lower at 35 (30–37) mg/mL in patients on PD (Figure 4.2A).  
Transferrin median (IQR) was 4.7 (4.4–5.1) mg/mL in healthy individuals falling to 
3.8 (3.2–4.3) mg/mL in patients on PD (Figure 4.2B).  Median (IQR) was 
calculated for IgG level in plasma as 14.4 (11.8–15.5) mg/mL in healthy 
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individuals and 11.3 (9.4–14.1)mg/mL in patients on PD (Figure 4.2C).  Median 
(IQR) was calculated for the B2M level in plasma as 1.7 (1.4–2) µg/mL in healthy 
volunteers and 18.3 (11.9–31.2) µg/mL in PD patients (Figure 4.2D)  
 
 
 
Figure 4.2 Albumin (A), Transferrin (B), IgG (C) and beta2-Microglobulin (D) in 
healthy volunteers and patients on PD in SKI-2 
Albumin, transferrin, IgG, and beta-2 microglobulin were assayed in plasma samples by commercial 
ELISA. GraphPad Prism 6 used for statistical analysis (Unpaired t test in A & C and Mann Whitney test 
in B &D). Box and Whisker Plots show median, 25th Percentile, 75th Percentile, and the range. 
Abbreviations: B2M: beta-2 microglobulin, IgG: immunoglobulin, and SKI-2: Sheffield Kidney Institute 
PD cohort 2.   
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4.5.2 Effect of dwell time on Albumin, Transferrin, IgG and B2M in the 
PDE samples 
Increases in dwell times were directly proportional to the levels of albumin, 
transferrin, IgG and B2M in PDE samples.  Most of the 51 samples had multiple 
dwell time data, but 18 of them were collected prior to tube flushing in PET at 
different time points (0, 2hr, and 4hr) (Figure 4.3). 
 
 
  
Figure 4.3 Effect of dwell times on albumin, transferrin, IgG, and β2-
microglobulin levels in PDE samples in the SKI-2 cohort 
PDE samples were collected from patients undergoing a PET test after 0, 2 and 4 hr dwell times and 
assayed by commercial ELISA for albumin, transferrin, IgG, and B2M.  GraphPad Prism 6 was used for 
statistical analysis (One way ANOVA). Data represent mean with SD.  
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4.5.3 Rate of filtration 
Patient samples were classified to three groups as less than 1 year on PD, 
1-3 years on PD, and more than 3 years on PD and plots of Log10 molecular 
weight for creatinine, β2-microglobulin, albumin, transferrin and IgG vs the Log10 
D/P creatinine, β2-microglobulin, albumin, transferrin and IgG at the 2hr dwell 
point to create (molecular weight) Mwt/filtration rate (standard curve).  After that, 
Log10 molecular weight of TIMPs and MMPs were plotted against Log10 D/P 
TIMPs and MMPs at the 2hr dwell point for 46 patients (Figure 4.4), and at less 
than 1 year on PD, 1-3 years on PD, and more than 1 year on PD (Figure 4.5).   
Initially standard plots of the dialysate/plasma ratio to molecular weight 
were performed by using albumin, transferrin, IgG, B2M (straight line).  However, 
this had the issue that not all points were passing by the line which made them 
inaccurate.  Post discussions with Prof Davies and Dr Lambie (Keele University), 
the decision was made to re-plot the data with including D/P Cr data to have 
wider range with performing a negative log non-linear fit (i.e. max log D/P ratio 
would be 0), rather than a straight line as with our initial approach. 
TIMP-1, TIMP-2, MMP-2 and MMP-3 had a D/P ratio higher than would 
have been predicted at 2 hour from the D/P vs molecular weight plot suggesting 
that all had some peritoneal production.  TIMP-1 and MMP-2 were much further 
away from the line than TIMP-2 and MMP-3 suggesting that these had greater 
peritoneal production.  TIMP-2 was only just above the predicted level at all-time 
points suggesting this had low levels of peritoneal production.  Therefore, there is 
some local MMPs and TIMPs production that exceeds the levels that would be 
achieved by filtration from the blood alone, but there may be increase in the 
MMPs and TIMPs transportation from blood to PDEs too. 
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Figure 4.4 TIMPs and MMPs are produced in the peritoneum (all samples) 
A Log10 plot of proteins in dialysate/plasma (D/P) ratio in a 2hr dwell time vs. Log10 of their molecular 
weight (MW) were plotted to construct a plasma to dialysate transfer rate (standard curve) by using 
circulating proteins with no peritoneal production i.e. creatinine (MW: 113.1 Da), β2-microglobulin (MW: 
11800 Da), albumin (MW: 69000 Da), transferrin (MW: 85000 Da) and IgG (MW: 150000 Da).  Log10 of 
TIMP and MMP in D/P ratio at 2hr dwell time for 46 patients were plotted against Log10 of their 
molecular weight. It demonstrated that MMP-2 (71000 Da) and TIMP-1 (28000 Da), and to lesser extent 
MMP-3 (54000 Da) and TIMP-2 (21000 Da) are produced in the peritoneum. Data represent Log10 of 
mean with SEM. 
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Figure 4.5 TIMPs and 
MMPs are produced in 
the peritoneum 
irrespective of time on 
PD 
Patients were grouped by time 
on PD to less than 1 year (19 
patients) (A), 1-3 years on PD 
(15 patients) (B), and more 
than 3 years on PD (12 
patients) (C). A Log10 plot of 
proteins in dialysate/plasma 
(D/P) ratio in a 2hr dwell time 
vs. Log10 of their molecular 
weight (MW) were plotted to 
construct a plasma to 
dialysate transfer rate 
(standard curve) by using 
circulating proteins with no 
peritoneal production i.e. 
creatinine (MW: 113.1 Da), 
β2-microglobulin (MW: 11800 
Da), albumin (MW: 69000 Da), 
transferrin (MW: 85000 Da) 
and IgG (MW: 150000 Da).  
Log10 of TIMP and MMP in 
D/P ratio at 2hr dwell time 
were plotted against Log10 of 
their molecular weight. It 
demonstrated that MMP-2 
(71000 Da) and TIMP-1 
(28000 Da), and to lesser 
extent MMP-3 (54000 Da) and 
TIMP-2 (21000 Da) are 
produced in the peritoneum in 
A, B, and C. Data represent 
Log10 of mean with SEM. 
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4.5.4 Correlations  
4.5.4.1 Correlations of UF and D/Pcr to D/P of the albumin, transferrin, IgG, 
B2M, TIMPs, and MMPs 
A set of correlations were run between UF and D/P of the albumin, 
transferrin, IgG, B2M, TIMP-1, TIMP-2, MMP-2, and MMP-3 levels at 2hr.  U.F. 
was strongly negatively correlated to D/PTIMP-1 in both genders and similar to 
the correlation between UF and D/Pcr.  Additional correlations are given in (Table 
4.2) 
Another set of correlation were run between D/Pcr and D/P of the albumin, 
transferrin, IgG, B2M, TIMP-1, TIMP-2, MMP-2, and MMP-3 levels at 2hr.  D/Pcr 
was either strongly or very strongly positively correlated to D/P of albumin, 
transferrin, IgG, B2M, TIMP-1, TIMP-2, MMP-2, and MMP-3 levels at 2hr in both 
genders.  Two exceptions were DPcr versus D/P B2M (female) and DPcr versus 
D/P MMP-2 (Male) which are both less well correlated.  Additional correlations 
are illustrated in (Table 4.3). 
This may indicate that in addition to the local production of TIMPs and 
MMPs, they may cross the peritoneal membrane to the peritoneal cavity.  This 
may be because peritoneal membrane is more vascular, more inflammation with 
more protein crossing the peritoneal membrane. 
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Correlations U.F. (Male), n=25 U.F. (Female), n=18 
D/P Immunoglobulin G (IgG) r= - 0.43 
p= 0.03 
r= - 0.35 
p= 0.15 
D/P Transferrin r= - 0.53 
p= 0.007 
r= - 0.38 
p= 0.12 
D/P Albumin r= - 0.59 
p= 0.002 
r= - 0.28 
p= 0.26 
D/P β2-microglobulin (B2M) r= - 0.24 
p= 0.25 
r= 0.11 
p= 0.67 
D/P Timp-1 r= - 0.63 
p= 0.0007 
r= - 0.56 
p= 0.016 
D/P Timp-2 r= - 0.44 
p= 0.03 
r= - 0.32 
p= 0.19 
D/P MMP-2 r= - 0.39 
p= 0.05 
r= - 0.29 
p= 0.25 
D/P MMP-3 r= - 0.43 
p= 0.03 
r= - 0.51 
p= 0.03 
D/Pcr, 2 hr r= - 0.66 
p= 0.0003 
r= - 0.72 
p= 0.0007 
 
Table 4.2 Correlations of Ultrafiltration (U.F.) to various D/P molecule ratio in both 
genders 
Correlations between U.F.and dialysate/plasma (D/P) ratio for albumin, transferrin, IgG, B2M, TIMP-1, 
TIMP-2, MMP-2, MMP-3 and creatinine after a2hr dwell.  GraphPad Prism 6 was used to perform the 
correlation test (Compute Pearson correlation coefficient). Abbreviations: tissue inhibitors of 
metalloproteinase (TIMP), and matrix metalloproteinase (MMP). 
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Correlations D/Pcr, 2hr (Male), n=27 D/Pcr, 2hr (Female), n=19 
D/P Immunoglobulin G (IgG) r= 0.7058 
p < 0.0001 
r= 0.7216 
p= 0.0005 
D/P Transferrin r= 0.7707 
p < 0.0001 
r= 0.7392 
p= 0.0003 
D/P Albumin  r= 0.7971 
p < 0.0001 
r= 0.6793 
p= 0.0014 
D/P β2-microglobulin (B2M) r= 0.6349 
p= 0.0004 
r= 0.2151 
p= 0.3764 
D/P Timp-1 r= 0.7764 
p < 0.0001 
r= 0.7507 
p= 0.0002 
D/P Timp-2 r= 0.7664 
p < 0.0001 
r= 0.7772 
p < 0.0001 
D/P MMP-2 r= 0.3432 
p= 0.0796 
r= 0.6949 
p= 0.0010 
D/P MMP-3 r= 0.7791 
p < 0.0001 
r= 0.6973 
p= 0.0009 
Table 4.3 Correlations of D/Pcr to various D/P molecules in both genders 
Correlations between D/Pcr against dialysate/ plasma (D/P) albumin, transferrin, IgG, B2M, TIMP-1, TIMP-2, 
MMP-2, and MMP-3 at 2hr.  GraphPad Prism 6 was used to perform the correlation test (Compute Pearson 
correlation coefficient). Abbreviations: dialysate-to-plasma ratio of creatinine (D/Pcr), tissue inhibitors of 
metalloproteinase (TIMP), and matrix metalloproteinase (MMP). 
4.5.4.2 Correlation of total protein to the albumin, transferrin, IgG, and B2M 
in the PDE samples 
To determine if the levels of albumin, transferrin, IgG and B2M in PDE at 
2hr were related to the total protein load in PDE, correlations were run between 
total protein in the PDE and each of the four proteins at 2hr.  The correlations are 
illustrated in (Table 4.4) which shows much weaker correlation in B2M. 
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Correlations Total protein 
Albumin r= 0.98, P < 0.0001 
Transferrin r= 0.97, P < 0.0001 
Immunoglobulin G (IgG) r= 0.92, P < 0.0001 
β2-microglobulin (B2M) r= 0.35, P = 0.01 
Table 4.4 Correlations of total protein to the four molecules in peritoneal dialysis 
effluents (PDE) 
Correlations between total protein against albumin, transferrin, IgG, and B2M in PDE at 2hr. GraphPad 
Prism 6 was used to perform the correlation test (Compute Pearson correlation coefficient). 
4.5.4.3 Correlations of the albumin, transferrin, IgG, and B2M to each other 
in the PDE samples 
A set of correlations was run between PDE levels of albumin, transferrin, 
IgG and B2M at 2hr to determine if there were any links between the four 
molecules.  B2M was the least correlated protein to the other three molecules. 
On the other hand, the correlation between albumin and transferrin, albumin and 
IgG, as well as transferrin and IgG were very strongly correlated (Figure 4.6).   
179 
 
 
 
 
 
Figure 4.6 Correlation between 
albumin, transferrin, and IgG in 
PDE samples in SKI-2 cohort 
Albumin, transferrin, and IgG were 
assayed by commercial ELISA and a 
correlation run between them A) albumin 
and transferrin B) albumin and IgG, and 
C) transferrin and IgG.  All were 
measured in PDE samples after a 2h 
dwell time. GraphPad Prism 6 was used 
to perform the correlation test (Compute 
Pearson correlation coefficient). 
Abbreviations:PDE: peritoneal dialysis 
effluent,  IgG: Immunoglobulin, and SKI-
2: Sheffield Kidney Institute PD cohort 2. 
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4.6 Discussion 
This chapter aimed to understand if there was local production of TIMPs 
and MMPs in the peritoneum during PD.  Circulating proteins with no peritoneal 
production were chosen to construct plasma to dialysate vs molecular weight 
standard curve at a 2hr dwell point using samples collected accurately during 
routine PET.  The data clearly demonstrated local production of TIMP-1, TIMP-2, 
MMP-2 and MMP-3 was occurring in the peritoneal cavity, in particular TIMP-1 
and MMP-2 seemed to demonstrate the greatest intra-peritoneal contribution to 
levels in PDE.  . 
  There were some technical challenges to overcome, the most frustrating 
being the effect of line flushing on PDE sample measurements as this was 
undertaken in different ways by those doing the PET tests.  Samples after line 
flushing would therefore be diluted by varying amounts so all measured proteins 
will also be variably diluted.  PDE samples at 2hr dwell time were chosen to 
overcome this problem as samples at 2hr were not collected with line flushing 
making the measurements accurate and precise. 
A number of correlations were performed.  They showed that albumin, 
transferrin, and IgG levels in PDE are strongly positively correlated to the total 
protein level and also to each other.  These proteins were chosen as they are not 
produced in the peritoneum and thus need to be filtered.  Only B2M was less 
positively correlated to these 3 proteins and total protein.  Due to the fact that 
B2M does not correlate with total protein or other proteins measured, this does 
question the accuracy of this point on the molecular weight to D/p curves and 
may suggest the gradient of the curve is greater than it should be and thus some 
of the MMPs and TIMPs may have greater peritoneal production than this data 
predicts. 
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Gender has a significant effect on correlations of D/Pcr or U.F. versus D/P 
of all molecules tested, but U.F. was strongly negatively correlated to D/P of 
TIMP-1 in female and male groups, not affected by gender and thus the main 
finding stands cross gender.  The peritoneal membrane inflammation and 
damage may leads to protein loss including TIMP-1. 
Albumin, transferrin, and IgG levels were higher in plasma of healthy 
individuals in compare to patients on PD.  B2M level was higher in patients on 
PD in compare to healthy individuals.  The elevated level of B2M may be due to 
impaired renal clearance of this molecule. 
Hirahara and collegues have previously performed similar studies to those 
carried out in this chapter but they were unable to detect TIMP-2 in PDE. It is 
likely this relates to either the assay they used as sensitivity could be an issue or 
the way their samples were stored,   However they did show very similar findings 
for TIMP-1 as described here despite their lack of curve fitting in constructing 
plasma or serum/dialysate transfer rate standard curves.  They also did not 
include serum or plasma creatinine which gave them a less data points for line 
(Hirahara, Inoue et al. 2011).  The other group that did similar work was Barreto 
and collegues.  They used four molecules curve and they only tested MMP-2 and 
PAI-1, and they did not perform curve fit.  MMP-2 was also proved to be 
produced locally in this study.  (Barreto, Coester et al. 2013). 
The data here clearly shows local production for TIMP-1, MMP-2, and to 
lesser extent TIMP-2, and MMP-3 in all groups irrespective of time on PD.  This 
is interesting because TIMP is associated with the fibrotic lesions across many 
organs including kidney and as such its production in response to PD could have 
implications for PS.  What is more, this local production shows that the 
peritoneum has the capacity to generate TIMP-1 and thus the very high levels 
seen late in EPS patients in the previous chapter.  Simply put, there may come a 
time in PD when the local TIMP-1 production is exaggerated in response to some 
182 
 
event and thus controlling the local production early could have benefical effects 
on EPS development. 
 In conclusion, TIMPs and MMPs specially TIMP-1 and MMP-2 are 
produced partly in the peritoneum.  Intraperitoneal production of TIMP-1 may 
cause systemic elevation as measured in plasma.  The process of PD may 
trigger this enhanced TIMP-1 and thus it can potentially be used as a biomarker 
of PD damage as well as a potential therapeutic target.  
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CHAPTER FIVE 
Characterisation of three 
proteins identified as potential 
predictors of EPS by peritoneal 
dialysis effluent proteomics   
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5.1 Introduction 
Recent application of 2D gel proteomics on PDE samples from the GFS 
carried out at the Sheffield Kidney Institute has identified changes in several 
proteins in patients that develop EPS compared to patients that do not.  However 
none of these proteins have been followed up and quantified accurately by 
classical assays in the wider GFS cohort to validate.  In this chapter, three of the 
more promising proteins identified by proteomics have been selected for 
accurate quantification in PDE samples by Enzyme-linked immunosorbent 
assays (ELISA).  These proteins are Intelectin-1 (omentin), Dermatopontin and 
Collagen (alpha1) I.  These 3 proteins were selected from a provisional list.  The 
rest of the identified proteins were also measured by others (2 laboratory team 
workers).  The reasons of choosing these 3 targets were because of the 
following: 
1) Intelectin-1 was very clear protein spot in GFS (EPS) cohort and changed 
in all EPS patients put through proteomics.  
2) Dermatopontin was similar to the intelectin-1.  It seemed to increase with 
time on PD. 
3) Collagen (alpha1) I was the only obvious ECM protein to come out of 
proteomics and thus may play as a direct marker of changes in the ECM 
production.  
In humans, there are 2 known intelectins termed -1 and -2.  Intelectin-1 
(omentin) (120 kDa) is an adipocytokine.  Intelectin-1 has no effect on the basal 
glucose uptake; however, it helps in insulin-stimulated glucose uptake in the 
adipocytes.  It may take part in the immune defence system by having a role 
against microorganisms by recognising carbohydrate chains on the pathogens.  
Finally, it may play a role in iron metabolism (Tsuji, Uehori et al. 2001, Yang, Lee 
et al. 2006).   
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Intelectin-1 is mainly expressed in omental adipose tissue (Shibata, Ouchi 
et al. 2012).  It is also highly expressed in the small intestine with further 
expression in the colon, pancreas, heart, skeletal muscle, salivary gland, thyroid, 
and testis.  Intelectin-1 has lower expression in the prostate, uterus, thymus, 
lymph node and spleen (Lee, Schnee et al. 2001, Suzuki, Shin et al. 2001, Tsuji, 
Uehori et al. 2001, Yang, Lee et al. 2006).  Goblet cells in gastrointestinal tract 
are the main cells secreting intelectin-1 in humans.  Intelectin-1 is secreted to the 
intestinal lumen along with mucus (Washimi, Yokose et al. 2012).  In 2012, 
circulating intelectin-1 level was shown to be negatively correlated against a 
multiplicity of metabolic risk factors.  This suggested that intelectin-1 may act as 
a metabolic disorders biomarker (Shibata, Ouchi et al. 2012).  Intelectin-2 may 
also have a role in defense against pathogens.  Unlike intelectin-1, intelectin-2 is 
expressed in the small intestine only (Lee, Schnee et al. 2001) 
Dermatopontin (DPT) (24 kDa) comprises a significant proportion of the 
non-collagenous protein in ECM.  The ECM in vertebrates consists of collagens 
and non-collagenous proteins for example proteoglycans.  The non-collagenous 
proteins have many functions such as maintenance of tissue architecture and 
integrity as well as their involvement in the cellular behavior (Yamatoji, 
Kasamatsu et al. 2012).  Dermatopontin is a tyrosine rich acidic protein (Neame, 
Choi et al. 1989).  Half of the tyrosine residues in dermatopontin are sulfated.  
Sulfated tyrosine is crucial as it helps dermatopontin to interact with other 
proteins in ECM.  Dermatopontin interacts with numerous components in ECM, 
especially collagen, decorin and TGF-beta (Okamoto and Fujiwara 2006, 
Yamatoji, Kasamatsu et al. 2012).  Dermatopontin is expressed in fibroblasts, 
skeletal muscle, heart, pancreas, brain, kidney, lung, placenta, and liver.  It is 
expressed more in normal skin fibroblasts than in fibroblasts of systemic 
sclerosis patients and fibroblasts of patients with hypertrophic scar lesions in 
their skin suggesting its loss is associated with inappropriate ECM biology 
(Superti-Furga, Rocchi et al. 1993, Kuroda, Okamoto et al. 1999). 
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 Collagen I represents the most abundant collagen among the collagen 
family.  Collagen I is a heterotrimer comprising two chains of α1(I) and one chain 
of α2(I) encoded by theCOL1A1 and COL1A2 respectively.  Collagen α1(I) is 139 
kDa and Collagen α2 (I) is 129 kDa.  Collagen α1(I) and collagen α2 (I) are 
located on chromosome 17 and 7 respectively (Dalgleish 1997). In organ fibrosis 
not only does collagen production go up, but there are relative increases in 
collagen types I & III as a percentage of the overall collagen load (Johnson, 
Fisher et al. 2007).  Collagen I expression is increased in the other fibrosis forms 
such as bone marrow fibrosis, liver fibrosis, lung fibrosis, and scleroderma 
(Karsenty and Park 1995)  
5.2 Hypothesis 
Proteomics analysis of PDE samples comparing the proteome from EPS 
patients to that from patients not developing EPS has identified changes in 
several proteins.  There is a possibility that some of these proteins may underlie 
the development of EPS or act as biomarkers.  Therefore this chapter aims to 
test the hypothesis that is changes in intelectin-1, DPT and COL1A1 may have 
value as biomarkers or diagnostic markers for PS and EPS in PD patients. 
5.3 Aims 
The aim of this chapter is to determine if intelectin-1, dermatopontin and 
collagen (1) I (COL1A1) are biomarkers of, or have diagnostic value in EPS.  To 
do this, the aims in this chapter will be to: 
1. Measure the levels of intelectin-1, dermatopontin and COL1A1 in PDE 
samples in the SKI-1 cohort to assess feasibility of detection. 
2. Determine how these proteins change with loss of membrane function using 
the SKI-2 cohort. 
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3. Any with sufficient abundance in PDE samples will be measured in non-EPS 
(control) and EPS populations from the GFS to establish if they can be predictive 
or diagnostic. 
5.4 Methods 
Commercially available sandwich ELISAs for measuring Intelectin-1, 
dermatopontin and collagen (1) I (COL1A1) were used as described in chapter 
2 (section 2.8.3.6) using the 3 patient cohorts (SKI-1, SKI-2, and GFS).  All 
ELISAs were ordered from USCN as following: 
 E90933Hu 96 Tests, Enzyme-linked Immunosorbent Assay Kit For 
omentin (intelectin-1), Organism: Homo sapiens (Human), USCN 
 E92432Hu 96 Tests, Enzyme-linked Immunosorbent Assay Kit For 
dermatopontin, Organism: Homo sapiens (Human), USCN 
 E90350Hu 96 Tests, Enzyme-linked Immunosorbent Assay Kit For 
collagen (a1) I, Organism: Homo sapiens (Human), USCN 
   All ELISAs measured at optical density (OD) 450 nm in an ELISA reader 
immediately after adding stopping solutions.  Examples of the standard curves 
for these three proteins are illustrated in the Figure 5.1.  The standard curve in 
intelectin-1 was in pg/mL, while the standard curves of dermatopontin and 
COL1A1 were in ng/mL.   
5.4.1 Assay sensitivity 
The minimum detectable values are typically less than 52 pg/mL for 
dermatopontin, 115 pg/mL for COL1A1 and 3.1pg/mL for intelectin-1.  This 
indicate that even low concentration of human intelectin-1 in the samples can be 
detected using the ELISA kit from USCN (E90933Hu).  
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Figure 5.1 Standard curves for intelectin 1, dermatopontin and COL1A1 
The intelectin-1 (A) dermatopontin (B), and COL1A1 (C) concentrations are plotted on the x-axis, 
while the absorptions are plotted on the y-axis. Optical density changes were measured in the 96 
well microplate reader at 450 nm. Standard curves were made for intelectin-1, dermatopontin, and 
COL1A1 either by using Microsoft Excel or Thermo Labsystems Multiskan Ascent plate reader 
software 
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5.5 Results 
PDE samples from cohort SKI-1 were used for early ―first look‖ studies‖ for 
assay development as they had significant volumes but limited clinical data or 
exact dwell time information.  They also had variable line flushing performed 
giving variable sample dilution.  The SKI-2 cohort samples were collected as the 
study progressed during PET so had precise data available.  The SKI-2 cohort 
contained both PDE and plasma samples.  PDE samples after 2 hours dwell time 
were selected for use since these were collected without line flushing.  The 
plasma samples in SKI-2 were collected at the 2 hours dwell time too.  In the 
GFS cohort, there were only small volumes of PDE samples, but is probably the 
best collection of EPS samples available.  Therefore anything of interest and 
measurable in the small samples was looked at in the GFS cohort.  
SKI-1 was important cohort to practise and find the ideal dilution for the 
samples.  Dermatopontin was assayed using neat PDE   or a dilution up to 1:5.  
COL1A1 was assayed were between neat and 1:8 dilution while intelectin-1 was 
assayed between 1:50 and 1:100 dilution.  Consequently all 3 proteins were 
measurable in the SKI-1 and 2 patient cohorts as sufficient sample was available, 
however only intelectin-1 was able to be measured in the GFS as intelectin-1 
required less than 20 µL volumes of PDE samples to be performed.  
In SKI-2, dwell times had an effect on PDE samples i.e. PDE samples 
(overnight) contain a higher concentration of various proteins than PDE samples 
after 2hr dwell time, thus need more dilution. For example, some samples 
required 100 times dilution to measuring intelectin-1 in PDE samples (overnight) 
by ELISA, while intelectin-1 measured in same samples at 2hr dwell time and it 
required less dilution during ELISA.  To measure intelectin-1 in the PDE samples, 
1:10-1:100 dilutions were used.  Intelectin-1 in the plasma samples also required 
dilution with that from healthy individuals and patients on PD needing diluting 
190 
 
2500 and 5000 fold respectively.  These dilutions were approximate as some 
individual samples required greater or lesser dilution.       
5.5.1 Intelectin-1, dermatopontin and COL1A1 in PDE samples (SKI-1 
cohort) 
The SKI-1 cohort was used to establish the ideal dilutions for intelectin-1, 
dermatopontin and COL1A1 in the PDE samples, and to compare levels in PDE 
samples after grouping the samples according to the time on PD.  SKI-1 cohort 
measurements were corrected to total protein concentration (mg/mL) in PDE 
samples to minimise the effect of variable dwell times and sample dilution caused 
by line flushing between PDE samples.  PDE samples were divided into 4 groups 
based on time on PD or EPS as described previously (<1 year, 1-3 years, >3 
years on PD and EPS) (Figure 5.2).  Intelectin-1 expressed per mg of protein in 
the sample gave a higher level in the EPS patient than the other groups as would 
have been predicted from the proteomics.  In contrast COL1A1 and 
dermatopontin did not show clear changes from the rest in the EPS sample.  The 
median (range) for corrected intelectin-1, dermatopontin and COL1A1 to proteins 
were 4945 (1723-14754), 2531 (619-19922), and 10238 (1907-29000) pg/mg 
respectively. 
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Figure 5.2 Collagen (1) I, dermatopontin and intelectin-1 levels in PDE from the 
SKI-1 cohort 
PDE samples were divided by time on PD (<1 year, 1-3 years, and >3 years) or EPS development.  
They were assayed by commercial ELISA for A) intelectin-1, B) dermatopontin, and C) COL1A1.  All 
PDE samples were from an overnight dwell with a line flush and as such all values were corrected for 
protein.  GraphPad Prism 6 was used for statistical analysis (One way ANOVA test for A &C, while 
Kruskal-Wallis test for B).  The EPS sample was excluded from all statistical analysis because it is a 
single patient. Data represent mean with SEM. Abbreviations: PDE: peritoneal dialysis effluent, COL1A1: 
Collagen (1) I, SKI-1: Sheffield Kidney Institute PD cohort 1, and EPS: encapsulating peritoneal 
sclerosis. 
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5.5.2 Intelectin-1, dermatopontin and COL1A1 in PDE samples from the 
SKI-2 cohort 
Intelectin-1, dermatopontin and COL1A1 were detectable in the SKI-1 
cohort and thus tested in the second Sheffield cohort where full dwell and clinical 
data was available allowing better relationship to the clinical status.  Intelectin-1 
was also measured in plasma of PD patients, permitting a calculation of the rate 
of filtration (section 5.5.2.5) to understand whether intelectin-1 is produced locally 
or not.  The median (range) levels in PDE samples for intelectin-1, dermatopontin 
and COL1A1 levels median (range) in SKI-2 patient cohort were 1171 (317-
10688), 801 (86-5650), and 4100 (1160-18500) pg/mL respectively.   
5.5.2.1 Relationship between Intelectin-1, dermatopontin and COL1A1 with 
solute transport rate (D/Pcr and D/D0 glucose) 
Peritoneal solute transport rate may be useful for evaluating peritoneal 
membrane injury.  This is assessed during PET by D/Pcr and D/D0 glucose.  
There were positive correlations between intelectin-1, dermatopontin and 
COL1A1 with D/Pcr at 2hr (Figure 5.3), while the correlation was negative with 
D/D0 glucose (Figure 5.4).  In both cases intelectin-1 and Collagen a1(I) had 
equivalent and better correlations than dermatopontin. 
  
   
 
193 
 
 
 
 
Figure 5.3 Correlation between 
D/Pcr at 2hr and intelectin-1 (A), 
dermatopontin (B), COL1A1 (C) 
levels in PDE samples from the 
SKI-2 cohort 
Intelectin-1, dermatopontin, COL1A1 were 
assayed by commercial ELISA. All 
molecules were measured in PDE samples 
at 2h dwell time. D/Pcr at 2hr was positively 
correlated to A) intelectin-1, B) 
dermatopontin, and C) COL1A1. GraphPad 
Prism 6 was used to perform the correlation 
test (Compute Pearson correlation 
coefficient). Abbreviations: PDE: peritoneal 
dialysis effluent, COL1A1: Collagen (1) I, 
SKI-2: Sheffield Kidney Institute PD cohort 2, 
EPS: encapsulating peritoneal sclerosis, and 
D/Pcr: dialysate-to-plasma ratio 
of creatinine. 
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Figure 5.4 Correlations between 
D/D0 glucose at 2hr and 
intelectin-1 (A), dermatopontin 
(B), COL1A1 (C) levels in PDE 
samples from the SKI-2 cohort 
Intelectin-1, dermatopontin, COL1A1 were 
assayed by commercial ELISA.  All 
molecules were measured in PDE samples 
at 2h dwell time.    D/D0 glucose at 2hr was 
negatively correlated to A) intelectin-1, B) 
dermatopontin, and C) COL1A1.  GraphPad 
Prism 6 was used to perform the correlation 
test (Compute Pearson correlation 
coefficient). Abbreviations: PDE: peritoneal 
dialysis effluent, COL1A1: collagen (1) I, 
SKI-2: Sheffield Kidney Institute PD cohort 
2, EPS: encapsulating peritoneal sclerosis 
and D/D0 glucose at 2hr: ratio of dialysate 
glucose at 2hr dwell time to dialysate 
glucose at 0 dwell time. 
195 
 
5.5.2.2 Relationship between Intelectin-1, dermatopontin and COL1A1 with 
ultrafiltration 
It is well-known that peritoneal membrane fibrosis is associated with 
ultrafiltration failure (Lambie, John et al. 2010, Sampimon, Coester et al. 2011).  
Intelectin-1, DPT and COL1A1 in the PDE samples were thus correlated against 
ultrafiltration rate displaying a negative correlation with UF (Figure 5.5).    
 
  
 
Figure 5.5 Correlation between UF and intelectin-1 (A), dermatopontin (B), and 
COL1A1 (C) levels in PDE samples from the SKI-2 cohort 
Intelectin-1, dermatopontin, COL1A1 were assayed by commercial ELISA. All molecules were measured 
in PDE samples at 2h dwell time.   UF was negatively correlated to A) intelectin-1, B) dermatopontin, and 
C) COL1A1.  GraphPad Prism 6 was used to perform the correlation test (Compute Pearson correlation 
coefficient). Abbreviations: PDE: peritoneal dialysis effluent, COL1A1: collagen (1) I, SKI-2: Sheffield 
Kidney Institute PD cohort 2, EPS: encapsulating peritoneal sclerosis, and UF: ultrafiltration. 
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5.5.2.3 Effect of dwell time on intelectin-1, dermatopontin and COL1A1 in 
the PDE samples in the SKI-2 cohort 
A few samples were chosen to measure the levels of intelectin-1, 
dermatopontin and collagen (1) I with increasing dwell times.  Intelectin-1 and 
COL1A1 were similar to TIMPs and MMPs in that they progressively increased 
with dwell times.  Dermatopontin was different as longer dwell times did not 
always cause an increase in the levels of dermatopontin in PDE samples.  This 
may mean that at a certain time point there will be saturation of dermatopontin in 
PDE samples and therefore no further diffusion of dermatopontin from plasma to 
PDE samples can occur. 
5.5.2.4 Plasma level in healthy volunteers compared to PD patients in SKI-2 
To compare if intelectin-1 level is elevated in PD patients compared to 
healthy individuals, it was hypothesized that changes in intelectin-1 would find 
their way into the blood thus allowing a direct comparison with healthy volunteers 
as previously described.  The healthy volunteers were lab technicians, scientists, 
students, lecturers with age ranging from 22 – 49 years old (7 Females and 11 
males).  Intelectin-1 was lower in healthy volunteers compared to those on PD 
(p=0.046).  Intelectin-1 median (IQR) in plasma was 327 (272–426) ng/mL in the 
healthy group, compared with 508 (261–857) ng/mL in PD patients (Figure 5.6).  
 
 
Figure 5.6 Plasma level of intelectin-1 in 
healthy volunteers and patients on PD 
Intelectin-1 was assayed in plasma samples by 
commercial ELISA in healthy volunteers and PD 
patients from the SKI-2 cohort. GraphPad Prism 6 
was used for statistical analysis (Mann Whitney 
test). Box and Whisker Plots show median, 25th 
Percentile, 75th Percentile, and the range. 
Abbreviation: SKI-2: Sheffield Kidney Institute PD 
cohort 2. 
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5.5.2.5 Rate of filtration 
Sample volume and assay dilution indicated that Intelectin-1 was the only 
molecule able to be tested in GFS cohort (section 5.5.3) and as a consequence 
this was more fully investigated.  Using the same protocol as in chapter 4 
(section 4.5.3), the Log10 molecular weight of creatinine, β2-microglobulin, 
albumin, transferrin and IgG were plotted against their Log10 D/P creatinine, β2-
microglobulin, albumin, transferrin and IgG at the 2hr dwell time to generate a 
Mwt/filtration rate (standard curve).  After that, Log10 molecular weight of 
intelectin-1 was plotted against Log10 D/P intelectin-1 at the 2hr dwell point for 
46 patients (Figure 5.7), and at less than 1 year on PD, 1-3 years on PD, and 
more than 1 year on PD (Figure 5.8).  Intelectin-1 was almost on the line of the 
Mwt/filtration rate (standard curve) for a protein of its size.  Thus the D/P vs 
molecular weight plot suggested that intelectin-1 did not have local production in 
peritoneal cavity.  This did not change whether using an average of all 46 PDE 
samples or grouping by time on PD (less than 1 year on PD, 1-3 years on PD, 
and more than 1 year on PD). 
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Figure 5.7 Intelectin-1 is not produced locally in the peritoneum (all samples) 
A Log10 plot of proteins in dialysate/plasma (D/P) ratio in a 2hr dwell time vs. Log10 of their molecular 
weight (MW) were plotted to construct a plasma to dialysate transfer rate (standard curve) by using 
circulating proteins with no peritoneal production i.e. creatinine (MW: 113.1 Da), β2-microglobulin (MW: 
11800 Da), albumin (MW: 69000 Da), transferrin (MW: 85000 Da) and IgG (MW: 150000 Da).  Log10 of 
intelectin-1 in D/P ratio at 2hr dwell time for 46 patients were plotted against Log10 of their molecular 
weight. It demonstrated that intelectin-1 (120000 Da) is not produced in the peritoneum. Data represent 
Log10 of mean with SEM.  
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Figure 5.8 Intelectin-1 
is not produced in 
the peritoneum 
irrespective of time 
on PD 
Patients were grouped by 
time on PD to less than 1 
year (19 patients) (A), 1-3 
years on PD (15 patients) 
(B), and more than 3 years 
on PD (12 patients) (C). A 
Log10 plot of proteins in 
dialysate/plasma (D/P) ratio 
in a 2hr dwell time vs. 
Log10 of their molecular 
weight (MW) were plotted to 
construct a plasma to 
dialysate transfer rate 
(standard curve) by using 
circulating proteins with no 
peritoneal production i.e. 
creatinine (MW: 113.1 Da), 
β2-microglobulin (MW: 
11800 Da), albumin (MW: 
69000 Da), transferrin (MW: 
85000 Da) and IgG (MW: 
150000 Da).  Log10 of 
intelectin-1 in D/P ratio at 
2hr dwell time were plotted 
against Log10 of its 
molecular weight. It 
demonstrated that 
intelectin-1 (120000 Da) is 
not produced in the 
peritoneum in A, B, and C. 
Data represent Log10 of 
mean with SEM. 
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5.5.3 ELISA measurement of proteins identified as biomarkers of EPS 
using proteomics in the Global Fluid Study (GFS) cohort 
The decision was made to only measure intelectin-1 in the GFS cohort 
based on that in the SKI-1 cohort intelectin-1 was the only protein elevated in 
EPS and that intelectin-1 measurement only requires a few microliters of PDE so 
it was possible to measure it in the GFS cohort where only limited volume of 
sample is available.  In contrast, dematopontin and COL1A1 required at least 
450uL to measure both molecules in PDE samples which was not realistic.  
Intelectin-1 also had the strongest positive correlation between intelectin-1 in 
PDE samples with D/Pcr and negative correlation with UF. 
5.5.3.1 Intelectin-1 level in the GFS cohort 
Individual patients had their intelectin-1 level plotted against time on PD 
(Figure 5.9).  For control patients, intelectin-1 level was plotted for 158 samples 
taken from 42 patients.  In the EPS group, intelectin-1 level was plotted for 43 
samples that were taken from 12 patients.  From the Spaghetti plots of the 
intelectin-1 there is only one sample in the EPS group which shows elevated 
intelectin-1 in PDE (10200 pg/mL) and this is immediately prior to diagnosis.  
There are a number of samples in the non-EPS control group with high level of 
intelectin-1 in PDE samples.  The samples from control group with high intelectin-
1 were associated with D/Pcr of 0.75 or more which may explain why intelectin-1 
was high in these PDE samples.    
Individual samples grouped by time to EPS diagnosis or stopping PD were 
calculated for mean and an average value plotted with time.  There was no clear 
significant shift in the level of intelectin-1 between control and EPS diagnosed 
samples, although there was a late increase in intelectin-1. This late increase in 
intelectin-1 between control and EPS was due to a huge increase in the 
intelectin-1 level based on one sample only and this is not truly representative.   
Median (range) of intelectin-1 in PDE samples of the control and EPS groups 
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were 1 (0.17-12.5) and 1 (0.12-10.2) ng/mL respectively (Figure 5.10).  This 
range is clearly showing that maximum intelectin-1 was in control group (12.5 
ng/mL) and this is the highest in the control.     
 
 
Figure 5.9 Spaghetti plots of intelectin-1 level in PDE samples (control and EPS) 
Intelectin-1 was assayed by commercial ELISA in PDE samples from the GFS (control and EPS).  After 
that, (A) Intelectin-1 was plotted against sample days till PD end without developing EPS in the control 
group and (B) Intelectin-1 was plotted against days from sample to EPS diagnosis in EPS group.  
Abbreviations: PDE:   peritoneal dialysis effluent, GFS: global fluid study, and EPS: encapsulating 
peritoneal sclerosis.  
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Figure 5.10 Mean intelectin-1  concentrations in control and EPS groups (GFS) 
Means intelectin-1 in PDE samples were plotted for every 200 days and every 100 days in the last 200 
days for EPS and control groups.  There is huge elevation in the intelectin-1 in one sample within 100 
days of the EPS diagnosis in EPS group which caused this shift in the last 100 days. Data represents 
mean with SEM. Abbreviations: GFS: Global Fluid Study, PD: peritoneal dialysis and EPS: encapsulating 
peritoneal sclerosis.   
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5.6 Statistical analysis after this study 
5.6.1 SKI-2 
Power is to allow a reasonable chance for detecting a predetermined 
difference (effect size) in the outcome variable, at a given level of statistical 
significance.  Sample size is critically dependent on the purpose of the study, the 
proposed effect size, the outcome measure and how it is summarised, and the 
method of calculating the statistical tests.  It is often taken as a = 0.05 and 1-b = 
0.8 (i.e. 5% significance, 80% power).  The statistician was approached to 
analysis the power of the SKI-2 cohort using the program G*power 31.3.  The 
sample size or power required for detecting full and half effect shown in this 
study for intelectin-1 in SKI-2 was calculated using G*power 31.3 software.  
Small studies which are significant often tend to overestimate the effect, thus half 
effect used as a more cautious approach.  In SKI-2, sample sizes required to 
detect full effect of intelectin-1 correlation against D/Pcr, UF, and D/D0 glucose 
were 22, 35, and 27 PD patients respectively.  Sample sizes required to detect 
half effect of intelectin-1 correlation against D/Pcr, UF, and D/D0 glucose were 
106, 155, and 122 samples respectively. In SKI-2, 51 samples were available for 
these assays. 
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5.7 Discussion 
Previous 2D gel and ITRAQ proteomic analysis of PDE samples identified 
differences in the proteome between EPS and a non EPS control patients.  Three 
of these proteins; intelectin-1, dermatopontin and COL1A1 were analysed in PDE 
samples by ELISA.  Intelectin-1, DPT and COL1A1 were positively correlated to 
the D/Pcr and negatively correlated to D/D0 glucose since high transporters have 
a larger effective on the peritoneal surface area.  Intelectin-1 may be a marker of 
transport status.  They were also negatively correlated to the UF.  Peritoneal 
membrane injury and fibrosis are associated with high D/Pcr and UFF (Lambie, 
John et al. 2010, Sampimon, Coester et al. 2011).  Intelectin-1 was subsequently 
analysed in the GFS cohort which failed to fully validate the proteomic 
identification of this as a major shifting protein in the EPS proteome, although 
one late EPS sample did show a dramatic increase in intelectin-1 level.  Of note 
is that while only 1 of the 2 late EPS samples showed an increase in the EPS 
patient PDE, the single EPS patient in the SKI-1 cohort was also higher than all 
the other PDE samples analysed from that cohort.     
Surprisingly data also suggested that intelectin-1 was not produced locally 
in the peritoneum given that it is also highly expressed in the small intestine with 
further expression in the colon in normal individuals (Lee, Schnee et al. 2001, 
Suzuki, Shin et al. 2001, Tsuji, Uehori et al. 2001, Yang, Lee et al. 2006).  It thus 
seemed logical to assume that this would be a source of intelectin-1 given the 
―stress‖ exerted on the gut during PD and especially in EPS.  However, the 
increased levels were seen in 2 of the 3 patients with EPS.  This begs the 
question as to why.  There is also high intelectin-1 in PDE samples in some of 
control patients with high D/Pcr.  This high intelectin-1 in PDE samples could be 
due to different peritoneal surface area, peritoneal membrane permeability, and 
pressure gradients.   
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Intelectin-1 was not produced locally and this mean the intelectin-1 level in 
the peritoneal cavity is crossing the membrane from plasma without local 
production.  The other finding was that the plasma level of intelectin-1 was higher 
in PD patients than in healthy individuals and this is possibly due to impaired 
renal clearance of these molecules in PD patients, but it is also may be due to 
more production of intelectin-1 in these patients. 
Intelectin-1 and COL1A1 were similar to TIMPs and MMPs described 
previously in that their levels increased in PDE samples with longer dwell times, 
but in dermatopontin, the longer dwell times were not always associated with 
higher dermatopontin concentrations in PDE samples.  This is may be due to 
saturation of dermatopontin transport after certain time point. 
A few samples from control group also showed sporadic high intelectin-1 in 
the PDE samples.  The ELISA kit assays in all chapters were chosen based on 
the sequences the antibodies recognized or were generated against.  The reason 
for this is because it was unclear from the proteomics if fragments (possibly post 
degradadtion) were being detected or the full protein.  As such, the sequences 
identified by MS within each protein had to be within the target area of antibodies 
or between identified sequences.  In some cases such as col1(I) it was clear 
this was a fragment as the spot on the 2D gels was 50kDa compared to 139 kDa 
of the mature protein so a kit recognizing that fragment was essential.  For 
intelectin-1 and dermatopontin the spots were nearer to the proteins normal 
molecular size but due to the resolution of 2D gels it was not conclusive that the 
full protein was present.  In selecting ELISA a second criteria was sensitivity and 
specificity were always checked before purchasing the items.  For example, the 
minimum detectable values using the commercially available ELISA kits for 
dermatopntin and COL1A1 were less than 52 and 115 pg/mL respectively 
compared to the superior 3.1pg/mL for intelectin-1.  This allowed intelectin-1 to 
be assayed in GFS samples using a few microliters of PDE samples whereas the 
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other two required a larger volume of PDE samples (more than 200 µL for each) 
which was unavailable in the GFS cohort. 
 Inter and intra assay variation was established by placing the same 
samples on every assay plate and at different places within each plate.  Values 
should not exceed 10% of the expected measurements and if they did the assays 
was repeated.  Further as different PDE would have different glucose 
concentrations then a range of PD fluids were tested to verify high or low glucose 
did not alter the assay response.   
In summary, changes in the intelectin-1, dermatopontin and COL1A1 in the 
peritoneum correlated well with higher transport rates and negatively with UF.  
Intelectin-1 was found to be not produced in the peritoneum.  One EPS sample 
from SKI-1 (after diagnosis with EPS) and one out of two patients in the last 100 
days before diagnosis with EPS were associated with elevated level of intelectin-
1.  OF note, sporadic samples in control group of GFS showed high in the 
intelectin-1 level in PDE samples, but all these patients had a D/Pcr of 0.75 or 
more. 
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CHAPTER SIX 
Changes in the cells found in 
peritoneal dialysis effluent with time 
on dialysis 
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6.1 Introduction 
It had been shown that long-term PD causes changes in the peritoneum 
morphology such as peritoneal mesothelial cell degeneration and  increased 
fibroblasts, and these may cause defects in the peritoneal membrane function 
(Verger, Brunschvicg et al. 1981, Gotloib, Shostack et al. 1987).  There are also 
changes in other peritoneal cells such as peritoneal macrophages and 
leukocytes as shown in (section 6.1.1) and these could influence the 
development of peritoneal fibrosis.  Fibroblasts and Macrophages are able to 
secrete various ECM regulatory molecules such as TIMPs and MMPs which are 
able to change ECM homeostasis (Figure 3.1).   
It is well-known that lymphocytes, polymorphonuclear neutrophils, 
macrophages and mesothelial cells are the main cell types in the peritoneal 
cavity, but fibroblasts and myofibroblasts are also important peritoneal cells that 
are highly influential on ECM levels.  Proliferation of fibroblasts (Wynn 2007) or 
cellular differentiation such as epithelial to mesenchymal transition (EMT) are 
observed in CAPD patients with PS (Aroeira, Aguilera et al. 2007).   
6.1.1 Leukocytes and macrophages in the peritoneal dialysis effluent  
Lymphocytes and macrophages are two important elements of the host 
immune system, typically residing in less than 50 mL of fluid in the peritoneal 
cavity.  Lymphocyte and macrophage levels change in PD patients.  In healthy 
individuals, peritoneal macrophages represent about 90% of the cells, while 
peritoneal lymphocytes and polymorphonuclear neutrophils represent about 5% -
10%, and less than 5% respectively.  The percentages of cell types found in the 
uninfected PDE of PD patients are: 23-86% macrophages, 0-27% 
polymorphonuclear neurtrophils 5-77% lymphocytes (Lewis and Holmes 1991, 
Brulez and Verbrugh 1995, Kazancioglu 2009).  This wide range of percentages 
obtained from various studies reflects the large variation in published values.  For 
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example, peritoneal macrophages account for 86% of cells in one paper 
(Goldstein, Bomalaski et al. 1984), while another paper showed that peritoneal 
macrophages represent 45% of the total cells (Cichocki, Hanicki et al. 1983).  
Light microscopy was used in both cases.  The same variation was evident when 
flow cytometry was used (Brulez and Verbrugh 1995). 
The macrophage is one of the most abundant cells in PDE samples, but the 
regular removal of cells during PD considerably weakens the capability of the 
peritoneal defense mechanism.  In addition to that, peritoneal macrophages in 
CAPD patients are relatively immature cells due to rapid turnover and therefore, 
many macrophage functions may be impaired (Li 1999).  In contrast, peritoneal 
lymphocytes increase in PD patients and they show signs of activation : T 
lymphocytes are decreased, whereas B lymphocytes are increased as compared 
to the peripheral blood of PD patients (Lewis, Kutvirt et al. 1993) 
6.1.2 Mesothelial cells in the peritoneal dialysis effluent 
Mesothelial cells (MCs) are mononuclear cells that are characterized by 
their polygonal shape and flattened surface.  They form a continuous superficial 
layer of squamous epithelium that lines the peritoneal cavity.  MCs have many 
crucial functions such as the prevention of peritoneal fibrous adhesion formation 
through fibrinolytic properties.  They also synthesise and secrete 
phosphotidylcholine and phospholipids which lubricate the peritoneal surface to 
facilitate abdominal visceral movement (Di Paolo, Sacchi et al. 2005).  In addition 
to that, they are involved in modulating the microcirculation of the peritoneum 
through the secretion of vasodilators such as nitric oxide and prostaglandin E2, 
as well as vasoconstrictors such as endothelin (Nagy 1996).  Numerous microvilli 
are present on the luminal surface of MCs.  These microvilli increase the surface 
area of peritoneal membrane and play an important role in prevention of infection 
through entrapment of bacteria (Yung and Chan 2012).  As a consequence of 
time on peritoneal dialysis, mesothelial cells undergo a process called EMT 
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(section 6.1.4), during which peritoneal MCs lose some of their epithelial 
characteristics in response to certain pathological factors such as low pH, 
inflammatory mediators, high glucose concentrations in dialysate and exposure 
to glucose degradation products.   The end result of EMT is that peritoneal MCs 
develop a fibroblast-like phenotype (Aguilera, Loureiro et al. 2013). 
6.1.3 Fibroblasts in the peritoneal dialysis effluent 
Fibroblasts are spindle shaped cells. They are characterised by contractility 
and motility.  They have different origins such as regional fibroblast proliferation, 
fibrocytes of bone marrow and from local epithelium through the process of EMT 
(section 6.1.4) (Wynn 2008).  Peritoneal fibroblasts are sporadically scattered 
within the interstitium of the submesothelial area, and have a role in 
inflammation, adhesion and peritoneal fibrosis (Witowski and Jörres 2006).  
Fibroblasts express a protein called fibroblast specific protein (FSP-1). This 
protein is used commonly as an indicator for identifying cells which have 
undergone EMT.  FSP-1 is also called S100A4. It is a member of S100 family 
and it is a 10-kDa calcium-binding protein. FSP-1 is involved in interactions of 
cytoskeletal membrane, transduction of calcium signal, cell growth and 
differentiation (Zimmer, Cornwall et al. 1995, Barraclough 1998, Österreicher, 
Penz-Österreicher et al. 2011).  Myofibroblasts are activated fibroblasts.  They 
express smooth muscle actin (α-SMA).  They are contractile cells with multiple 
functions including synthesis of cytokines, growth factors and ECM.  They also 
participate in the inflammatory reaction (Powell, Mifflin et al. 1999). 
6.1.4 Epithelial to mesenchymal transition (EMT)  
EMT is the process of transition of epithelial into mesenchymal cells.  The 
process begins with the dissociation of intercellular junctions and loss of microvilli 
followed by loss of apical-basal polarity of MCs.  The cells acquire a more  
fibroblast-like phenotype including enhanced ECM protease production leading to  
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basement membrane degradation and thus enhanced motility (Aroeira, Aguilera 
et al. 2007).  EMT of mesothelial cells (MCs) has been demonstrated both in vivo 
and ex vivo (Yanez-Mo, Lara-Pezzi et al. 2003).  Cultures of confluent MCs from 
PD effluents demonstrate epithelioid and nonepithelioid (similar to fibroblast) 
morphologies.  The prevalence of nonepithelioid cells is proportionally correlated 
with time on PD and episodes of peritonitis or hemoperitoneum (Yanez-Mo, Lara-
Pezzi et al. 2003). 
Immunohistochemical analysis of peritoneal membrane from PD patients 
taken from parietal peritoneal biopsies showed the existence of fibroblast-like 
cells and α- smooth muscle actin (α-SMA) expression in the fibrotic stroma 
(Jimenez-Heffernan, Aguilera et al. 2004).  Myofibroblastic cells may arise from 
conversion of MC through EMT during PD (Margetts, Bonniaud et al. 2005).  
Transdifferentiated MC may play a crucial role in the beginning of fibrosis and 
subsequent decline of peritoneal function (Aroeira, Aguilera et al. 2007).  
Fibroblasts and peritoneal mesothelial cells play important roles in production of 
collagen which is often related to over expression of growth factors and cytokines 
(Miyazaki and Yuzawa 2005).  EMT acts as trigger for peritoneal fibrosis through 
up-regulation of TGF-β and angiogenesis through vascular endothelial growth 
factor (VEGF).  EMT or mesothelial to mesenchymal transition (MMT) is 
regulated in part by the TGF-β (Figure 6.1) (Aguilera, Loureiro et al. 2013).  
Recently, several authors suggested to rename the mesenchymal conversion of 
MCs to a more suitable term and this is mesothelial to mesenchymal transition 
(López-Cabrera 2014).  EMT has been associated with beginning of peritoneal 
fibrosis.  Blocking of EMT may act as a therapeutic target specially in early 
stages of the peritoneal fibrosis (Loureiro, Gónzalez-Mateo et al. 2013).  
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6.2 Hypothesis 
There are various cell types known to be present in peritoneal dialysis 
effluents (PDE) including macrophages, lymphocytes, fibroblasts, and 
mesothelial cells.  It is likely that these will change with time on PD due to the 
constant stress that PD fluids place on the peritoneum.  Given the varying and 
differing effects of each of these cell types on ECM homeostasis it is probable 
 
Figure 6.1 Normal peritoneum and PD peritoneum suffering MMT 
(A) Normal peritoneum is without angiogenesis, MMT, and fibrosis.  It shows cobblestone mesothelial 
cells with few scattered fibroblasts. (B) Peritoneum in a patient who has been exposed to PD.  There is 
loss of MC microvilli, transformation of MC to fibroblasts through MMT and invasion of the 
submesothelial area.  The glucose content and inflammatory mediators of dialysate stimulate TGF-beta 
which acts as a key mediator for initiating MMT.  VEGF is produced by submesothelial fibroblasts 
resulting in angiogenesis, proliferation and EMC production. It is reproduced by permission of the © 
2013 Aguilera A, Loureiro J, Gónzalez-Mateo G, Selgas R, López-Cabrera M. Originally published in 
[International journal of nephrology] under CC BY 3.0 license. Available 
from: http://dx.doi.org/10.5772/56598.  Abbreviations: MMT: Mesothelial to mesenchymal transition, MC: 
Mesothelial cell,TGF-beta: Transforming growth factor beta, VEGF: Vascular endothelial growth factor. 
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that the balance of the cells found in the PDE could have a profound effect on the 
composition and quantity of the peritoneal membrane.  This has led to the 
proposal of the hypothesis that the cell types found in PDE alter with time on PD.  
This change in cells alters ECM composition, membrane function and the 
development of PS or EPS. 
6.3 Aims 
 To test this hypothesis 
1) Cells will be isolated from overnight PD bag 
2) Cells will be stained for cell markers of leukocytes, macrophages, 
fibroblasts and mesothelial cells. 
3) Cell populations will be quantified by cell counting, comparing each of the 
peritoneal cells in 3 groups based on duration of PD (<1 year, 1-3 years, 
and >3 years). 
4) Changes in cells will be related back to levels of ECM regulatory 
molecules and activities described in previous chapters 
6.4 Methods 
The method is illustrated in detail in chapter 2.  The Processes of PD slide 
preparation for cell staining is described in (section 2.3).  The slides were 
prepared from overnight bags (The dwell times should be standardized during 
the assessment) in PD patients.  There were three groups according to exposure 
to PD (<1 year, 1-3 years, and >3 years) and all samples were from SKI-2 cohort.  
After that, cell staining was performed for leukocytes, macrophages, fibroblasts 
and mesothelial cells and then, cell count for the positive percentage of each 
peritoneal cell (section 2.8.4).  Finally, these data were analysed to: 
 Determine the relationship between cellular changes and time on PD. 
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 Determine the relationships between the dialysate glucose exposure 
during the year prior to sampling and cellular changes. 
Slides of normal rat kidney 49F (NRK-49F) and human kidney 2 (HK-2) 
cells were kindly donated by Linghong Huang.  Slides of human macrophage 
preparation from peripheral blood were kindly donated by Fiona J Wright.   
6.5 Results 
Macrophages, leukocytes, fibroblasts and mesothelial cells were stained for 
using cytospins slides obtained from overnight bags of 21 patients in the SKI-2 
cohort Staining specificity was verified by replacing the primary antibody by either 
non-immune IgG or IgM.  Positive or negative controls were generated by taking 
slides of normal rat kidney fibroblasts (NRK-49F), epithelial cells (HK-2) cells, 
and cytospins of fresh human macrophages prepared from peripheral blood.   
6.5.1 Peritoneal macrophage staining 
Slides of human macrophage preparations from peripheral blood were used 
as positive controls.  These were stained with monoclonal mouse Anti-Human 
CD68 Clone PG-M1 as the primary antibody, showing a strong clean staining 
demonstrating the protocol and antibody worked (Figure 6.2.A).  This protocol 
gave equally strong staining in some cells in a cytopsin taken from patient SKI-
145 (figure 6.2 C).  A cytospin of human macrophages (Figure 6.2.B) as well as a 
slide from patient SKI-145 (Figure 6.2.D) were used as controls for non-specific 
staining from the secondary antibody or endogenous peroxidase activity by 
replacing the primary antibody with Mouse IgG, vector laboratories inc., 
Burlingame, 1mg/mL (There was no staining visible in either case).  To verify 
there was no cross reactivity with non-macrophage cell types, a slide of HK-2 
cells was also stained Monoclonal Mouse Anti-Human CD68 Clone PG-M1 
(Figure 6.2.E) again giving no staining. 
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Figure 6.2 Control staining for peritoneal macrophages 
A) Peripheral blood macrophages slide stained with Monoclonal Mouse Anti-Human CD68 Clone PG-M1 
as the primary antibody (control positive). B) Peripheral blood macrophages slide stained with mouse 
IgG Antibody was used instead of CD68 as a control negative. C)  Cells obtained from an overnight PD 
bag of SKI 145 were cytospun and stained with CD68 showing positive staining in some cells. D) Slide of 
SKI 145 was also stained with mouse IgG antibody which shows no staining. E) HK-2 epithelial 
cellcytospin stained with CD68 (negative control). All images were captured on an Olympus BX61 
microscope with a CC-12 FW colour digital camera. Scale bar = 20µm (X400). 
A 
E 
D C 
B 
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For analysis, patient cytospins were captured at three different 
magnifications (100 µm for x100, 50 µm for x200, 20µm for x400) (Figure 6.3).  
Cells stained positively were defined better at 400X magnification due to the high 
cell density on some sections and therefore this magnification was used not only 
for counting macrophages, but also for counting all other cells.  Fifteen images 
were taken for each slide to calculate the percentage of macrophages on each 
slide of the twenty one patients.  Positive peritoneal macrophages are 
distinguished by the brown colour in the cytoplasm.  The optimal dilution for 
staining peritoneal macrophage was 1:100. 
SKI 35 and SKI 141 are two examples of low and high macrophage levels 
(Figure 6.4).  SKI 35 (Figure 6.4.A) was on PD for more than three years and it 
shows few macrophages in the slide, while SKI 141 (Figure 6.4.B) was 
approximately one and half year on PD,  in which the percentage of macrophage 
was much higher  
Twenty one slides from the SKI-2 patient cohort were divided into 3 groups 
based on time on PD as previously (<1 year, 1-3 years, and >3 years).  All slides 
were prepared from overnight bags of PDE.  There was a large range in the 
percentage of peritoneal macrophages counted ranging from 5%-61%, however, 
the percentage of macrophages showed a decline as a percentage of the total 
peritoneal cell count with time on PD.  (Mean±SD) 37%±11% in patient on PD for 
less than 1 year, to, 29%±8% for those on PD for 1 to 3 years with a dramatic fall 
in those on PD for longer than 3 years 11%±5% (Figure 6.5). 
 
217 
 
  
 
 
.  
  
 
Figure 6.3 peritoneal macrophage cell staining in three different magnifications 
8 cytospins were generated from the total cells isolated from an overnight PD bag by centrifugation.  
Monoclonal Mouse Anti-Human CD68 Clone PG-M1 is used as primary antibody for staining at a dilution 
of 1:100. Images were captured on a Olympus BX61 microscope using a CC-12 FW colour digital 
camera  Stained peritoneal macrophage on slides  generated from patient slide of SKI 123 at (A) x100, 
scale bar = 100µm. (B) x 200, scale bar= 50µm. and (C) x 400, scale bar= 20µm. 
A 
C 
B 
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Figure 6.4 High and low levels of peritoneal macrophages in cytospins from 
PDE bags of PD patients 
Cytospins from overnight bags collected from patients SKI-35 and SKI-141 were stained with 
Monoclonal Mouse Anti-Human CD68 Clone PG-M1.  Images were captured on a Olympus BX61 
microscope with a CC-12 FW colour digital camera.  Macrophages stained brown in the cytoplasm. 
Magnification is x 400, scale bar = 20µm. (A) SKI 35 was on PD for more than three years. (B) SKI 141 
was on PD for one and a half years. 
A B 
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Figure 6.5 Quantification of changes in peritoneal macrophages with time on 
peritoneal dialysis 
Peritoneal macrophages were quantified in 21 PDE samples in the SKI-2 patient cohort by counting the 
total number of cells on the cytospin and calculating the percentage of CD68 positive cells. PD patients 
were subsequently divided into 3 groups based on time on PD (<1 year, 1-3 years, and >3 years). The 
Peritoneal macrophages decreased as the duration on PD increased.  Statistical analysis was done by 
using One-way ANOVA. Post-hoc comparisons using the Tukey's multiple comparisons test indicated 
that >3 years was significantly different from <1year (p=0.0002).   >3 years was significantly different 
from 1-3 years (p=0.016).1-3 years did not differ significantly from <1year. Data represent mean with 
SEM. Abbreviations: PD: peritoneal dialysis. PDE: peritoneal dialysis effluent.  
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6.5.2 Peritoneal leukocytes staining 
Fifteen images were taken in 20µm (x400) for each slide to calculate mean 
of leukocytes percentage in each slide of the twenty one patients.  Human 
leukocytes are stained with Monoclonal Mouse Anti-Human CD45 Leukocyte 
Common Antigen (Clone 2B11 + PD7/26) as primary antibody.  Positive 
peritoneal leukocytes are distinguished by their brown colour cell membrane.  
The best dilution for staining peritoneal leukocytes was 1:50. 
To verify the staining protocols slides from an overnight PD bag from patient 
SKI 129 were used.  Monoclonal Mouse Anti-Human CD45 Leukocyte Common 
Antigen (Clone 2B11 + PD7/26) was used to stain the cytospin giving a strong 
staining in a proportion of the cells and no staining in others when used at a 1:50 
dilution(Figure 6.6.A).  The  primary antibody was then replaced by mouse IgG, 
vector laboratories inc., Burlingame, 1mg/mL which showed no staining at all 
(Figure 6.6.B) confirming no endogenous peroxidase activity of non-specific 
binding of the secondary antibody.  Finally cytospins of normal rat 
kidney fibroblasts (NRK-49F) (Figure 6.6.C) and human kidney proximal tubular 
epithelial cells (HK-2) (Figure 6.6.D) were used as control negative to validate 
cell specificity of the Anti-Human CD45 Leukocyte Common Antigen (Clone 2B11 
+ PD7/26) antibody. Both cells slides were stained negatively.   
Cytospins from patient SKI 124 and SKI 137 are examples of low and high 
leukocyte staining in the effluent respectively (Figure 6.7).  SKI 124 (Figure 
6.7.A) was on PD for approximately four months, while SKI 137 (Figure 6.7.B) 
was on PD for more than two and half years in which the percentage of 
leukocytes stained was much higher. 
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Figure 6.6 Control for peritoneal leukocytes 
A) Overnight PD bag from patient SKI 129 was cytospun & slide stained for CD45 showing positive 
staining in a large number of cells. B) Slide of SKI 129 was also stained with mouse IgG antibody which 
shows no staining. C) NRK-49F fibroblasts cells and D) HK-2 proximal tubular epithelial cells were 
cytospun and stained with CD45 antibody and again no staining was evident demonstrating the 
specificity of the CD45 protocol to leukocytes.  Images were captured on an Olympus BX61 microscope 
with a CC-12 FW colour digital camera. Scale bar = 20µm (X400).  
A 
D 
C 
B 
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Changes in leukocytes with time on PD were calculated based on time on 
PD as previously described (Figure 6.8).  Peritoneal leukocytes were 39%±11% 
(mean ± SD) within the first year of starting PD, but this consistently increased 
with time on PD increasing to , 41%±5%, between 1 and 3 years on PD and 
reaching 58%±8% in those on PD for more than 3 years.  Overall the range of 
peritoneal leukocytes were between 21% and 69%.  
 
   
Figure 6.7 High and low levels of peritoneal leukocytes in cytospins from PDE 
bags of PD patients 
Cytospins were prepared from overnight PD bags of patients SKI-124 and SKI 137 and stained with 
Monoclonal Mouse Anti-Human CD45 Leukocyte Common Antigen (Clone 2B11 + PD7/26) at 1:50 
dilution. Images were captured by Olympus BX61 microscope with a CC-12 FW colour digital camera at x 
400 magnification, scale bar = 20µm.  Leukocytes appear brown colour cell membrane. A) Lower 
leukocyte staining was seen for SKI 124 that had been on PD for four months. Compared to B) Higher 
peritoneal staining in SKI 137 who had been on PD for two and half years. 
A B 
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Figure 6.8 Changes in peritoneal leukocytes during peritoneal dialysis 
Peritoneal leukocytes were quantified in all 21 PDE samples from the SKI-2 cohort. PD patients were 
divided into 3 groups based on time on PD (<1 year, 1-3 years, and >3 years) and the percentage of 
positive stained cells calculated. The Peritoneal leukocytes increased as the duration on PD increased.  
Statistical analysis was done by using One-way ANOVA. Post-hoc comparisons using the Tukey's 
multiple comparisons test indicated that >3 years was significantly different from <1year (p=0.005).   >3 
years was significantly different from 1-3 years (p=0.02).1-3 years did not differ significantly from <1year. 
Data represent mean with SEM. Abbreviations: PD: peritoneal dialysis. PDE: peritoneal dialysis effluent. 
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6.5.3 Peritoneal mesothelial cells staining 
Staining for mesothelail cells was validated initially using cytospins from an 
overnight PD bag collected from Patient SKI 35.  Using Monoclonal Mouse Anti-
Human Mesothelial Cell Clone HBME-1 as the primary antibody at a dilution of 
1:75, one cytospin showed strong and specific staining in discrete cells (Figure 
6.9.A).    Conversly when this primary antibody was replaced by an Anti-mouse 
IgM (µ-chain specific) Biotin Conjugate no staining was seen (Figure 6.9.B) 
confirming no secondary antibody non-specific binding or endogenous 
peroxidase activity. Normal rat kidney fibroblasts (NRK-49F) (Figure 6.9.C) and 
human kidney proximal tubular epithelial cells (HK-2) (Figure 6.9.D) both failed to 
stain with the HBME-1 antibody supporting mesothelial cell specificity 
Fifteen images were taken in 20µm (at x400 magnification for each slide in 
the SKI-2 patient cohort to calculate mean percentage of mesothelial cells on 
each slide of the twenty one patients.  Positive peritoneal mesothelial cells are 
distinguished by brown colour of cytoplasm and cell membrane.   
Peritoneal mesothelial cells represented a much lower percentage of the 
total cell population than the other cell types examined (Figure 6.10) with counts 
in the region of 1-5 % of the peritoneal effluent cells.  Changes in mesothelial 
cells with time on PD were studied in the SKI-2 cohort as described previously 
(Figure 6.11).   Mesothelial cells showed no significant change in between the 
three groups being (Mean±SD) 1.8%±1.2%, 1.6%±0.5%, and 1.6%±0.5% at <1 
year, 1-3 years, and >3 years respectively.   
 
 
.   
225 
 
 
   
   
Figure 6.9 Control staining for peritoneal mesothelial cells 
A) Overnight PD bag from patient SKI 35 was cytospun & slide stained for Monoclonal Mouse Anti-
Human Mesothelial Cell Clone HBME showing positive staining cells. B) Slide of SKI 35 was also 
stained with Anti-mouse IgM Antibody which shows no staining. C) NRK-49F fibroblasts cells and D) HK-
2 proximal tubular epithelial cells were cytospun and stained with Monoclonal Mouse Anti-Human 
Mesothelial Cell Clone HBME-1 and again no staining was evident demonstrating the specificity of the 
Monoclonal Mouse Anti-Human Mesothelial Cell Clone HBME protocol to mesothelial Cell. Images were 
captured on a  Olympus BX61 microscope with  a CC-12 FW colour digital camera at x 400 
magnification with scale bar = 20µm. 
A 
D C 
B 
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Figure 6.10 Peritoneal mesothelial cell staining 
Monoclonal Mouse Anti-Human Mesothelial Cell Clone HBME-1 was used as primary antibody for 
staining a cytospin of cells recovered from an overnight bag from patient SKI 148. Mesothelial cells in 
the peritoneal dialysis effluent stained discreetly with about 1% of the total cell population. Images were 
captured on a Olympus BX61 microscope with a CC-12 FW colour digital camera at x400 magnification, 
scale bar = 20µm.   
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Figure 6.11 Changes in peritoneal mesothelial cells with time on peritoneal 
dialysis 
Peritoneal mesothelial cells were quantified in 21 PDE samples in the SKI-2 cohort.  PD patients were 
divided into 3 groups based on time on PD (<1 year, 1-3 years, and >3 years) and the percentage of 
positive stained cells calculated. Peritoneal mesothelial cells showed no significant change in between 
the three groups.  Statistical analysis was performed using One-way ANOVA. Data represent mean with 
SEM. Abbreviations: PD: peritoneal dialysis. PDE: peritoneal dialysis effluent.  Post-hoc comparisons 
using the Tukey's multiple comparisons test indicated that there are no different significant between any 
groups. 
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6.5.4 Peritoneal fibroblasts staining 
FSP-1 was used as a cell marker for fibroblasts present on peritoneal cell 
cytospins.  The NRK49F rat fibroblast cell line was used to optimise staining 
protocols using a 1:200 dilution of a Polyclonal Rabbit Anti-Human S100A4 as 
the primary antibody (Figure 6.12.A).  Matching NRK49F cytospins were used to 
assess any endogenous peroxidase activity and nob-specific binding of the 
secondary antibody by replacing the primary antibody with mouse IgG, vector 
laboratories inc., Burlingame, 1mg/mL. No staining was seen with this antibody 
(Figure 6.12.B).  When a cytospin from patient SKI 123 was stained with 
polyclonal Rabbit Anti-Human S100A4 discrete cellular staining was seen (Figure 
6.12.C), which no staining was present when the S100A4 antibody was 
substituted for the control antibody with mouse IgG, vector laboratories inc., 
Burlingame, 1mg/mL (Figure 6.12.D).  
It is important to refer that FSP +ve cells is not staining fibroblasts alone 
because there are other cells in human bodies which are staining with FSP-1.  
Changes in FSP +ve cells with time on PD were quantified in PD patients by 
calculating the mean percentage of positivity stained cells within each time frame 
(Figure 6.13).    The range of FSP-1 +ve cells across all slides counted was 6 to 
17%.  FSP-1 +ve cells showed a progressive increase in the percentage of the 
total peritoneal cells with time on PD, increasing from 10%±2.5% (Mean±SD) of 
the total cell population in patients on PD for less than 12 months, rising to, 
14%±1.6%,between 1 and 3 years on PD  and reaching 16%±1.1%  after 3 years 
on PD.  Positive peritoneal FSP-1 +ve cells are detected by their brown colour 
nucleus, cytoplasm and/or cell membrane.  The best dilution for staining 
peritoneal FSP-1 +ve cells was 1:200. 
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Figure 6.12 Control staining for peritoneal fibroblasts 
 A) cytospin of the NRK-49F renal  fibroblast cell line was  stained with  a Polyclonal Rabbit Anti-Human 
S100A4  antibody to validate the staining protocol for FSP-1. The brown colour nucleus, cytoplasm 
and/or cell membrane can be seen. B) Parallel cytospins of NRK-49F had S100A4 replaced with mouse 
IgG antibody as a negative control. C) An overnight PD bag of SKI 123 had cells recovered, cytospun 
and the slide stained with Polyclonal Rabbit Anti-Human S100A4 showing positive discrete staining in 
about ¼ of the cell. D) Repeat staining of a cytospin from patientSKI 123 slide by substituting S100A4 
with mouse IgG antibody which showed no staining.   Images were captured on an Olympus BX61 
microscope with a CC-12 FW colour digital camera at x400 magnification, scale bar = 20µm.   
A 
D C 
B 
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6.5.6. Changing populations of peritoneal cells with time on PD 
The four peritoneal cell populations stained in twenty one PD patients in the 
SKI-2 patient cohort represented the majority of total peritoneal cells.  The 
percentages of FSP-1 +ve cells (Figure 6.14), leukocytes (CD45 +ve cells) 
(Figure 6.15), macrophages (CD68 +ve cells) (Figure 6.16) and mesothelial cells 
(Figure 6.17).  All together ranged from 74%-95% of all cells counted.  Cell 
proportions in each patient was plotted by time on PD (left to right = shortest to 
longest time on PD).  For example SKI 71 is for a patient who is on PD for more 
than 9 years and it shows the highest percentage of FSP-1 +ve cells and 
 
Figure 6.13 Changes in peritoneal FSP-1 +ve cells with time on  peritoneal 
dialysis 
Peritoneal FSP-1 +ve cells were quantified in 21 PDE samples in the SKI-2 cohort. PD patients were 
divided into 3 groups based on time on PD (<1 year, 1-3 years, and >3 years) and the percentage of 
positive stained cells calculated. The Peritoneal FSP-1 +ve cells increased as the duration on PD 
increased.  Statistical analysis was done by using One-way ANOVA. Post-hoc comparisons using the 
Tukey's multiple comparisons test indicated that <1year was significantly different from >3 years 
(p=0.0001).  <1year was significantly different from 1-3 years (p=0.007).1-3 years did not differ 
significantly from >3 years. Data represent mean with SEM. 
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Leukocytes in comparison to the rest of PDE samples, while macrophage in SKI 
71 is the least in comparison to the rest. 
 
 
 
 
Figure 6.14 Changing 
populations of FSP-1 
+ve cells in PDE  with 
time on PD 
Samples were arranged left 
to right by time on PD (left to 
right = shortest to longest 
time on PD) and the 
percentage of FSP-1 +ve 
cells in the SKI-2 cohort.  
Abbreviations: PD: peritoneal 
dialysis. SKI: Sheffield 
Kidney Institute. 
Figure 6.15 Changing 
populations of CD45 
+ve cells in PDE  with 
time on PD 
Samples were arranged left 
to right by time on PD (left 
to right = shortest to longest 
time on PD) and the 
percentage of CD45 +ve 
cells in the SKI-2 cohort.  
Abbreviations: PD: 
peritoneal dialysis. SKI: 
Sheffield Kidney Institute. 
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Figure 6.16 Changing 
populations of CD68 
+ve cells in PDE  
with time on PD 
Samples were arranged left 
to right by time on PD (left 
to right = shortest to longest 
time on PD) and the 
percentage of CD68 +ve 
cells in the SKI-2 cohort. 
Abbreviations: PD: 
peritoneal dialysis. SKI: 
Sheffield Kidney Institute. 
Figure 6.17 Changing 
populations of 
mesothelial cells in 
PDE  with time on PD 
Samples were arranged left 
to right by time on PD (left to 
right = shortest to longest 
time on PD) and the 
percentage of mesothelial 
cells in the SKI-2 cohort. 
Abbreviations: PD: peritoneal 
dialysis. SKI: Sheffield Kidney 
Institute. 
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6.5.7 Associations between peritoneal cell population and glucose 
exposure 
Dialysate glucose exposure during the year prior to effluent sampling was 
calculated for each patient as described in chapter 2.  Then four correlations 
were run between glucose exposure and percentage of each peritoneal cell 
population.  The last year‘s glucose exposure to the peritoneal membrane was 
positively correlated to peritoneal leukocyte (r=0.45, p= 0.4) with a much stronger 
correlation to peritoneal FSP-1 +ve cells (r=0.7, p= 0.0004).  It was also strongly 
negatively correlated to peritoneal macrophages (r= - 0.7, p= 0.0006) (Figure 
6.18).  There was no correlation to peritoneal mesothelial cells.    
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Figure 6.18 Correlation between 
last year glucose exposure and 
peritoneal leukocytes, FSP-1 +ve 
cells and macrophages 
 
Peritoneal leukocytes (A), FSP-1 +Ve cells 
(B), and macrophages (C) populations were 
quantified in 21 PD patients in the SKI-2 
cohort and then correlated against Dialysate 
glycose exposure during the last year prior to 
effluent sampling. GraphPad Prism 6 was 
used to perform the correlation test 
(Compute Pearson correlation coefficient). 
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6.6 Statistical analysis after this study 
A statistician was approached to analyse the power of the study using the 
program G*power 31.3.  Sample size required for detecting full and half effect 
shown in this study for FSP-1, leukocytes, macrophages, and mesothelial cells in 
SKI-2 was performed.  Small studies which are significant often tend to 
overestimate the effect, thus half effect was used as a more cautious approach.  
In SKI-2, sample sizes required in detecting full effect of FSP-1, leukocytes, and 
macrophages were 15, 24, and 15 PD patients respectively.  Sample sizes 
required to detect half effect were 48, 81, and 48 samples respectively. In SKI-2, 
21 samples were available for these assays.  Note: power calculations were 
performed with p=0.05 and power=95%.  Mesothelial cells would need a much 
larger sample size as the difference detected was very small, but if the difference 
between the first and the second groups is D, and then between the second and 
the third groups is 2D and if this pattern is assumed, then with p=0.05 and 
power=95%, 252 samples would be required (i.e. 84 samples for each group) for 
mesothelial cell staining.  The 3 groups based on time on PD (<1 year, 1-3 years, 
and >3 years).   
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6.7 Discussion 
Cytological analysis of peritoneal washings was first performed by Keettell 
and Elkins in 1956.  The purpose of their analysis was to assess tumour cell 
spreading for ovarian carcinoma (Keettel and Elkins 1956).  In this chapter cell 
staining for four peritoneal cells was performed to analyse their changes with 
time on PD to see if these changes were at all linked to ECM processing 
changes reported in early chapters.  These four cells were macrophages, 
leukocytes, fibroblasts and mesothelial cells.   
When using cell markers to assess cell populations, there is the assumption 
that antibodies (primary and secondary) are bound to their targets selectively.  
There are several causes of weak or the complete absence of cell staining such 
as sub-optimal cell staining process, insufficient antigen-antibody affinity or 
epitope masking.  Repeated cell counting for each slide is required by an 
operator blinded to the sample code before the average cell count can be 
calculated.  This is a technical challenge as the cells counted can vary between 
individuals as a degree of subjectivity cannot be avoided.  In this chapter, it had 
been shown that peritoneal fibroblasts and leukocytes increase with time on PD, 
while macrophages decrease with time.  Mesothelial cells did not show 
significant changes.  However, few samples in early stage on PD showed slight 
higher percentage of mesothelial cells.   
In comparison with other studies, for leukocytes and macrophages various 
studies had measured levels of these cells in PDE samples as illustrated in 
section 6.1.1  Mesothelial cells undergo a process called EMT as a consequence 
of time on peritoneal dialysis. The end result of EMT is that peritoneal MCs 
develop a fibroblast-like phenotype (Aguilera, Loureiro et al. 2013) and this may 
explain the increase of fibroblast with time on PD.  It is important to note that 
FSP-1, while a good marker of fibroblasts and not just myofibroblasts like 
Smooth Muscle actin,  can be expressed by different cell types which have 
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mesenchymal origin (Lawson, Polosukhin et al. 2005, Österreicher, Penz-
Österreicher et al. 2011) and as such it cannot be said with 100% certainty that 
every cell counted is a fibroblast. 
Opsonins (molecules which promote phagocytosis by coating an antigen for 
an immune reaction) are present in the peritoneal fluids in the peritoneal cavity.  
They are important in the process of recognising micro-organisms that enter the 
peritoneal cavity.  Micro-organisms coated by opsonins are recognised and 
phagocytised by macrophages.  The regular cycling of dialysate during PD leads 
to removal and dilution of opsonins, resulting in a reduction in opsonin 
concentrations in peritoneal effluent in PD patients in compared to normal 
individuals (McGregor, Brock et al. 1989, de Fijter, Verbrugh et al. 1992, Brulez 
and Verbrugh 1995).  As well as general washout, this may explain the decrease 
macrophage counts in peritoneal effluent with time on PD. 
Opsonic activity is also affected by type of dialysate fluid in PD.  There are 
previous studies which showed that there are different opsonic activities in cases 
of using different type of dialysate (Brulez, Dekker et al. 1996).  It is also 
established in other studies that physioneal cause less death of macrophage 
cells in compare to dianeal.  Physioneal played better role in defense cells 
population in the peritoneum (Pajek, Kveder et al. 2008).  This is also seen with 
different types of PD fluid, but in this chapter the main aims were to look at the 
change with time on PD and to compare with changes in ECM processing 
systems. 
The regular removal of peritoneal macrophages during PD considerably 
weakens the peritoneal macrophage capacity of the peritoneal defense 
mechanism.  In CAPD patients, peritoneal macrophages may be relatively 
immature cells due to rapid turnover and therefore, many macrophage functions 
may be impaired (Li 1999).  On the other hand, peritoneal lymphocytes are the 
main contributor to the peritoneal leukocyte population.  The percentage of 
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peritoneal lymphocytes increased with time on PD in numerous other studies and 
is likely to be the cause of the increase in peritoneal leukocytes with time in this 
chapter.  However these authors noted that effluent lymphocytes also had 
functional abnormalities since they demonstrated a significantly low production of 
IL-2 compared to peripheral lymphocytes (Lewis and Holmes 1991).  This means 
that increase of any peritoneal cells, such as lymphocytes and fibroblasts, may 
not have normal functionality and as such may not perfume as required.  
Peritoneal FSP-1 +ve cells and leukocytes (%) were positively correlated to 
glucose exposure to the peritoneal membrane during the last year prior to 
sampling.  Peritoneal macrophage numbers declined as a percentage of the total 
population after a long period on PD so was negatively correlated to the glucose 
exposure of the peritoneal membrane in last year.  It is reported in other study 
that high concentration of glucose can cause cell cycle stimulation of peritoneal 
fibroblasts (Higuchi, Sanaka et al. 1997).  It is known that PD fluid will activate 
macrophages and mesothelial cells to produce growth factors and inflammatory 
cytokines and these will activate fibroblasts and this will play a role in remodeling 
of tissue after long-term PD (Schilte, Celie et al. 2009). 
Mesothelial cells (MCs) also responsible in secreting prostaglandins, 
cytokines, and chemokines.  MCs contribute to the leukocytes recruitment 
(Topley, Mackenzie et al. 1993, Lai, Tang et al. 2007).  Chronic exposure of the 
peritoneal membrane to peritoneal dialysis fluids and peritonitis episodes will 
damage MCs and this will leads to partial disappearance of MCs from the 
peritoneal membrane (Dobbie, Anderson et al. 1994), but the remaining MCs will 
be activated (Mutsaers, Whitaker et al. 2000, Hekking, Zweers et al. 2005) and 
MCs will produce fibrotic and angiogenic factors such as VEGF, TGF-β, 
hyaluronic acid (HA), and FGF-2 which is a basic fibroblast growth factor 
(Witowski, Korybalska et al. 2000) and that is why mesothelial cells (MCs) are 
also important cellular components in the peritoneum.  Investigators have 
demonstrated a reduction in PDE levels of CA 125, which is a marker of 
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mesothelial mass, with time on PD (Krediet 2001).  However, a second study did 
not find a relationship between time on PD and the percentage of MCs in the 
cytospin of PDE (Betjes, Bos et al. 1991) as has been demonstrated here.  The 
average of peritoneal mesothelial cells of the later study was 3.1% which this is 
similar to percentage of peritoneal MCs in SKI-2 cohort where levels 
ranged from 0.9%-5%.  Betjes and colleagues demonstrated a relationship 
between peritonitis and decline in the peritoneal mesothelial cells (Betjes, 
Bos et al. 1991). 
The cell staining procedure can be varied on a day to day basis for a variety 
of reasons including time, room temperature and unknown factors.  Therefore, 
positive and negative controls were repeated each time cell staining was 
conducted so that the staining could be quality controlled to within acceptable 
boundaries.  The majority of cells were picked up in overnight PD bags but the 
percentage of the cells never reached 100% so clearly some other cells were 
present which could not be analysed such as endothelial cells.  Ideally other 
markers including those for better characterization would have been performed, 
but a lack of the slides prevented more staining as a limited number of slides 
were available per patient based on initial assumptions where by only 8 cytospins 
were done from each bag – which in hindsight was naive.  Plenty of cells were 
recovered from each bag, & most of the cytospins were also too cell dense which 
complicated analysis.  Thus if repeated a better approach would have been to 
undertake cytospins with a known cell number for giving better clarity and greater 
slide number.  Another issue was a need for better positive and negative 
controls.  Ideally we should have had a wide bank of cells to validate the staining 
against such that each antibody would be tested against fibroblasts, epithelial 
cells, neutrophils, B and T lymphocytes, endothelial cells, mesothelial cells etc.  
However, a limited number of cell lines were available as were sensible 
preparations of isolated blood cell and the robustness of the measurements must 
be taken in this context. 
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One of the limitations is using single markers for cell phenotype and this is a 
problem because there are several cell markers, but not all cells are expressing 
all of their markers.  For example, a fibroblast may be negative for one of the 
markers, but it still could be a fibroblast.  Another limitation is counting by manual 
cell counting.  The limitations are cell identification errors (inter-observer 
variability), slide cell distribution error such as increase in the cell concentration 
along edges of the slides, statistical sampling error, finally manual method needs 
more time because there are some automated cell counters that can process 
120-150 samples/hr.  However, it was difficult to use automated cell counting 
option because some slides were crowded with cells and they were more 
approachable by manual cell counting.  Manual cell counting was not counted 
only by me, but also by Dr Chra Qasm Majeed.  The variability was calculated in 
between the manual cell counting for 2 individuals and it was below 10%. 
Due to the large numbers of cells in each cytospin the decision was made 
to look at percentages rather than absolute counts of cells.  Thus when a 
population is decreasing or increasing in percentage terms it could be doing so 
based on its absolute numbers are changing or the numbers in other populations 
are altering the percentage of that cell.  So, for example while the data in some 
slides point to a reducing macrophage population in essence it could have been 
static and the decrease may be as a result of more fibroblasts and leukocytes.  
Again this needs to be recognized when interpreting the data.  
Flow cytometry is a procedure through which specific characteristics of 
large number of cells can be measured simultaneously.  Initially the cells are 
labeled with fluorescently conjugated monoclonal antibodies, and then in the flow 
cytometer the cells pass via a flow chamber and a focused laser beam to excite 
the flurochrome.  At the excitation wavelength there will be fluorescent activation 
of the fluorophore. Finally the emitted fluorescence and light scattering property 
241 
 
for each cell is processed via a detector which can be detected (Michelson 
1996).  There are several advantages of using this technique such as more than 
one parameter can be measured for single cell by flow cytometry (Chattopadhyay 
and Roederer 2012), it is possible to obtain WBC differential counts (Bignardi 
2015).  Further dead cells can be gated out of the analysis, weakly expressed 
can be detected (Dunphy 2004), and the results in flow cytometry can be 
obtained in as short as 60-80 seconds with providing accurate quantitation 
(Mahieu, Vertessen et al. 2004, Butch, Wises et al. 2008, Goubard, Marzouk et 
al. 2011, Zur, Eichhorn et al. 2012).  However, flow cytometry was not suitable 
for the study undertaken here.  One of the major disadvantages of flow cytometer 
is that it requires on-site access to a flow cytometer (Herculano-Houzel, von 
Bartheld et al. 2015) due to cell lysis within hours of sample collection (Bignardi 
2015) which made it difficult when collecting samples at SKI as there was no 
immediate access to a suitable flow cytometer while the availability of samples 
complicated this approach.  However the biggest issue was the nature of the 
sample.  The pellet from a PD effluent bag contained significant amounts of 
debris and fragmented cells that made a flow cytometry approach difficult with 
initial attempts to do this causing either blockage or a noisy signal.  
Immunohistchemistry approach allowed damaged cells to be counted and debris 
to be ignored.   
 In conclusion, peritoneal leukocytes and macrophages formed the majority 
of peritoneal cells, while the peritoneal mesothelial cells represent the smallest 
population.  The peritoneal fibroblasts sit in between the two.  Peritoneal 
leukocytes and fibroblasts increase with time on PD (more than 3 years), while 
macrophages decline with time on PD.  Peritoneal fibroblasts and leukocytes 
show significant positive correlations with dialysate glucose exposure during the 
year prior to effluent sampling.  As fibroblasts are a major source of TIMPs and 
MMPs then the increasing contribution of this cell type to the population could 
reflect changes in MMPs and TIMPS with time on PD.  
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CHAPTER SEVEN 
General Discussion 
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7.1 General discussion 
Peritoneal dialysis (PD) is one of the options for renal replacement therapy 
in patients with end-stage kidney failure.  PD offers home dialysis permitting 
patients to be autonomous from the hospital.  However prolonged usage of PD 
may be limited by scarring and fibrosis of the peritoneal membrane (Fusshoeller 
2008).  In some 3% of patients on PD, a rare but potentially fatal complication 
can develop known as encapsulating peritoneal sclerosis (EPS).  
EPS is a difficult disease to study for several reasons such as it is rare 
disease with vague diagnostic criteria and there is no clear diagnostic test 
(Kawanishi, Harada et al. 2001, Korte, Sampimon et al. 2011).  There is difficulty 
in finding suitable animal models in EPS study.  The important differences in the 
animal models in comparison to PD in humans remain the main problem 
(Nikitidou, Peppa et al. 2015) for example, long incubation time is an important 
factor in EPS, while long incubation period is difficult in animal models.  There is 
even disagreement as to whether EPS represents the severe end of a continuum 
of peritoneal sclerosis (PS) or they are entirely two different pathological entities.  
Aetiopathogeny of EPS has not been explained clearly and changes in peritoneal 
function could be due to the reflection of effects of long exposure to PD (De 
Sousa, del Peso-Gilsanz et al. 2012). However, those PD patients who are 
developing EPS have a tendency to UF failure before stopping PD (Lambie, John 
et al. 2010). 
This thesis proposes the hypothesis that there are proteins present in the 
peritoneal dialysis effluent that will inform on the rate of simple peritoneal 
sclerosis and EPS.  These proteins are likely to be those involved in tissue 
remodeling or fibrosis.  MMPs, TIMPs, and proteins identified by proteomics are 
examples on these potential proteins.   To address this, each chapter sought to 
parts of this wider hypothesis.  Chapter 3 proposed that changes in the MMP 
system in the peritoneum would underlie PS &/or the switch to EPS and may 
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have value as biomarkers or diagnostics in PDE while chapter 4 tested the 
hypothesis that MMP family members had a peritoneal production.  Chapter 6 
took this information and proposed that changes in the peritoneal cell population 
would change with time on PD and that this underpinned changes in ECM 
processing systems with time on PD.  Finally, using data from parallel proteomic 
interrogation of PDE being performed in the same laboratory, chapter 5 
attempted to validate some of these data by classical ELISA in the patient 
cohorts available.  The above chapters are important to identify markers of 
peritoneal injury (biomarkers) that could be monitored to provide indication of the 
development of peritoneal injury including PS and EPS.  Biomarkers that can be 
measured in the PDE samples can potentially be used to monitor changes 
occurring in the peritoneal ECM in response to time on treatment.  Therefore, the 
overall aims of this thesis were to identify biomarkers or diagnostic tools for PS 
and EPS.  
This study had several key findings, perhaps the most significant findings 
were low ECM proteolytic activity with progressively decreasing in plasmin 
activity and low to undetected MMP activity in PDE samples.  The lack of MMP 
activity seems to be due to high TIMP-1 which has a significant intra-peritoneal 
production and perhaps lower MMP levels than would have been predicted, 
especially for MMP-1.  This is consistent with a fibrotic phenotype which could 
underlie the development of PS in PD patients where typically ECM clearance is 
low.  Plasma levels of TIMP-1, TIMP-2, MMP-2, and MMP-3 were higher in 
patients on PD compared to healthy individuals.  TIMP-1, 2, & MMP-2 in PDE 
samples were positively correlated with D/Pcr and negatively correlate with UF.   
The study clearly showed that TIMP-1 is rapidly elevated close to or during 
diagnosis of EPS and this is suggesting it may have value as a late biomarker or 
at least a diagnostic tool.  Changes in TIMP-1 may result from a change in the 
cell population in the PDE with progressive increases in peritoneal fibroblasts 
which are powerful local TIMP producing cells.  The other important finding was 
local production in the peritoneal cavity in particular TIMP-1 and MMP-2 which 
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were produced locally higher than MMP-3 and TIMP-2.  MMP-3 was produced 
less locally and TIMP-2 was the least when compared to the other three.  
Plasmin activity declined in patients with long duration of PD therapy (more than 
3 years).     
There were limitations in the cohorts used for this study such as none of the 
three cohorts (SKI-1, SKI-2, and GFS) were ideal in isolation, but each 
contributes to the question being asked in differing ways such that each 
complements the others.  There were deficiencies in the both SKI cohorts. In the 
SKI-1 cohort, there were no records for the exact dwell times and samples were 
not collected during a PET.  There was also an absence of records concerning 
the occurrence or volumes used for line flushing in the collection of the PDE 
samples and this affected sample dilution.   However these samples were 
already available and allowed a rapid study start being ideal for assay work up 
and gaining basic information.  In the SKI-2 cohort, there was no EPS patients 
which was not ideal for either PDE biochemical analysis or cytology, instead 
changes with time on PD and glucose exposure to the peritoneal membrane in 
the last year were studied as surrogate markers of peritoneal membrane damage 
(Lambie, John et al. 2010). In addition, all related clinical data such as D/Pcr and 
UF was available which allowed good correlation analysis to be performed.  The 
SKI-2 cohort was used for all cytology work, but in hindsight cell slides were not 
ideally prepared, with too many cells cytospun which made the counting difficult 
and time consuming as it had to be performed manually. In retrospect, rather 
than just loading all cells across 8 slides defined cell numbers should have been 
cytospun.  In the GFS cohort, perhaps the primary limitation was the limited 
volume of the PDE samples available which restricted what assays could be 
performed.  Irregular timing of sample collections and an absence of records 
concerning the line flushing at sample collection were also problematic in the 
GFS cohort.  Finally, for the 12 PD patients in the EPS group, only 2 samples 
were collected within 100 days of EPS diagnosis (before diagnosis or during 
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diagnosis) was a significant limitation, which from the work carried out in this 
study appears to be a very critical period in EPS development.   
This is certainly not the first study to look at the ECM proteolysis in PD.    
Hirahara and colleagues have previously performed similar studies in MMP 
system, but in their studies TIMP-2 was undetectable in their PDE samples, 
whileTIMP-2 was easily detectable in PDE samples of all tested cohorts (SKI-1, 
SKI-2, and GFS).  The most likely reason for this is the detection limit of the 
different ELISA kits used although one cannot exclude how the samples were 
processed and stored.  However they did show similar local production of TIMP-1 
and MMP-2 as described in SKI-2 despite the lack of ideal curve fitting in their 
construction of a plasma or serum/dialysate transfer rate standard curve.  They 
also did not include serum/plasma creatinine which gave them a shorter standard 
curve and thus inferior line fit (Hirahara, Inoue et al. 2011).  Barreto and 
colleagues have also worked in this area, using a four point curve, but like 
Hirahara et al, they did not perform any curve fitting.  This group looked at MMP-
2 and PAI-1, again showing MMP-2 was produced locally in the peritoneal cavity 
(Barreto, Coester et al. 2013).  The approach used in Sheffield was different in 
that five molecules were used to perform fitting curve of plasma to dialysate 
transfer rate standard curves.  TIMP-1&-2, MMP-2&-3, and intelectin-1 were 
tested for locality production in peritoneal cavity of SKI-2 cohort.  Finally the 
measured plasma levels of TIMPs, MMPs, intelectin-1, albumin, transferrin, IgG, 
and B2M were compared between PD patients in SKI-2 cohort against healthy 
individuals.   A summary of approaches used for developing a dialysate transfer 
rate standard curve between the two published studies versus this study is 
illustrated in (Table 7.1). 
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Variable Hirahara and 
colleagues 
Barreto and 
colleagues 
Present study 
Tested Molecules TIMP-1, MMP-2 and 
MMP-3 
MMP-2 and PAI-1 TIMP-1, TIMP-2, MMP-2, 
MMP-3, and intelectin-1 
D/P of the standard rate Albumin, transferrin, 
B2M, and IgG 
 B2M, albumin, IgG 
and α2-M 
Cr, albumin, transferrin, 
B2M, and IgG. 
Molecular weight of the 
Standard rate (Kda) 
11.8 - 150 11.8 - 820 0.1-150  
TIMP and MMP levels in 
plasma of PD patients 
were compared to the 
healthy volunteers 
No No Yes 
Standard Curve Linear Linear Polynomial excel curve fit  
Produce locally TIMP-1 and MMP-2, but 
not MMP-3 
MMP-2 and PAI-1 TIMP-1 and MMP-2, to a 
lesser extent MMP-3, very 
low TIMP-2 and no 
interlectin-1 production 
   
Table 7.1 Summary of different studies to evaluate MMP family protein and 
intelectin-1 source in PD 
The comparison between published studies by Hirahara etal and Barreto etal,with the study performed in 
Sheffield on the SKI-2 cohort. 
There are several studies showing  high levels of MMPs and TIMPs in 
serum in various types of tissue injury (Table 7.2) (Hirahara, Kusano et al. 2011).  
This suggests a relationship between the pathology of tissue injury with serum or 
plasma levels of MMPs and TIMPs.  The two studies on MMP system in PD 
patients [ (Hirahara, Inoue et al. 2011) and (Barreto, Coester et al. 2013) ] did not 
compare plasma or serum level of healthy individuals and PD patients, while 
important findings in chapter 3 and 5 of this thesis were high plasma levels of 
TIMP-1&-2, MMP-2&-3, and intelectin-1 in PD patients in comparison to healthy 
individuals.  These high levels of MMPs, TIMPs and intelectin-1 in plasma may 
be due to high production in the body and due to impaired renal clearance.  
Firstly: tissue injury is associated with high MMPs and TIMPs as part of body 
response to the injury and the dialysate induced stress in the peritoneum.  
Intelectin-1 is highly expressed in the small intestine and this may be a source of 
intelectin-1 given the ―stress‖ exerted on the gut during PD.  Secondly, impaired 
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renal clearance of these molecules in PD patients may cause further high level of 
TIMPs, MMPs and intelectin-1 in plasma.    
Increase in serum level Tissue injury 
MMP-1 and MMP-3 Rheumatoid arthritis (Green, Gough et al. 2003) 
MMP-9 Chronic obstructive pulmonary disease (Brajer, Batura-Gabryel 
et al. 2008) 
MMP-1, MMP-8, and MMP-9 Cystic fibrosis (Roderfeld, Rath et al. 2009) 
MMP-9 and TIMP-1  
 
Aortic sclerosis (Rugina, Caras et al. 2007) 
MMP-2, MMP-9, and TIMP-1  Acute coronary syndrome (Tziakas, Chalikias et al. 2004) 
MMP-2 and TIMP-1  Hepatic fibrosis (Kasahara, Hayashi et al. 1997) 
MMP-2  Liver cirrhosis (Murawaki, Yamada et al. 1999) 
MMP-2  Chronic kidney disease (Nagano, Fukami et al. 2008) 
Table 7.2 Summary of studies showing changes in MMPs and TIMPs in the serum 
of patients with various tissue injuries 
Tissue injury is associated with increased levels of various MMPs and TIMPs in plasma as these shown in 
various studies. 
Similar to plasma levels of MMPs and TIMPs, B2M plasma levels were 
higher in patients on PD in compared to healthy individuals.  The reverse was 
true for the other three molecules (albumin, transferrin, and IgG) as their plasma 
levels were higher in healthy individuals as compared to patients on PD.  
Inadequate protein intake, inflammation or protein losses from the dialysate could 
be responsible for the low levels of albumin and transferrin in plasma of CKD or 
dialysis patients (Kaysen 2003, Friedman and Fadem 2010). 
In many types of fibrosis, MMPs and TIMPs are thought to play an 
important role (Catania, Chen et al. 2007, Hemmann, Graf et al. 2007).  In this 
study, the hypothesis that MMPs and TIMPs may have a role in the PS & EPS 
was tested.  The balance of MMPs and TIMPs has an important role in regulating 
turnover of ECM during tissue remodeling during PD.  It is known that the level of 
MMP-2 in PDE reflects increased solute transport and peritoneal injury in PD 
patients (Hirahara, Inoue et al. 2007, Hirahara, Inoue et al. 2011).  In a 
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regression analysis, TIMP-1 was one of the outstanding predictors for cell stress 
in PDE using a marker called HSP-27 (Musial and Zwolinska 2012)  
The plasmin system also plays an important role in fibrosis alongside the 
MMP system.  They work together to breakdown most ECM components.  Both 
the MMP and plasmin systems have their own regulatory proteins.  MMP activity 
is inhibited by TIMPs, while plasminogen activator inhibitors (PAIs) prevent the 
activation of plasminogen by blocking plasminogen activator proteins.  Plasmin 
activity is responsible for conversion of Pro-MMPs to MMPs and MT-MMPs.  
There are several pro-MMPs which are activated by the plasmin system (Galis 
and Khatri 2002) such as MMPs-1, 3, 7, 9, 10 and 13 (Amalinei, Caruntu et al. 
2007).  Patients on PD for a long time (more than three years), have less plasmin 
activity.  This will lead to decrease in MMPs-1, 3, 7, 9, 10 and 13 which means 
less ECM breakdown and this contributes to peritoneal fibrosis. 
It would seem likely that any MMP that was present would have been 
completely inhibited by the huge levels of TIMPs present (Figure 7.1).  Most 
MMPs are low or undetected in PDE samples in this study, MMP-2 level was the 
highest detected in PDE samples, but TIMPs levels were high in PDE samples 
specially TIMP-1.  There were approximately 10 folds of molar excess of TIMP-1 
than MMP-2 in PDE samples which would effectively block MMP activity and lead 
to a decrease in ECM breakdown.  ECM deposition is almost certainly not down 
regulated to match, with the consequence being an increase in peritoneal 
membrane thickness.  Due to the close relationship between the plasmin and the 
MMP systems, plasmin activity was also measured in PDE samples in the SKI-1 
and SKI-2 cohorts.  Plasmin activity was decreased in PDE samples from 
patients who were on PD for a long period (> 3 years) including the single sample 
from a patient diagnosed with EPS.  Loss of MMP activity with diminishing 
plasmin activity over time could facilitate the development of PS.  The large spike 
in TIMP-1 level in PDE samples as EPS is approached may have a role to switch 
the disease process into EPS with its extensive scar tissue production.  
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The TIMP-1 level in PDE samples was the highest of the TIMPs measured 
and significantly higher than MMPs in PDE samples.  TIMP-3 was low in PDE 
samples, although the single EPS sample in SKI-1 cohort showed the highest 
level of TIMP3 compared to the other samples.  Low TIMP-3 in PDE samples 
could be due to the fact that TIMP-3 is the only TIMP which remains bound to the 
ECM and therefore less TIMP-3 is released as a soluble protein which would be 
in the PDE samples.  TIMP-3 is different from the rest of TIMPs by it is property 
of tightly binding to the ECM (Pavloff, Staskus et al. 1992).  The other cause of 
 
Figure7.1 Potential changes in ECM synthesis and deposition in PD patients 
Components of ECM are synthesized intra-cellularly then passed extracellularly for deposition.  Some of 
collagens are degraded prior to deposition.  Once deposited 2 main systems degrade the ECM.  These 
are the MMP and Plasmin system.  Each has its own regulatory system.  MMP activity is inhibited by 
TIMPs, while plasminogen activator inhibitors (PAIs) prevent the activation of plasminogen.  Note TG2 is 
abbreviation for (Transglutaminase type 2).    
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low TIMP-3 may be because human TIMP-3 kit was ordered from R&D systems 
which is only detecting natural and recombinant TIMP-3.  TIMP-3 DuoSet 
(DY973) does not recognize recombinant human TIMP-3 when it complexed to 
mature recombinant human MMP-2.  TIMP-1,-2,-3 and MMP-2 were high in the 
EPS sample in the SKI-1 cohort, but TIMP-3 level in PDE samples was very low, 
therefore the decision was made to only measure TIMP-1, TIMP-2 and MMP-2 in 
PDE samples from the GFS due to limited sample volume from that study.   
In the GFS cohort, TIMP-1 was elevated in EPS within 100 days of 
diagnosis, so it may have value as a late noninvasive biomarker or in 
confirmation of EPS diagnosis.  It was also elevated in the single EPS sample 
compared to other samples from the SKI-1 cohort.  TIMP-1 is an important 
molecule because it is a potent inhibitory effect for all the latent pro-MMPs and 
active MMPs (Ahmed 2009).  Unfortunately only 2 late samples were available in 
the GFS cohort, but statistical advice (Dr Jean Russell, University of Sheffield 
medical statistics unit) was that it was appropriate to apply a statistical test to 
these 2 samples in order to compare them to the non EPS samples at the same 
time point.  This was tested using an Exact Mann-Whitney as the sample size 
was small.  TIMP-1 from the two EPS PDE samples was significantly higher than 
those from the control samples at 100 days (p=0.03).  One of the key issues 
encountered when undertaking this study was line flushing as this was variable 
between clinical staff and the amounts not recorded, hence variable PDE dilution 
could occur.  The GFS samples were taken from a 4 hours dwell time, but it was 
not recorded whether the ―line flush‖ had been included or not.  This could have 
the effected of dilution of the samples by about 10%, if a 200 mL flush in a 2 litres 
bag of dialysate.  TIMP-2 had relatively stable level throughout dialysis in both 
groups in GFS and thus appeared to have the attributes of a good internal 
standard and thus calculation of a TIMP-1:TIMP-2 ratio was used to minimize this 
potential variable.  Unlike TIMP-3, DuoSets for TIMP-1 and TIMP-2 are detecting 
natural and recombinant TIMP-1 and TIMP-2 respectively (Table 7.3).  The 
TIMP-1:TIMP-2 ratio demonstrated an increased ratio near the time of 
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developing EPS.  If a ratio of 3 x mean baseline was set, then no patients that did 
not develop EPS had ―odd‖ samples exceeding this and it was 100% accurate in 
predicting patients developing EPS (given the small numbers used).  MMP-2 in 
PDE samples of the GFS cohort did not show a clear shift in the level of MMP-2 
averages between control and EPS in the last 100 days in EPS group. 
ELISA kits The detection by ELISA kits Discussion points 
TIMP-1 Natural and recombinant TIMP-1 TIMP-2 used as internal reference 
to TIMP-1 
TIMP-2 Natural and recombinant TIMP-2 
TIMP-3  Natural and recombinant TIMP-3, but this 
DuoSet does not recognize recombinant 
human TIMP-3 when complexed to mature 
recombinant human MMP-2. 
One of the reasons for low TIMP-
3 in PDE samples is not 
recognizing recombinants human 
TIMP-3 and MMP-2 complex. 
MMP-1 Pro form of recombinant human MMP-1 and 
the mature form of recombinant human MMP-
1 by itself or when complexed to recombinant 
human TIMP-1 (Total) 
Total MMP-1 was low or 
undetected in PDE samples. That 
is why MMP-1/TIMP-1 complex 
was low too.  There is high level 
of TIMP-1, but very low MMP-1 in 
PDE samples to bind with them.   
MMP-2 Active and Pro recombinant human (rh) MMP-
2 but does not recognize rhMMP-2 complexed 
to rhTIMP-2 
Recently, Total MMP-2 
Quantikine ELISA Kit  (MMP200), 
R&D systems has been 
announced which will be better as 
it detect total MMP-2. 
MMP-3 Pro-, mature, and TIMP complexed forms of 
recombinant human MMP-3 (Total) 
 
MMP-9  This assay measures the 92 kDa Pro-MMP-9 
and the 82 kDa active MMP-9. It does not 
measure the 65 kDa form. It recognizes 
human MMP-9 when complexed to Lipocalin-
2/NGAL isolated from human source material. 
 
MMP-13 It is detecting total MMP-13 level.  
Table 7.3 Summary of MMPs and TIMPs ELISA kits with discussion points 
The ELISA kits will or will not detect the total individual MMP or TIMP.  All ELISA kits were from R&D 
systems except MMP-13 (abcam). 
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Having established TIMP-1 had potential as a diagnostic marker, and also 
potentially a pathogenic driver, it was important to illustrate whether TIMPs and 
MMPs were produced locally in the peritoneal cavity or they were just filtered 
from plasma to peritoneal cavity which would effectively be a filtration change.  
Given the absent of peritoneal biopsy samples available to us, this was carried 
out by calculating the rate of accumulation of TIMPs and MMPs in the PDE 
samples with comparison to the rate of accumulation of similar weight proteins 
known to only be produced else where such as creatinine, albumin, transferrin, 
B2M, and IgG.  If the rate is consistent with similar weight proteins, then it would 
indicate these molecules are being purely filtered, but if the rate of accumulation 
in PD fluid is quicker, then it is a strong indicator of local production in peritoneal 
cavity. 
The previous 2D gel proteomic study of PDE samples (chapter 5) facilitated 
the identification of several changes in proteins when comparing EPS to non-
EPS developing control patients.  Given this proteomic approach is semi 
quantitative and can compare limited samples in any run, and then it is important 
to validate any hits using traditional quantitative measurements in a wider 
population.  In this study, three of these proteins were chosen to determine 
changes if changes identified between those developing EPS and those PD 
patient not.  Changes in the intelectin-1, dermatopontin and collagen (1) I in the 
PDE samples were associated with increased solute transport during peritoneal 
dialysis, most notably seen with intelectin-1 (positive correlations with D/Pcr and 
negative correlations D/D0 glucose and UF).  The key outcome here was that the 
change identified by proteomics was not upheld when the GFS cohort was 
quantified for intelectin-1 by ELISA.  Surprisingly given the known production 
sites of intelection-1 there was no local production in the peritoneal cavity.  This 
suggests that the intelectin-1 level in the peritoneal cavity is due to transport of 
the molecule from plasma to peritoneal cavity.  Proteomics incorrectly picked 
intelectin-1 in EPS and this may be because the ―stress‖ exerted on the gut 
during PD and especially in EPS which leads to more intelectin-1.  A statistical 
254 
 
analysis (Roc curve) was performed to compare TIMPs and MMPs (chapter 3) 
and intelectin-1 (chapter 5) of the control and EPS groups of GFS in the last 100 
days.  The analysis showed TIMP-1 and TIMP-1/TIMP-2 were the best among 
the measured molecules in PDE samples to predict EPS as a biomarker or 
diagnostic tool. 
The mean level of Intelectin-1 in the plasma of PD patients was 1.6 fold 
higher than in the plasma of healthy individuals.  The reason behind the elevated 
level of plasma intelectin-1 might be due to impaired renal clearance of this 
molecule, but it is also may be due to more intelectin-1 production.  Plasma 
intelectin-1 level has  also previously been shown to be higher in haemodialysis 
patients than controls (Alcelik, Tosun et al. 2011).  However, this is first study to 
measure intelectin-1, dermatopontin and collagen (1) I in the PDE so there are 
no other comparable studies.  Apart from intelectin-1, dermatopontin and 
collagen (1) I, a list of 9 other proteins were identified as potential predictors of 
EPS from proteomics analysis of GFS in Sheffield and are the subject of on-
going measurement and analysis.   
 Given different types of cells can have hugely differing ECM processing 
systems, changes in the types of cells found in the PDE with time on PD could 
dramatically alter the ECM homeostasis.  For example, fibroblasts will generate a 
large amount of ECM rich in fibrillary collagens, while Mesothelium derived cells 
will generate a basement membrane collagen rich matrix.  It is known that 
peritoneal cells can be divided into two categories (Leung, Chan et al. 2013) as 
follows: 
1. Residential effector cells including fibroblasts, endothelial cells, adipocytes, 
mesothelial, macrophages and mast cells. 
2. Recruited effector cells, including macrophages, mast cells, T or B 
lymphocytes and polymorphonuclear cells. 
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In this study four types of cell were chosen for immunocytological staining 
and quantification to assess their changes with time on PD.  These were 
leukocytes, macrophages, fibroblasts, and mesothelial cells (Table 7.4).  These 4 
types of cells were chosen because of their potential role in producing ECM 
proteins such as fibroblasts and macrophages.  In addition to that, these chosen 
cells are covering the majority of peritoneal cells.  In fact they represented (74%-
95%) of the total cells had been found in the SKI-2 cohort.  A single cell marker 
stain was used to see if the cell population for each cell changed with long 
duration of PD therapy.  Cells were isolated from overnight PD bags.  It would 
have been advantageous if cells could have also been analysed such for alpha - 
smooth muscle actin (α-SMA) or a marker of endothelial cells, or breaking down 
the leukocytes into its sub populations, but the lack of available slides prevented 
doing this in more detail.   
Cell 
 
Changed with long duration of PD therapy 
(On PD for <1 year, 1-3 years, and >3 years) 
FSP-1 +ve cells Increase 
Leukocytes Increase 
Macrophages Decrease 
Mesothelial cells Slight decrease, but not statistically significant 
Table 7.4 Changes in the cell types found in the PDE with long duration of PD 
therapy 
Cellular changes were observed in PDE samples for twenty one patients in SKI-2 cohort.  The duration of 
PD were from 39 days to more than 9 years on PD. Abbreviations: PD: peritoneal dialysis and PDE: 
peritoneal dialysis effluent. 
The Sample size for cytology study was 21 patients, and sample sizes 
required in detecting full effect of FSP-1, leukocytes, and macrophages were 15, 
24, and 15 PD patients respectively.  Post study sample sizes required to detect 
the half effect were 48, 81, and 48 samples respectively (power calculation with 
p=0.05 and power=95%).  This means that more samples would be required than 
available to draw significant conclusions.  Mesothelial cells need the largest 
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sample size as the difference detected was small and cell counts low, but if the 
difference in between first and second groups is D, and then between second 
and third groups is 2D and if this pattern is assumed, then with p=0.05 and 
power=95%, 252 samples are required (i.e. 84 samples for each group) for 
mesothelial cell staining.  The 3 groups based on time on PD (<1 year, 1-3 years, 
and >3 years).  It is well known that EPS is strongly associated with long duration 
of peritoneal dialysis therapy (Lambie, Braun et al. 2013). 
It is already known that proliferation of fibroblasts (Wynn 2007) and/or 
differentiation to fibroblast-like cells by the process of EMT occurs in PD patients.  
Changes in Fibroblasts will undoubtedly change ECM homeostasis as they are a 
potent producer of TIMP-1.  Another main function of fibroblasts is the production 
of fibrillary collagens and this may explain why collagen 1 was identified from the 
proteomics.  It is thus unfortunate that the sensitivity of ELISA‘s for COL1A1 are 
insensitive and thus it was not possible to quantify in the GFS cohort.  A key 
driver of both fibroblast proliferation and the EMT process isTGFb1 (Willis and 
Borok 2007).  TGFb1 has the ability to induce synthesis of numerous ECM 
components such as Collagen I & III, but TGFb1can also block the transcription 
of several MMPs (Yan and Boyd 2007) & cause the expression of several TIMPS 
(Cotton, Herrick et al. 1998) & both PAI1 & 2 (Samarakoon, Higgins et al. 2008).  
Of note there is already some evidence to suggest that both FGFb & TGF beta 1 
may play a role in both PS & EPS (Mlambo, Hylander et al. 1999, Honda, Nitta et 
al. 2003).  Peritoneal leukocytes (including lymphocyte) were also increasing with 
time on PD.  These cells also have the potential to release TGF-which can 
contribute to the development of peritoneal fibrosis.  T lymphocyte infiltration can 
occur in other organs such as lungs in animal models and patients with 
pulmonary fibrosis and the data here suggests similar may occur in peritoneal 
fibrosis.  The role of lymphocytes in regulating the ECM accumulation, 
particularly collagen, is not completely understood (Luzina, Todd et al. 2008). 
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One patient among the 21 patients studied in the SKI-2 cohort had high 
percentage of the peritoneal mesothelial cells (up to 5%) and this patient was in 
the first year of PD therapy.  The rest of the patients showed less mesothelial 
cells in all the three groups (<1 year, 1-3 years, and >3 years).  Peritoneal 
mesothelial cells ranged from 0.9%-5% of the total population.  This is close to 
the other published studies on peritoneal mesothelial cells.  Mesothelial cells 
undergo the process of EMT as a consequence of time on peritoneal dialysis, 
resulting in peritoneal MCs developing a fibroblast-like phenotype (Aguilera, 
Loureiro et al. 2013).  This process would likely explain in part by the increase of 
fibroblast with time on PD.  Investigators have demonstrated a reduction in PDE 
CA 125, which is a marker of mesothelial mass, with time on PD (Krediet 2001).  
However, a second study did not find a relationship between time on PD and the 
percentage of MCs in the cytospin of PDE (Betjes, Bos et al. 1991).  The average 
of peritoneal mesothelial cells of the later study was 3.1% and this is similar to 
the percentage of peritoneal MCs in the SKI-2 cohort.  The degenerative 
changes of the peritoneal membrane such as loss of mesothelial cells, sub-
mesothelial ECM accumulation as well as vasculopathy are associated with long-
term PD  (Williams, Craig et al. 2002, Fraser and Topley 2009). 
It is likely that combinations of markers may be of far more value than single 
molecules to identify peritoneal membrane damage (figure 7.2), although in this 
study there was one potential protein identified, TIMP-1, but there are other 
adding important findings such as changes in MMP system in general and there 
are also changes in peritoneal cells and plasmin activity with long duration of PD 
therapy.  TIMP-1 is the most promising marker, although it was not possible to 
test fully COL1A1 and dermatopontin due to detectable levels and the GFS fluid 
volumes available. 
Based on the work here, future studies would be best aimed at expanding 
cell staining on other cohorts with larger sample size and inclusion of slides from 
EPS patients.  Sequential slides are essential to monitor changes in the 
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peritoneal cellular in the same patient with time.  Examining the impact of various 
types of dialysate will also be important because it affects peritoneal cells 
function / survival.  However the most exciting finding from this work will be to 
examine TIMP-1 (likely as a ratio to TIMP-2) to additional cohorts and in larger 
numbers to fully evaluate the usefulness of it as a diagnostic tool.   
 
 
 
Figure 7.2 Overall understanding of the MMP system, plasmin activity and 
cellular changes in PDE samples with long duration on PD therapy 
Summary of our understanding of MMP system involvement after long duration of PD therapy including 
activation and inhibition pathways. 
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In conclusion this work has identified that the TIMP-1 and TIMP-1/TIMP-2 
ratio as a late predictor or early diagnostic tool of EPS onset.  If this observation 
can be repeated and is consistent it would provide a rapid and simple test on 
PDE to complement or even replace existing diagnostic approaches which can 
be inconclusive.  It may also give sufficient warning to either stop PD or possibly 
apply the new anti-fibrotics being introduced to clinical practice such as 
pirfenidone, nintedanib, Lysophosphatidic Acid receptor antagonists and LOXL2 
inhibitory antibodies. 
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Appendix 1: Methods of Kt/V urea and creatinine clearance calculations.  It is 
reproduced by permission of the Baxter © Copyright 1996. Baxter Healthcare 
Corporation. All rights reserved. 
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Appendix 2: Study protocol and related documents for Sheffield kidney institute 
PD cohort 1 (SKI-1) 
 
A Study of Clinical and Genetic Risk Factors for Encapsulating Peritoneal 
Sclerosis 
 
Protocol for Each Participating Centre 
Stage 1 
Ethical approval (2-3 months, standard application written by study co-coordinator to be 
adapted for regional variations) 
 
Stage 2 (1-2 weeks) 
Identification of all patients on PD by local investigator 
Blood sample and Dialysis effluent from each patient 
Biopsy tissue from some patients at the time of surgery. 
MR scans on some patients (not all centres) 
 
Stage 3 (Whilst collecting Blood samples) 
Clinical Details entered 
 
 
Stage 4 (E-mail from Study Co-coordinator every 6 months) 
Regular screen for any EPS patients 
Peritoneal Biopsy tissue from patients undergoing surgery for EPS or having tenckhoff 
catheter removal for membrane problems. 
 
 
There will be regular meetings of all the local investigators and the study co-coordinator 
at conferences such as the renal association to maintain communication and keep all 
participants updated and informed. Once a critical number of samples have been 
collected then research proposals will be invited from the group. 
   
Genotype Studies 
Blood samples (1X 3mls EDTA) will be frozen and subsequently transported from each 
participating centre to Manchester. The DNA will be extracted using a standard DNA 
isolation kit. (Qiamp, Qiagen). 
 Genotyping for SNPs will be performed using Taqman allelic discrimination with the ABI 
PRISM 7500 sequence detection system. This method allows for high throughput 
genotyping. 
 
UKEPS Protocol updated version 4 23/08/2007 
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Participant Information Sheet 
 
A Study of Clinical and Genetic Risk Factors for Encapsulating Peritoneal 
Sclerosis 
 
You are being invited to take part in a research study. Before you decide it is important 
for you to understand why the research is being done and what it will involve. Please 
take time to read the following information carefully and discuss it with friends and 
relatives if you wish. Ask us if there is anything that is not clear or if you would like more 
information. Take time to decide whether or not you wish to take part. You will be given a 
copy of this information sheet and a signed consent form to keep. 
 
What is the purpose of this study?  
We are investigating possible causes of Encapsulating Peritoneal Sclerosis a condition 
which occurs because of damage to the peritoneal membrane. The disease is rare and 
we think that that some people may develop this condition because of their genetic 
make-up. We think that variations in individual gene markers may affect the way peoples 
immune systems respond and hence may make some people more likely to develop 
EPS. If we could identify a genetic factor it may be possible to predict those people likely 
to develop this disease. This may allow early clinical intervention and monitoring to 
prevent the disease. For this study we need to recruit a large number of patients who 
have been on peritoneal dialysis in order to compare the genetic makeup of patients who 
develop EPS with those who don‘t. 
 
Why have I been chosen? 
 
1) You are on Peritoneal Dialysis  
or  
2) You have been identified as having Encapsulating Peritoneal Sclerosis, now or 
previously, and are therefore being asked to take part in this study. 
or 
3) You are having surgery for complications of dialysis. 
 
Do I have to take part? 
It is up to you to decide whether or not to take part. If you do decide to take part you will 
be given this information sheet to keep and be asked to sign a consent form. If you 
decide to take part you are still free to withdraw at any time and without giving a reason. 
This will not affect the standard of care you receive. 
 
What will happen to me if I take part? 
We would ask your consent to take one 10ml (three teaspoons) blood sample. We will 
extract DNA from this blood for genetic studies. We would also ask you to donate 50mls 
of your dialysis fluid (collected after your dialysis session). We would also like 
permission to look at your medical notes and record details in a password protected 
database. 
For those of you having a surgical procedure performed we ask for a small sample of 
your peritoneum 2-3mm to be collected by the surgeon whist you are under anaesthetic. 
We may also ask you to have a MR scan of your peritoneum. This would take about 40 
minutes and is a painless procedure which does not involve radiation. 
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What are the possible benefits of taking part? 
We do not expect that there will be any benefit to you directly from this study, but neither 
will there be any harm. The results of this research may allow us to understand the 
reasons why some people develop EPS. Then we hope to identify patients at risk and 
develop treatments, which may prevent the development of EPs and therefore prolong 
the function of the peritoneum. This will help other people who receive CAPD treatment 
in the future.   
 
Will my taking part in this study be kept confidential? 
Your clinical information will be confidential and will not be released to anyone outside 
the research team. When the results of the study are reported and published, your name 
will not be released and it will be impossible to identify your results. It will not be possible 
to link the results of the genetic study to you and this data will only be seen by 
researchers on this study who have signed a confidentiality agreement. The genetic 
information collected will be anonymised and will not be released to any third party. 
However, it may be necessary for the ethics committee or hospital regulatory authorities 
to review your notes to confirm that the research has been conducted properly.  
 
What will happen to the results of the study? 
This is a long term study and it will take five years to enrol all of the patients who wish to 
take part. We expect to do the first analysis and publish the results two years later. We 
keep copies of all the research results we publish and we will give you a copy on request 
of any publications that come from this study. You will not be identified in any of these 
reports. 
 
Who is funding the research? 
The study is being funded and endorsed by the International Society of Peritoneal 
Dialysis. 
 
Who has reviewed this study? 
The Local Research Ethics Committee has reviewed this research study and it has 
agreed that it may go ahead. 
 
Contact for further information 
If you wish to know more about the study please contact: 
 
Name of Local PI 
If you wish to know more about the study please contact: 
Dr Angela Summers 
Dept of Renal Research 
Manchester Royal Infirmary 
Oxford Road,  
Manchester  
M13 9WL 
E-mail –Angela.Summers@cmmc.nhs.uk 
 
 
Participant Information Sheet 
Updated Version 5 23/08/2007 
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Appendix 3: Study protocol and related documents for Sheffield kidney institute 
PD cohort 2 (SKI-2) 
UK EPS Registry and DNA Bank 
 
Protocol for Each Participating Centre 
Stage 1 
Ethical approval (2-3 months, standard application written by study co-coordinator to be 
adapted for regional variations) 
 
Stage 2 (1-2 weeks) 
Identification of all patients on PD  by local investigator 
Blood sample and Dialysis effluent from each patient 
Biopsy tissue from some patients at the time of surgery. 
MR scans on some patients (not all centres) 
 
Stage 3 (Whilst collecting Blood samples) 
Clinical Details entered 
 
 
Stage 4 (E-mail from Study Co-coordinator every 6 months) 
Regular screen for any EPS patients 
Peritoneal Biopsy tissue from patients undergoing surgery for EPS or having tenckhoff 
catheter removal for membrane problems. 
Extra blood samples and dialysate collected on an annual basis (not all centres). 
 
 
There will be regular meetings of all the local investigators and the study co-coordinator 
at conferences such as the renal association to maintain communication and keep all 
participants updated and informed. Once a critical number of samples have been 
collected then research proposals will be invited from the group. 
   
Genotype Studies 
Blood samples (1X 10mls EDTA) will be frozen and subsequently transported from each 
participating centre to Manchester. The DNA will be extracted using a standard DNA 
isolation kit. (Qiamp, Qiagen). 
 Genotyping for SNPs will be performed using Taqman allelic discrimination with the ABI 
PRISM 7500 sequence detection system. This method allows for high throughput 
genotyping. 
 
UKEPS Protocol  version 6 02/12/2010 
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Participant Information Sheet 
 
A Study of Clinical and Genetic Risk Factors for Encapsulating Peritoneal Sclerosis 
 
You are being invited to take part in a research study. Before you decide it is important 
for you to understand why the research is being done and what it will involve. Please 
take time to read the following information carefully and discuss it with friends and 
relatives if you wish. Ask us if there is anything that is not clear or if you would like more 
information. Take time to decide whether or not you wish to take part. You will be given a 
copy of this information sheet and a signed consent form to keep. 
 
What is the purpose of this study?  
We are investigating possible causes of Encapsulating Peritoneal Sclerosis a condition 
which occurs because of damage to the peritoneal membrane. The disease is rare and 
we think that that some people may develop this condition because of their genetic 
make-up. We think that variations in individual gene markers may affect the way peoples 
immune systems respond and hence may make some people more likely to develop 
EPS. If we could identify a genetic factor it may be possible to predict those people likely 
to develop this disease. This may allow early clinical intervention and monitoring to 
prevent the disease. For this study we need to recruit a large number of patients who 
have been on peritoneal dialysis in order to compare the genetic make up of patients 
who develop EPS with those who don‘t. 
 
Why have I been chosen? 
1) You are on Peritoneal Dialysis  
or  
2) You have been identified as having Encapsulating Peritoneal Sclerosis, now or 
previously, and are therefore being asked to take part in this study. 
or 
3) You are having surgery for complications of dialysis. 
Do I have to take part? 
It is up to you to decide whether or not to take part. If you do decide to take part you will 
be given this information sheet to keep and be asked to sign a consent form. If you 
decide to take part you are still free to withdraw at any time and without giving a reason. 
This will not affect the standard of care you receive. 
What will happen to me if I take part? 
We would ask your consent to take one 10ml (three teaspoons) blood sample. We will 
extract DNA from this blood for genetic studies. If you continue in the study for more 
than a year, we would like to take a further 10 ml blood sample each year – this blood 
will be stored to measure molecules that might give information about the causes of 
EPS.  We would also ask you to donate samples of your dialysis fluid (collected after 
your dialysis session). We may extract cells from this fluid and perform laboratory tests 
on these cells.We would also like permission to look at your medical notes and record 
details in a password protected database. 
For those of you having a surgical procedure for catheter insertion or removal we ask for 
a small sample of your peritoneum 2-3mm to be collected by the surgeon whist you are 
under anaesthetic. For those of you having a surgical procedure for EPS usually the 
surgeons remove the fibrous tissue we ask that this is retained for research instead of 
being disposed of. 
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We may also ask you to have a MR scan of your peritoneum. This would take about 40 
minutes and is a painless procedure which does not involve radiation. 
What are the possible benefits of taking part? 
We do not expect that there will be any benefit to you directly from this study, but neither 
will there be any harm. The results of this research may allow us to understand the 
reasons why some people develop EPS. Then we hope to identify patients at risk and 
develop treatments, which may prevent the development of EPs and therefore prolong 
the function of the peritoneum. This will help other people who receive CAPD treatment 
in the future.   
Will my taking part in this study be kept confidential? 
Your clinical information will be confidential and will not be released to anyone outside 
the research team. When the results of the study are reported and published, your name 
will not be released and it will be impossible to identify your results. It will not be possible 
to link the results of the genetic study to you and this data will only be seen by 
researchers on this study who have signed a confidentiality agreement. The genetic 
information collected will be anonymised and will not be released to any third party. 
However, it may be necessary for the ethics committee or hospital regulatory authorities 
to review your notes to confirm that the research has been conducted properly.  
What will happen to the results of the study? 
This is a long term study and it will take five years to enrol all of the patients who wish to 
take part. We expect to do the first analysis and publish the results two years later. We 
keep copies of all the research results we publish and we will give you a copy on request 
of any publications that come from this study. You will not be identified in any of these 
reports. 
Who is funding the research? 
The study is being funded and endorsed by the International Society of Peritoneal 
Dialysis. 
 
Who has reviewed this study? 
The Local Research Ethics Committee has reviewed this research study and it has 
agreed that it may go ahead. 
 
Contact for further information 
If you wish to know more about the study please contact:  
Dr Martin Wilkie, Sorby Renal Outpatient Dept, Northern General Hospital, S5 7AU 
Martin.wilkie@sth.nhs.uk 
 
If you wish to know more about the study please contact: 
Dr Angela Summers 
Dept of Renal Research 
Manchester Royal Infirmary 
Oxford Road,  
Manchester  
M13 9WL 
E-mail –Angela.Summers@cmmc.nhs.uk 
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Appendix 4: Study protocol and related documents for the Global Fluid Study PD 
Cohort (GFS) 
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Appendix 5: Peritoneal equilibrium test (PET).  It is reproduced by permission of the 
Baxter © Copyright 1996. Baxter Healthcare Corporation. All rights reserved. 
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Appendix 6: Calculation for residual volumes 
Residual volume = V injected x [D3] - [D2] [D1] - [D3] 
1) Dilution of residual volume with a concentration of a molecule can be known 
[D1], urea and / or creatinine. 
2) Volume V of fresh dialysate containing pad the molecule [D2] = 0. 
3) The immediate drainage of the cavity after homogenization contains the 
molecule to the concentration [D3]. 
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Appendix 7: Figure numbers and list of the permissions obtained from 
publishers with name of the authors and articles. 
Figures Publishers Authors and articles 
1.1 American Board of Family 
Medicine 
Saxena, R. and C. West (2006). "Peritoneal dialysis: a 
primary care perspective." J Am Board Fam Med 19(4): 
384. 
1.2 & 1.5 Copyright © 2009, Karger Augustine, T., P. W. Brown, S. D. Davies, A. M. Summers 
and M. E. Wilkie (2009). "Encapsulating peritoneal 
sclerosis: clinical significance and implications." Nephron 
Clin Pract 111(2): c149-154; discussion c154. 
1.3 Peritoneal Dialysis International Honda, K. and H. Oda (2005). "Pathology of encapsulating 
peritoneal sclerosis." Perit Dial Int 25 Suppl 4: S19-29. 
1.4 John Wiley and Sons Sherif, A. M., H. Yoshida, Y. Maruyama, H. Yamamoto, K. 
Yokoyama, T. Hosoya, M. Kawakami and M. Nakayama 
(2008). "Comparison between the pathology of 
encapsulating sclerosis and simple sclerosis of the 
peritoneal membrane in chronic peritoneal dialysis." Ther 
Apher Dial 12(1): 33-41. 
1.7 John Wiley and Sons Gerald, K. (2013). Cell and molecular biology: concepts 
and experiments, 7th edition, John Wiley and Sons, 
Hoboken, NJ. 
1.8 National Academy of Sciences, 
U.S.A. 
Buehler, M. J. (2006). "Nature designs tough collagen: 
explaining the nanostructure of collagen fibrils." Proc Natl 
Acad Sci U S A 103(33): 12285-12290. 
1.10 Cambridge University Press Lafleur, M. A., M. M. Handsley and D. R. Edwards (2003). 
"Metalloproteinases and their inhibitors in angiogenesis." 
Expert Rev Mol Med 5(23): 1-39. 
1.11 BioTechniques Snoek-van Beurden, P. A. and J. W. Von den Hoff (2005). 
"Zymographic techniques for the analysis of matrix 
metalloproteinases and their inhibitors." Biotechniques 
38(1): 73-83. 
2.5 UK EPS Registry & DNA Bank. UK EPS Registry & DNA Bank, 2008. 
2.10 University of Sheffield Transfer report given by John Atkinson. 
3.1 Wounds International Gibson, D., B. Cullen, R. Legerstee, K. Harding and G. 
Schultz (2009). "MMP made easy." Wounds International 
1(1). 
6.1 Originally published in [short 
citation] under CC BY 3.0 
license. Available from: 
http://dx.doi.org/10.5772/56598.   
Aguilera, A., J. Loureiro, G. Gónzalez-Mateo, R. Selgas 
and M. López-Cabrera (2013). "The mesothelial to 
mesenchymal transition a pathogenic and therapeutic key 
for peritoneal membrane failure." The Latest in Peritoneal 
Dialysis. APA. 
Appendices 
1 and 5 
Baxter © Copyright 1996 Baxter Healthcare Corporation. 
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